var title_f3_37_3664="Proper grasping technique";
var content_f3_37_3664=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F56839&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F56839&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 501px\">",
"   <div class=\"ttl\">",
"    Proper grasping technique",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 481px; height: 215px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Firm and atraumatic grasping of a smooth and rounded foreign body with a foreign body forceps (A &amp; B). Traumatic and unsecured grasping with an alligator forceps (C &amp; D).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Charles Marquette, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f3_37_3664=[""].join("\n");
var outline_f3_37_3664=null;
var title_f3_37_3665="Nondisplaced femoral neck fracture";
var content_f3_37_3665=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F75798&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F75798&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Nondisplaced femoral neck fracture",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 296px; height: 500px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Intracapsular, or femoral neck, fractures have higher rates of nonunion and malunion, and are more likely to lead to avascular necrosis of the femoral head.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Lippincott Williams &amp; Wilkins. Copyright &copy; 2008.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f3_37_3665=[""].join("\n");
var outline_f3_37_3665=null;
var title_f3_37_3666="Patient information: Appendicitis in children (The Basics)";
var content_f3_37_3666=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"11\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div>",
"   &nbsp;",
"  </div>",
"  <div id=\"basicsTopicMinWidth\">",
"   <div id=\"basicsTopicRight\">",
"    <div id=\"placeholder\">",
"     <div id=\"basics-graphics\">",
"      <span class=\"basics-box-top\">",
"      </span>",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-graphics-title.png\"/>",
"       <span class=\"openRelatedGraphics\" id=\"PI/16432\" rel=\"graphic_box\">",
"        <a href=\"#\" title=\"View All Related Graphics\">",
"         View All",
"        </a>",
"       </span>",
"      </h4>",
"      <ul>",
"       <li>",
"        <a class=\"graphic graphic_figure\" href=\"UTD.htm?34/8/34946\">",
"         Appendicitis",
"        </a>",
"       </li>",
"      </ul>",
"      <a href=\"#\" id=\"basics-seeall\">",
"       See All Graphics",
"      </a>",
"     </div>",
"     <script type=\"text/javascript\">",
"      if ($(\"#basics-graphics li\").length &lt;= 4) {",
"				$(\"#basics-seeall\").remove();",
"			} else {",
"				$(\"#basics-graphics li:gt(3)\").addClass(\"hidden\");",
"				$(\"#basics-seeall\").click(function(){",
"					$(\"#basics-graphics li.hidden\").removeClass(\"hidden\");",
"					$(this).remove();",
"					return false;",
"				});",
"			}",
"     </script>",
"     <div class=\"ieSpacer\">",
"     </div>",
"     <div id=\"basics-more\">",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-more-title.png\"/>",
"      </h4>",
"      <dl>",
"       <dt class=\"basics\">",
"        The Basics",
"       </dt>",
"       <dd>",
"        <a href=\"UTD.htm?35/18/36129\">",
"         Patient information: Appendicitis in adults (The Basics)",
"        </a>",
"       </dd>",
"       <dt class=\"beyondthebasics\">",
"        Beyond the Basics",
"       </dt>",
"       <dd>",
"        <a href=\"UTD.htm?21/54/22371\">",
"         Patient information: Nausea and vomiting in infants and children (Beyond the Basics)",
"        </a>",
"       </dd>",
"      </dl>",
"      <div id=\"tooltipper\">",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"   <div id=\"basicsTopicLeft\">",
"    <div id=\"topicTitle\">",
"     Patient information: Appendicitis in children (The Basics)",
"    </div>",
"    <span class=\"view\">",
"     View in",
"     <a class=\"lang\" href=\"./es-419/appendicitis-in-children-the-basics?source=topic_page\">",
"      Spanish",
"     </a>",
"    </span>",
"    <a class=\"contributor contributor_credentials\" href=\"./authors-and-editors/patient-information\">",
"     Written by the doctors and editors at UpToDate",
"    </a>",
"    <div id=\"topicText\">",
"     <p class=\"headingAnchor\" id=\"H23610518\">",
"      <span class=\"h1\">",
"       What is the appendix?",
"      </span>",
"      &nbsp;&mdash;&nbsp;The appendix is a long, thin pouch that is shaped like a finger. It hangs down from the large intestine, which is also called the colon (",
"      <a class=\"graphic graphic_figure graphicRef81580 \" href=\"UTD.htm?34/8/34946\">",
"       figure 1",
"      </a>",
"      ).",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H23610525\">",
"      <span class=\"h1\">",
"       What is appendicitis?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Appendicitis is the term doctors use when the appendix gets infected and swells. When that happens, the appendix can sometimes burst. A burst appendix can be serious, because it can cause a bad infection.",
"     </p>",
"     <p>",
"      Appendicitis can happen in children and adults. When it happens in children, it is more likely to affect older children and teens than babies or younger children.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H23610532\">",
"      <span class=\"h1\">",
"       What are the symptoms of appendicitis?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Symptoms can be different, depending on a child&rsquo;s age. The most common symptoms are:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        Belly pain &mdash; In older children and teens, belly pain is usually the first symptom. The pain might start around the belly button and then move to the right side of the lower belly. Children can also have belly pain that gets worse with coughing or hopping.",
"       </li>",
"       <li>",
"        Vomiting",
"       </li>",
"       <li>",
"        Fever &mdash; Fever often starts after 1 to 2 days.",
"       </li>",
"       <li>",
"        Loss of appetite",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H23610539\">",
"      <span class=\"h1\">",
"       Should my child see a doctor or nurse?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Yes. Call your child&rsquo;s doctor or nurse if your child has the symptoms listed above.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H23610546\">",
"      <span class=\"h1\">",
"       Will my child need tests?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Maybe. Your child&rsquo;s doctor or nurse will first ask about the symptoms and do an exam. The doctor or nurse might be able to tell if your child has appendicitis without doing any tests.",
"     </p>",
"     <p>",
"      If the doctor or nurse can&rsquo;t tell for sure if your child has appendicitis, he or she might do 1 or more of the following tests:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Blood tests",
"       </li>",
"       <li>",
"        Urine tests",
"       </li>",
"       <li>",
"        An imaging test such as an ultrasound or CT scan &mdash; Imaging tests create pictures of the inside of the body.",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      No test can say for sure if a child has appendicitis. But the doctor or nurse can use the test results, symptoms, and exam to figure out how likely it is that your child has appendicitis.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H23610553\">",
"      <span class=\"h1\">",
"       How is appendicitis treated?",
"      </span>",
"      &nbsp;&mdash;&nbsp;The main treatment for appendicitis is surgery to remove the appendix. This surgery can be done in 2 ways:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        Open surgery &mdash; During open surgery, the doctor makes a cut in the belly near the appendix. Then he or she removes the appendix through that opening.",
"       </li>",
"       <li>",
"        Laparoscopic surgery &mdash; During laparoscopic surgery, the doctor makes a few cuts in the belly that are much smaller than cuts for open surgery. He or she puts long, thin tools into the belly through these openings. One of the tools has a camera (called a &ldquo;laparoscope&rdquo;) on the end, which sends pictures to a TV screen. The doctor can look at the image on the screen to know where to cut and what to remove. Then he or she uses the tools to do the surgery.",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      If your child&rsquo;s appendix has burst, the doctor will do surgery to remove the appendix. During the surgery, he or she will also clean out the area in the belly around the appendix to wash away the material that spilled out of the burst appendix. This surgery can be more complicated than the surgery that is done if the appendix has not burst.",
"     </p>",
"     <p>",
"      If it has been more than a few days since your child&rsquo;s appendix burst, your child might not have surgery right away. That&rsquo;s because the body sometimes forms a wall inside the belly, to block off the area that became infected when the appendix burst. In cases like these, the doctor will first treat your child with antibiotics and watch him or her. He or she might stick a needle in the walled-off area to drain the infected fluid. This treatment is usually done at the same time as an imaging test, so that the doctor can see where to put the needle.",
"     </p>",
"     <p>",
"      After the doctor treats the infection, he or she might recommend that your child have surgery later on.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H23610560\">",
"      <span class=\"h1\">",
"       More on this topic",
"      </span>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?35/18/36129?source=see_link\">",
"       Patient information: Appendicitis in adults (The Basics)",
"      </a>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?21/54/22371?source=see_link\">",
"       Patient information: Nausea and vomiting in infants and children (Beyond the Basics)",
"      </a>",
"     </p>",
"    </div>",
"    <div id=\"reviewProcess\">",
"     <span>",
"      All topics are updated as new evidence becomes available and our",
"      <a class=\"policy policy_editorialpolicy\" href=\"/home/editorial-policy\">",
"       peer review process",
"      </a>",
"      is complete.",
"     </span>",
"    </div>",
"    <div id=\"topicRetrievedDate\">",
"     <span class=\"emphasis\">",
"      This topic retrieved from UpToDate on:",
"     </span>",
"     Apr 20, 2013.",
"    </div>",
"    <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"     <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"      Find",
"     </a>",
"     <a class=\"toolbutton printicon\" href=\"UTD.htm?3/37/3666?view=print\" title=\"Print This Topic\">",
"      Print",
"     </a>",
"     <a class=\"toolbutton emailicon etacLink\" href=\"#\" title=\"Email This Topic\">",
"      Email",
"     </a>",
"    </div>",
"    <div id=\"disclaimer\">",
"     The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions.",
"The use of UpToDate content is governed by the",
"     <a class=\"legal legal_termsofuse\" href=\"/home/terms-use\" target=\"_blank\">",
"      UpToDate Terms of Use",
"     </a>",
"     . &copy;2013 UpToDate, Inc. All rights reserved.",
"    </div>",
"    <div id=\"topicVersionRevision\">",
"     Topic 16432 Version 1.0",
"    </div>",
"   </div>",
"   <!--  basicsTopicLeft -->",
"  </div>",
"  <!-- basicsTopicMinWidth -->",
" </div>",
" <!-- topicContent -->",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-125.39.66.147-B2407C6BAC-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f3_37_3666=[""].join("\n");
var outline_f3_37_3666=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H23610518\">",
"      What is the appendix?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H23610525\">",
"      What is appendicitis?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H23610532\">",
"      What are the symptoms of appendicitis?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H23610539\">",
"      Should my child see a doctor or nurse?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H23610546\">",
"      Will my child need tests?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H23610553\">",
"      How is appendicitis treated?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H23610560\">",
"      More on this topic",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PI/16432\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li>",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?34/8/34946\">",
"      Appendicitis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?35/18/36129?source=related_link\">",
"      Patient information: Appendicitis in adults (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?21/54/22371?source=related_link\">",
"      Patient information: Nausea and vomiting in infants and children (Beyond the Basics)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f3_37_3667="Cherry angiomas";
var content_f3_37_3667=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F54605&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F54605&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Cherry angiomas",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 325px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Multiple red and violaceous papules are present on the trunk.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f3_37_3667=[""].join("\n");
var outline_f3_37_3667=null;
var title_f3_37_3668="Immunohistology skin Alport";
var content_f3_37_3668=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F72404&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F72404&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Immunohistological analysis of the distribution of the &alpha;5(IV) collagen chain",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 446px; height: 300px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The analysis was carried out in the skin of (",
"    <strong>",
"     A",
"    </strong>",
"    ) controls, (",
"    <strong>",
"     B",
"    </strong>",
"    ) male and (",
"    <strong>",
"     C",
"    </strong>",
"    ) female patients with X-linked Alport syndrome, and (",
"    <strong>",
"     D",
"    </strong>",
"    ) patients with autosomal recessive Alport syndrome. The &alpha;5(IV) chain is (",
"    <strong>",
"     A",
"    </strong>",
"    ) present in the epidermal basement membrane (arrow) of the skin of controls, but is (",
"    <strong>",
"     B",
"    </strong>",
"    ) absent from the skin basement membrane (arrow) of the male patient with X-linked Alport syndrome. (",
"    <strong>",
"     C",
"    </strong>",
"    ) Segmental labeling (single arrow) is seen in the X-linked female patient. Nonspecific labeling of the keratin layer is indicated by a double arrow. (",
"    <strong>",
"     D",
"    </strong>",
"    ) Normal staining patterns of the epidermal basement membrane (single arrow) are observed in autosomal recessive Alport syndrome. Nonspecific labeling of the keratin layer is indicated by a double arrow.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reprinted with permission from: Gubler MC. Inherited diseases of the glomerular basement membrane. Nat Clin Pract Nephrol 2008; 1:24. Copyright &copy;2008 Macmillan Publishers Ltd.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f3_37_3668=[""].join("\n");
var outline_f3_37_3668=null;
var title_f3_37_3669="Bacitracin and polymyxin B: Patient drug information";
var content_f3_37_3669=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Bacitracin and polymyxin B: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"UTD.htm?11/14/11491?source=see_link\">",
"     see \"Bacitracin and polymyxin B: Drug information\"",
"    </a>",
"    and",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?27/3/27699?source=see_link\">",
"     see \"Bacitracin and polymyxin B: Pediatric drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F138726\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      AK-Poly-Bac&trade;;",
"     </li>",
"     <li>",
"      Polycin&trade;;",
"     </li>",
"     <li>",
"      Polysporin&reg; [OTC]",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F138727\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      LID-Pack&reg;;",
"     </li>",
"     <li>",
"      Optimyxin&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10022732\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691528",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to avoid or treat skin infections.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691501",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to stop or treat eye infections.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10022731\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701584",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to bacitracin, polymyxin B, or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10022736\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696928",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not use longer than needed. A second infection may happen.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697745",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Use care when putting on. Staining may happen.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696696",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Avoid wearing contacts unless told to wear them by your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697636",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are breast-feeding. You will need to talk about any risks to your baby.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10022737\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698364",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Swelling.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698191",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Itching.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698344",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Skin irritation.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2705392",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         Eye:",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697912",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Blurred eyesight. Use care when driving or doing other tasks that call for clear eyesight.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698368",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tearing.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10022739\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699077",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of infection. These include a fever of 100.5&deg;F (38&deg;C) or higher, chills, very bad sore throat, ear or sinus pain, cough, more sputum or change in color of sputum, pain with passing urine, mouth sores, wound that will not heal, or anal itching or pain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699049",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad skin irritation.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10022734\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696257",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Wash your hands before and after use.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2705550",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         Skin: Powder and ointment (topical):",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694623",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Clean affected part before use. Make sure to dry well.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2705549",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         Skin: Powder (topical):",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695672",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Sprinkle powder over affected skin.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2705548",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         Skin: Ointment (topical):",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694440",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Put a thin layer on the affected skin and rub in gently.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695952",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       The treated part may be covered with a dressing.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2705392",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         Eye:",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694913",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       For the eye only.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696127",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tilt your head back.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695550",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Pull down lower eyelid of affected eye/eyes.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694425",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Put a thin film of ointment into the lower eye.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694629",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Close eye and roll eyeball around for 1 to 2 minutes.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696182",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Use other eye drugs 10 minutes after the ointment.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10022735\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696563",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take a missed dose as soon as you think about it.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696496",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If it is close to the time for your next dose, skip the missed dose and go back to your normal time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696475",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take 2 doses at the same time or extra doses.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10022740\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699336",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store at room temperature.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699262",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Protect from heat.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10022741\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 12443 Version 32.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0605-197.136.42.3-27C422A60D-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f3_37_3669=[""].join("\n");
var outline_f3_37_3669=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F138726\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F138727\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10022732\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10022731\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10022736\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10022737\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10022739\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10022734\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10022735\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10022740\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10022741\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?11/14/11491?source=related_link\">",
"      Bacitracin and polymyxin B: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?27/3/27699?source=related_link\">",
"      Bacitracin and polymyxin B: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f3_37_3670="Fexofenadine: Pediatric drug information";
var content_f3_37_3670=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Fexofenadine: Pediatric drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_general\" href=\"UTD.htm?34/33/35350?source=see_link\">",
"    see \"Fexofenadine: Drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?37/43/38580?source=see_link\">",
"    see \"Fexofenadine: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F171069\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Allegra&reg;;",
"     </li>",
"     <li>",
"      Allegra&reg; Allergy 12 Hour [OTC];",
"     </li>",
"     <li>",
"      Allegra&reg; Allergy 24 Hour [OTC];",
"     </li>",
"     <li>",
"      Allegra&reg; Children's Allergy ODT [OTC];",
"     </li>",
"     <li>",
"      Allegra&reg; Children's Allergy [OTC]",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F171070\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Allegra&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list_set htclist drugH1Div drugBrandNames\" id=\"F1058710\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Therapeutic Category",
"    </span>",
"    <ul>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Antihistamine",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block dos drugH1Div\" id=\"F1058702\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Usual",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_general\" href=\"UTD.htm?34/33/35350?source=see_link\">",
"      see \"Fexofenadine: Drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Hayfever, upper respiratory allergies (OTC use):",
"     </b>",
"     Oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Children 2-11 years: 30 mg twice daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Children &ge;12 years, Adolescents, and Adults: 60 mg twice daily or 180 mg once daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Chronic idiopathic urticaria:",
"     </b>",
"     Oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Infants &ge;6 months to Children &lt;2 years: 15 mg twice daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Children 2-11 years: 30 mg twice daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Children &ge;12 years, Adolescents, and Adults: 60 mg twice daily or 180 mg once daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Seasonal allergic rhinitis:",
"     </b>",
"     Oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Children 2-11 years: 30 mg twice daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Children &ge;12 years, Adolescents, and Adults: 60 mg twice daily or 180 mg once daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Dosing adjustment in renal impairment:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &lt;80 mL/minute:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Infants &ge;6 months to Children &lt;2 years: 15 mg once daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Children 2-11 years: 30 mg once daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Children &ge;12 years, Adolescents, and Adults: 60 mg once daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hemodialysis: Not effectively removed by hemodialysis",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F171047\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Suspension, oral, as hydrochloride:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Allegra&reg;: 6 mg/mL (300 mL) [contains propylene glycol; raspberry cream flavor]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Allegra&reg; Children's Allergy: 6 mg/mL (120 mL) [contains propylene glycol, sodium 18 mg/5 mL; berry flavor]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, oral, as hydrochloride: 30 mg, 60 mg, 180 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Allegra&reg; Allergy 12 Hour: 60 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Allegra&reg; Allergy 24 Hour: 180 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Allegra&reg; Children's Allergy: 30 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, orally disintegrating, oral, as hydrochloride:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Allegra&reg; Children's Allergy ODT: 30 mg [contains phenylalanine 5.3 mg/tablet, sodium 5 mg/tablet; orange cream flavor]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F171032\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes: Excludes orally disintegrating tablet and suspension",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F1058713\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Suspension, tablet: May administer without respect to food. Take with water; avoid administration with fruit juices; shake suspension well before use",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Orally disintegrating tablet: Take on an empty stomach. Do not remove from blister pack until ready to administer. Using dry hands, place immediately on tongue. Tablet will dissolve within seconds, and may be swallowed with or without liquid; avoid taking with fruit juices. Do not split or chew.",
"    </p>",
"   </div>",
"   <div class=\"block sta drugH1Div\" id=\"F1058706\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Stability",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Store at 20&deg;C to 25&deg;C (68&deg;F to 77&deg;F); protect from excessive moisture.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F1058712\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Symptomatic relief of seasonal allergic rhinitis (FDA approved in ages &ge;2 years and adults); treatment of uncomplicated skin manifestations of chronic idiopathic urticaria (FDA approved in ages &ge;6 months and adults); relief of symptoms due to hayfever or upper respiratory allergies [OTC products: Oral suspension: FDA approved in ages &ge;2 years and adults; Meltable tablets: FDA approved in ages &ge; 6 years and adults; Tablets (12 or 24 hours): FDA approved in ages &ge;12 years and adults]",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F171108\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Fexofenadine may be confused with fesoterodine",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Allegra&reg; may be confused with Viagra&reg;",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      International issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Allegra [U.S, Canada, and multiple international markets] may be confused with Allegro brand name for fluticasone [Israel] and frovatriptan [Germany]",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block arm drugH1Div\" id=\"F171106\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Central nervous system: Dizziness, drowsiness, fatigue, fever, headache, pain, somnolence",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Endocrine &amp; metabolic: Dysmenorrhea",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gastrointestinal: Diarrhea, dyspepsia, nausea, vomiting",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Back pain, myalgia, pain in extremities",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Otic: Otitis media",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Respiratory: Cough, rhinorrhea, sinusitis, upper respiratory tract infection",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Miscellaneous: Viral infection",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Rare but important or life-threatening: Hypersensitivity reactions (anaphylaxis, angioedema, chest tightness, dyspnea, flushing, pruritus, rash, urticaria); insomnia, nervousness, sleep disorders, paroniria (terrifying dreams)",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F1058717\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to fexofenadine or any component",
"    </p>",
"   </div>",
"   <div class=\"block pre drugH1Div\" id=\"F1058701\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Precautions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Use with caution in patients with renal impairment; dosage adjustment required. Use cautiously in patients who are also taking ketoconazole and erythromycin; although increased plasma levels of fexofenadine have been observed, no adverse effects with concomitant administration have been reported including QT prolongation which occurred when terfenadine was combined with these agents; while less sedating than other antihistamines, fexofenadine may cause drowsiness and impair ability to perform hazardous activities requiring mental alertness. The orally disintegrating tablets and OTC meltable tablets contain aspartame which is metabolized to phenylalanine and must be used with caution in patients with phenylketonuria.",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F1058700\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Rare hypersensitivity reactions have been reported; manifestations have been described as angioedema, chest tightness, dyspnea, flushing, and systemic anaphylaxis.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F171096\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Substrate",
"     </b>",
"     of CYP3A4 (minor), P-glycoprotein, SLCO1B1;",
"     <b>",
"      Note:",
"     </b>",
"     Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential;",
"     <b>",
"      Inhibits",
"     </b>",
"     CYP2D6 (weak)",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F171041\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Acetylcholinesterase Inhibitors (Central): Anticholinergics may diminish the therapeutic effect of Acetylcholinesterase Inhibitors (Central). Acetylcholinesterase Inhibitors (Central) may diminish the therapeutic effect of Anticholinergics. If the anticholinergic action is a side effect of the agent, the result may be beneficial.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Aclidinium: May enhance the anticholinergic effect of Anticholinergics.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alcohol (Ethyl): CNS Depressants may enhance the CNS depressant effect of Alcohol (Ethyl).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Amphetamines: May diminish the sedative effect of Antihistamines.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antacids: May decrease the serum concentration of Fexofenadine. Management: No specific recommendations concerning the time required between their administration are provided. Separate administration of each agent by as much time as possible to decrease the risk of an interaction.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Calcium Carbonate; Magaldrate; Sodium Bicarbonate.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Anticholinergics: May enhance the adverse/toxic effect of other Anticholinergics.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Levocabastine (Nasal).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ARIPiprazole: CYP2D6 Inhibitors (Weak) may increase the serum concentration of ARIPiprazole.  Management: Monitor for increased aripiprazole pharmacologic effects. Aripiprazole dose adjustments may or may not be required based on concomitant therapy and/or indication. Consult full interaction monograph for specific recommendations.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Azelastine (Nasal): CNS Depressants may enhance the CNS depressant effect of Azelastine (Nasal).",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Benzylpenicilloyl Polylysine: Antihistamines may diminish the diagnostic effect of Benzylpenicilloyl Polylysine.  Management: Suspend systemic H1 antagonists for benzylpenicilloyl-polylysine skin testing and delay testing until systemic antihistaminic effects have dissipated. A histamine skin test may be used to assess persistent antihistaminic effects.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Betahistine: Antihistamines may diminish the therapeutic effect of Betahistine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Buprenorphine: CNS Depressants may enhance the CNS depressant effect of Buprenorphine.  Management: Consider reduced doses of CNS depressants used in combination with buprenorphine.  Consider avoiding other CNS depressants in patients thought to be at high risk of buprenorphine overuse or self-injection.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CNS Depressants: May enhance the adverse/toxic effect of other CNS Depressants.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Levocabastine (Nasal).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Droperidol: May enhance the CNS depressant effect of CNS Depressants. Management: Consider dose reductions of droperidol or of other CNS agents (e.g., opioids, barbiturates) with concomitant use.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Eltrombopag: May increase the serum concentration of OATP1B1/SLCO1B1 Substrates. Management: According to eltrombopag prescribing information, consideration of a preventative dose reduction may be warranted.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Erythromycin (Systemic): May increase the serum concentration of Fexofenadine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Grapefruit Juice: May decrease the serum concentration of Fexofenadine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Hyaluronidase: Antihistamines may diminish the therapeutic effect of Hyaluronidase.  Management: Patients receiving antihistamines (particularly at larger doses) may not experience the desired clinical response to standard doses of hyaluronidase.  Larger doses of hyaluronidase may be required.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     HydrOXYzine: May enhance the CNS depressant effect of CNS Depressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ipratropium (Oral Inhalation): May enhance the anticholinergic effect of Anticholinergics.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Itraconazole: May increase the serum concentration of Fexofenadine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ketoconazole (Systemic): May increase the serum concentration of Fexofenadine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Magnesium Sulfate: May enhance the CNS depressant effect of CNS Depressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Methotrimeprazine: CNS Depressants may enhance the CNS depressant effect of Methotrimeprazine. Methotrimeprazine may enhance the CNS depressant effect of CNS Depressants.  Management: Reduce adult dose of CNS depressant agents by 50% with initiation of concomitant methotrimeprazine therapy. Further CNS depressant dosage adjustments should be initiated only after clinically effective methotrimeprazine dose is established.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Metyrosine: CNS Depressants may enhance the sedative effect of Metyrosine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mirtazapine: CNS Depressants may enhance the CNS depressant effect of Mirtazapine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Paraldehyde: CNS Depressants may enhance the CNS depressant effect of Paraldehyde.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Perampanel: May enhance the CNS depressant effect of CNS Depressants. Management: Patients taking perampanel with any other drug that has CNS depressant activities should avoid complex and high-risk activities, particularly those such as driving that require alertness and coordination, until they have experience using the combination.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     P-glycoprotein/ABCB1 Inducers: May decrease the serum concentration of P-glycoprotein/ABCB1 Substrates. P-glycoprotein inducers may also further limit the distribution of p-glycoprotein substrates to specific cells/tissues/organs where p-glycoprotein is present in large amounts (e.g., brain, T-lymphocytes, testes, etc.).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     P-glycoprotein/ABCB1 Inhibitors: May increase the serum concentration of P-glycoprotein/ABCB1 Substrates. P-glycoprotein inhibitors may also enhance the distribution of p-glycoprotein substrates to specific cells/tissues/organs where p-glycoprotein is present in large amounts (e.g., brain, T-lymphocytes, testes, etc.).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pramipexole: CNS Depressants may enhance the sedative effect of Pramipexole.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pramlintide: May enhance the anticholinergic effect of Anticholinergics. These effects are specific to the GI tract.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rifampin: May decrease the serum concentration of Fexofenadine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ROPINIRole: CNS Depressants may enhance the sedative effect of ROPINIRole.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rotigotine: CNS Depressants may enhance the sedative effect of Rotigotine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Selective Serotonin Reuptake Inhibitors: CNS Depressants may enhance the adverse/toxic effect of Selective Serotonin Reuptake Inhibitors. Specifically, the risk of psychomotor impairment may be enhanced.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sodium Oxybate: May enhance the CNS depressant effect of CNS Depressants. Management: Consider alternatives to combined use. When combined use is needed, consider minimizing doses of one or more drugs. Use of sodium oxybate with alcohol or sedative hypnotics is contraindicated.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tiotropium: Anticholinergics may enhance the anticholinergic effect of Tiotropium.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Verapamil: May increase the bioavailability of Fexofenadine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Zolpidem: CNS Depressants may enhance the CNS depressant effect of Zolpidem.  Management: Reduce the Intermezzo brand sublingual zolpidem dose to 1.75 mg for men who are also receiving other CNS depressants.  No such dose change is recommended for women.  Avoid use with other CNS depressants at bedtime; avoid use with alcohol.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F2523452\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Food Interactions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Fruit juices may reduce the bioavailability of fexofenadine by 36%",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F171043\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F171056\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Adverse events have been observed in animal reproduction studies; therefore, the manufacturer classifies fexofenadine as pregnancy category C. The use of antihistamines for the treatment of rhinitis during pregnancy is generally considered to be safe at recommended doses. Information related to the use of fexofenadine during pregnancy is limited; therefore, other agents are preferred.",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F1058709\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Improvement in signs and symptoms of allergic rhinitis and chronic idiopathic urticaria",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F1058699\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Fexofenadine is an active metabolite of terfenadine; it competes with histamine for H",
"     <sub>",
"      1",
"     </sub>",
"     receptor sites on effector cells in the GI tract, blood vessels, and respiratory tract; it appears that fexofenadine does not cross the blood brain barrier to any appreciable degree, resulting in a reduced potential for sedation",
"    </p>",
"   </div>",
"   <div class=\"block phd drugH1Div\" id=\"F1058715\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Onset of action: 1 hour",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Maximum effect: 2-3 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Duration: &ge;12 hours",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F1058716\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacokinetics (Adult data unless noted)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Absorption: Rapid",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Distribution: V",
"     <sub>",
"      d",
"     </sub>",
"     : Children: 5.4-5.8 L/kg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Protein binding: 60% to 70%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: 5% in liver; 3.5% transformed into methylester metabolite found only in feces (possibly transformed by gut microflora)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life: 14-18 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Time to peak serum concentration: ODT: 2 hours (4 hours with high-fat meal); Tablets: 2.6 hours; Suspension: 1 hour",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Elimination: 11% excreted unchanged in urine; 80% excreted unchanged in feces",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Clearance: Children: 14-18 mL/minute/kg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Dialysis: Not effectively removed by hemodialysis",
"    </p>",
"   </div>",
"   <div class=\"block pai drugH1Div\" id=\"F1058708\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Patient Information",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?37/43/38580?source=see_link\">",
"      see \"Fexofenadine: Patient drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     May cause drowsiness and impair ability to perform activities requiring mental alertness or physical coordination; avoid alcohol",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 13300 Version 44.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1005-89.218.100.194-EFEE8658EB-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f3_37_3670=[""].join("\n");
var outline_f3_37_3670=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F171069\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F171070\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1058710\">",
"      Therapeutic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1058702\">",
"      Dosing: Usual",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F171047\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F171032\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1058713\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1058706\">",
"      Stability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1058712\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F171108\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F171106\">",
"      Adverse Reactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1058717\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1058701\">",
"      Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1058700\">",
"      Warnings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F171096\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F171041\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2523452\">",
"      Food Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F171043\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F171056\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1058709\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1058699\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1058715\">",
"      Pharmacodynamics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1058716\">",
"      Pharmacokinetics (Adult data unless noted)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1058708\">",
"      Patient Information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_PED/13300\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_PED/13300|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?34/33/35350?source=related_link\">",
"      Fexofenadine: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?37/43/38580?source=related_link\">",
"      Fexofenadine: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f3_37_3671="Olfactory neuroblastoma Light";
var content_f3_37_3671=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ONC%2F50794&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ONC%2F50794&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Olfactory neuroblastoma",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 389px; height: 262px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    High power photomicrograph of olfactory neuroblastoma, also called esthesioneuroblastoma. When present, rosette formation (black arrows) and a neurofibrillary background are helpful features in separating these lesions from other small blue cell tumors.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of G. Kenneth Haines, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f3_37_3671=[""].join("\n");
var outline_f3_37_3671=null;
var title_f3_37_3672="Growth hormone treatment for children born small for gestational age";
var content_f3_37_3672=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Growth hormone treatment for children born small for gestational age",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?3/37/3672/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?3/37/3672/contributors\">",
"     Alan D Rogol, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?3/37/3672/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?3/37/3672/contributors\">",
"     Mitchell Geffner, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?3/37/3672/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?3/37/3672/contributors\">",
"     Alison G Hoppin, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?3/37/3672/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Dec 27, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Growth hormone (GH) affects many of the metabolic processes carried out by somatic cells, the best known of which is the effect of increasing body mass. Although generalized growth is stimulated, it is not evenly distributed among the protein, lipid, and carbohydrate compartments. Body protein content increases, total body fat content falls, and an increase in plasma and liver lipid content occurs because of mobilization of free fatty acids (FFA) from peripheral fat stores. The ability of insulin to promote fatty acid synthesis is antagonized by growth hormone.",
"   </p>",
"   <p>",
"    Most children who were born small for gestational age (SGA) have adequate catch-up growth without pharmacologic intervention. However, for a minority, growth hormone can augment growth parameters.",
"   </p>",
"   <p>",
"    The indications for and efficacy of exogenous growth hormone treatment in children with intrauterine growth restriction are reviewed here. The causes of and diagnostic approach to the child with short stature are discussed separately. The use of growth hormone for children with growth hormone deficiency, chronic renal failure, Prader-Willi syndrome, Turner syndrome, Noonan syndrome, or idiopathic short stature also is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/18/10537?source=see_link\">",
"     \"Causes of short stature\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/60/18376?source=see_link\">",
"     \"Diagnostic approach to short stature\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/0/14345?source=see_link\">",
"     \"Treatment of growth hormone deficiency in children\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/14/27881?source=see_link\">",
"     \"Growth hormone treatment in children with chronic kidney disease and postrenal transplantation\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/63/14329?source=see_link\">",
"     \"Management of Turner syndrome (gonadal dysgenesis)\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/8/134?source=see_link\">",
"     \"Clinical features, diagnosis, and treatment of Prader-Willi syndrome\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/52/18248?source=see_link\">",
"     \"Growth hormone treatment for idiopathic short stature\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     SMALL FOR GESTATIONAL AGE INFANTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;By definition, 2.3 percent of human infants are born small for gestational age (SGA). Most, but not all, SGA infants (either term or premature) have sufficient postnatal catch-up growth to normalize their stature by 2 years of age [",
"    <a class=\"abstract\" href=\"UTD.htm?3/37/3672/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. Approximately 90 percent of term SGA infants display sufficient catch-up growth to attain a height above -2 SDS (standard deviation score) by the age of 2 years, whereas 10 percent remain short throughout childhood and adolescence [",
"    <a class=\"abstract\" href=\"UTD.htm?3/37/3672/abstract/3-5\">",
"     3-5",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/23/9593?source=see_link\">",
"     \"Small for gestational age infant\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Catch-up growth may be delayed in infants who are born preterm in addition to SGA [",
"    <a class=\"abstract\" href=\"UTD.htm?3/37/3672/abstract/6,7\">",
"     6,7",
"    </a>",
"    ]. These infants tend to have more severe growth restriction and are less likely to reach heights in the normal range by age 2 years, but catch-up growth may continue into mid- or late-childhood.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Fetal GH physiology",
"    </span>",
"    &nbsp;&mdash;&nbsp;Fetal plasma GH concentrations rise from approximately 50",
"    <span class=\"nowrap\">",
"     mcg/L",
"    </span>",
"    at 12 weeks gestation to approximately 150",
"    <span class=\"nowrap\">",
"     ng/nL",
"    </span>",
"    at midpregnancy and subsequently decrease to approximately 20",
"    <span class=\"nowrap\">",
"     mcg/L",
"    </span>",
"    at birth [",
"    <a class=\"abstract\" href=\"UTD.htm?3/37/3672/abstract/8\">",
"     8",
"    </a>",
"    ]. Inhibition by circulating IGF-1 may be involved in the gradual decrease in fetal GH secretion, as serum concentrations of endogenous IGF-1 rise in late gestation and exogenous IGF-1 is capable of suppressing fetal GH release [",
"    <a class=\"abstract\" href=\"UTD.htm?3/37/3672/abstract/9,10\">",
"     9,10",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Growth-restricted fetuses tend to hypersecrete GH. This may be the direct or indirect result of reduced negative feedback exerted by IGF-1 that circulates in lower concentrations in growth-restricted fetuses. The endocrine milieu of the human fetus with growth restriction is characterized not only by low circulating insulin, IGF-1, IGF-2, and IGFBP-3, but also by elevated IGFBP-1 and GH levels [",
"    <a class=\"abstract\" href=\"UTD.htm?3/37/3672/abstract/9,11\">",
"     9,11",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Hyperresponsiveness to GH releasing factor also has been described in SGA infants [",
"    <a class=\"abstract\" href=\"UTD.htm?3/37/3672/abstract/12\">",
"     12",
"    </a>",
"    ]. This may reflect either deficient negative regulation or diminished feedback, as occurs in GH-resistant states such as undernutrition.",
"   </p>",
"   <p>",
"    Intense activity of the somatotropic axis is thought to be one of the mechanisms driving the postnatal catch-up growth that occurs in the majority of SGA infants [",
"    <a class=\"abstract\" href=\"UTD.htm?3/37/3672/abstract/12\">",
"     12",
"    </a>",
"    ]. The role of the GH-IGF-I axis in postnatal growth in children born SGA is unclear. One study suggests the presence of GH resistance with high levels of circulating GH and low levels of IGF-1 and IGFBP-3 [",
"    <a class=\"abstract\" href=\"UTD.htm?3/37/3672/abstract/13\">",
"     13",
"    </a>",
"    ]. A separate report noted high circulating IGF-I levels consistent with IGF-I resistance [",
"    <a class=\"abstract\" href=\"UTD.htm?3/37/3672/abstract/14\">",
"     14",
"    </a>",
"    ]. &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     SGA children without catch-up growth",
"    </span>",
"    &nbsp;&mdash;&nbsp;Approximately 10 percent of children born SGA will remain short at 2 years of age (height &lt;-2 SDS, which corresponds to height less than the second percentile for age and gender). The mechanism underlying postnatal growth failure in these children is poorly understood. An irreversible deficit in cell number, inadequate calorie intake during the first years of life, and abnormalities in GH secretion have been hypothesized. Classic GH deficiency rarely is found in these children, however there may be subtle abnormalities in the GH secretory pattern similar to those documented in adults during prolonged critical illness [",
"    <a class=\"abstract\" href=\"UTD.htm?3/37/3672/abstract/15\">",
"     15",
"    </a>",
"    ]. &nbsp;",
"   </p>",
"   <p>",
"    Regardless of the mechanism, it appears that the abnormal environmental conditions causing intrauterine growth restriction also can have long-lasting effects on growth and metabolism [",
"    <a class=\"abstract\" href=\"UTD.htm?3/37/3672/abstract/16,17\">",
"     16,17",
"    </a>",
"    ]. This altered programming may either alter the tempo of development or permanently reset homeostatic control [",
"    <a class=\"abstract\" href=\"UTD.htm?3/37/3672/abstract/16\">",
"     16",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/23/9593?source=see_link&amp;anchor=H26#H26\">",
"     \"Small for gestational age infant\", section on 'Relationship to adult disorders'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In short SGA children, IGF-1 and IGFBP-3 levels are low-normal for chronological age, increase with high-dose GH therapy (77",
"    <span class=\"nowrap\">",
"     mcg/kg",
"    </span>",
"    per day), and decrease with the discontinuation of GH therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?3/37/3672/abstract/18\">",
"     18",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     GROWTH HORMONE TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;GH treatment is a recognized therapy for children who are born SGA but who fail to have catch-up growth (\"short SGA children\") [",
"    <a class=\"abstract\" href=\"UTD.htm?3/37/3672/abstract/19\">",
"     19",
"    </a>",
"    ]. The effective doses of GH are higher than those for children with growth hormone deficiency, suggesting relative GH",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    IGF-I resistance. &nbsp; &nbsp;",
"   </p>",
"   <p>",
"    The efficacy of GH treatment for short SGA children has been demonstrated in randomized, controlled, multicenter clinical trials [",
"    <a class=\"abstract\" href=\"UTD.htm?3/37/3672/abstract/20,21\">",
"     20,21",
"    </a>",
"    ]. Some short SGA children also may have GH deficiency or Turner syndrome, but these associated diagnoses are not required for GH treatment.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Indications",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the United States, growth hormone is approved for use in short SGA children whose height remains less than 2 standard deviation scores (SDS) below the mean for age and sex at 2 years of age [",
"    <a class=\"abstract\" href=\"UTD.htm?3/37/3672/abstract/6\">",
"     6",
"    </a>",
"    ]. In Europe, the approved indication is for short SGA children whose height is less than 2.5 SDS below the mean for age and sex at 4 years of age [",
"    <a class=\"abstract\" href=\"UTD.htm?3/37/3672/abstract/22,23\">",
"     22,23",
"    </a>",
"    ]. In addition, the European indications include low growth velocity (ie, height velocity less than average for age) and predicted height (&gt;1 SD below midparental height). &nbsp;",
"   </p>",
"   <p>",
"    In deciding whether to treat a short SGA child with growth hormone, one should consider the expected growth response and its potential benefits to the child, as compared to the risks and psychosocial burden of prolonged treatment on the child and family. The overall high cost of sustained treatment is also a reasonable consideration if the expected benefits are modest.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Growth response",
"    </span>",
"    &nbsp;&mdash;&nbsp;The magnitude of the growth response to treatment depends on the GH dose [",
"    <a class=\"abstract\" href=\"UTD.htm?3/37/3672/abstract/24\">",
"     24",
"    </a>",
"    ], the age of the child (younger children are more responsive), and the family-corrected individual height deficit (children with a greater height deficit are more responsive) [",
"    <a class=\"abstract\" href=\"UTD.htm?3/37/3672/abstract/25,26\">",
"     25,26",
"    </a>",
"    ]. A mathematical model has been developed to help predict the response to growth hormone treatment in these children [",
"    <a class=\"abstract\" href=\"UTD.htm?3/37/3672/abstract/27\">",
"     27",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    There are few long-term follow-up studies of children with assessment of adult height for children born SGA [",
"    <a class=\"abstract\" href=\"UTD.htm?3/37/3672/abstract/20,28,29\">",
"     20,28,29",
"    </a>",
"    ]. The information from these studies is limited because of variability in dose, duration of treatment, and the age that therapy was initiated. Nonetheless, an analysis of initial adult-height outcomes from three randomized controlled trials revealed significant effects of GH treatment on adult height [",
"    <a class=\"abstract\" href=\"UTD.htm?3/37/3672/abstract/21\">",
"     21",
"    </a>",
"    ]. When GH treatment was initiated by 8 years of age and continued for at least seven years, there was a treatment-induced increase in adult height of approximately 1 SDS (approximately 6 cm). There were only modest advantages of a higher-dose regimen as compared to a lower-dose regimen (67",
"    <span class=\"nowrap\">",
"     mcg/kg/day",
"    </span>",
"    versus 33",
"    <span class=\"nowrap\">",
"     mcg/kg/day);",
"    </span>",
"    higher doses yield greater short-term growth responses, but confer only modest advantages on long-term height outcomes. Children who are shorter at the start of GH therapy appear to benefit the most from the higher-dose regimen. Although early initiation of GH is optimal, one study suggests that later initiation of GH also has some benefit on linear growth. Among children who started GH at a median age of 11.2 years, the median height increase improved from -2.9 SDS at the start of GH treatment to -1.7 SDS after reaching adult height [",
"    <a class=\"abstract\" href=\"UTD.htm?3/37/3672/abstract/30\">",
"     30",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    All short SGA children may benefit from GH therapy, whether or not they have GH deficiency. In a study of treatment with GH (3 or 6",
"    <span class=\"nowrap\">",
"     IU/m2",
"    </span>",
"    per day for an average of 7.8 years) in 54 short SGA children with or without GH deficiency, height was normalized in childhood followed by growth along the target height percentile [",
"    <a class=\"abstract\" href=\"UTD.htm?3/37/3672/abstract/28\">",
"     28",
"    </a>",
"    ]. The response to GH was independent of baseline endogenous GH secretion. The degree of response to GH therapy in SGA children without GH deficiency may have genetic determinants [",
"    <a class=\"abstract\" href=\"UTD.htm?3/37/3672/abstract/31\">",
"     31",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Growth hormone treatment may be less effective for short SGA children than for short children with normal birth weights. In the KIGS database (Kabi International Growth Study, now maintained by Pfizer, Inc.), which contains information on a large cohort of children receiving GH treatment, the height gain during two years of treatment with GH was nearly 20 percent greater in children with normal birth weights than in those who had been SGA at birth [",
"    <a class=\"abstract\" href=\"UTD.htm?3/37/3672/abstract/32\">",
"     32",
"    </a>",
"    ]. The safety profile for GH treatment was similar among the two groups. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/0/14345?source=see_link\">",
"     \"Treatment of growth hormone deficiency in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Dosing and administration",
"    </span>",
"    &nbsp;&mdash;&nbsp;The optimal dose and duration of GH therapy have not been established. In our practice, we begin with doses similar to those used for treatment of growth hormone deficiency in children, approximately 40",
"    <span class=\"nowrap\">",
"     mcg/kg/day",
"    </span>",
"    based on ideal body weight. During growth hormone therapy, we readjust doses to maintain IGF-1 levels at approximately 1 SD above the mean for age",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    Tanner stage of development. In some cases, children may require doses of up to 67",
"    <span class=\"nowrap\">",
"     mcg/kg/day",
"    </span>",
"    or higher to maintain and IGF-1 level in the target range. Children should be monitored for evidence of complications of the treatment. Treatment is continued as long as the child is experiencing an accelerated growth rate compared with baseline, or until the growth rate slows to less than 2.5",
"    <span class=\"nowrap\">",
"     cm/year",
"    </span>",
"    in late puberty. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/0/14345?source=see_link&amp;anchor=H6#H6\">",
"     \"Treatment of growth hormone deficiency in children\", section on 'Dosing and monitoring'",
"    </a>",
"    and",
"    <a class=\"local\" href=\"#H13\">",
"     'Monitoring'",
"    </a>",
"    below.) &nbsp;",
"   </p>",
"   <p>",
"    Adjustment of GH dose based on IGF-1 levels has not been studied in this population. Nonetheless, we and others use this approach based on inferences from other populations, which suggest that it may improve both the safety and efficacy of treatment. The rationale for this approach is that IGF-1 levels are directly associated with the growth response and also with complications, including a hypothetical concern that higher IGF-I levels might increase long-term risks for cancer. This concern is based on epidemiological studies in adults showing that IGF-I levels are associated with risks for certain cancers; there is no direct evidence that short-term treatment with GH during childhood increases cancer risk. In the case of short SGA children, IGF-1 levels were directly related to GH dose, but a randomized controlled trial of this dosing scheme has not been reported [",
"    <a class=\"abstract\" href=\"UTD.htm?3/37/3672/abstract/13\">",
"     13",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/0/14345?source=see_link&amp;anchor=H6#H6\">",
"     \"Treatment of growth hormone deficiency in children\", section on 'Dosing and monitoring'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/52/18248?source=see_link&amp;anchor=H12#H12\">",
"     \"Growth hormone treatment for idiopathic short stature\", section on 'Dose adjustment for IGF-I levels'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A number of studies have evaluated different approaches to therapy:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Intensity of treatment &mdash; In a study in which GH was administered either as 0.1",
"      <span class=\"nowrap\">",
"       IU/kg",
"      </span>",
"      per day for four years or as 0.2",
"      <span class=\"nowrap\">",
"       IU/kg",
"      </span>",
"      per day for two years followed by two years without GH treatment, the increase in height SDS was similar in both groups at the end of four years [",
"      <a class=\"abstract\" href=\"UTD.htm?3/37/3672/abstract/33\">",
"       33",
"      </a>",
"      ]. This study supports the idea that the increase in height SDS is dependent on the total GH dose. Children who were extremely short at the beginning of the study (mean adjusted height -3.3 SDS) gained additional height benefit from another course of treatment either two or three years after completion of the first course [",
"      <a class=\"abstract\" href=\"UTD.htm?3/37/3672/abstract/18\">",
"       18",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Continuous versus discontinuous treatment &mdash; In a trial of growth hormone treatment of short SGA children, 59 children between 2 and 5 years of age were randomly assigned to one of two treatment regimens: four years of alternating treatment and observation (TOTO), or two years treatment followed by two years observation (TTOO) [",
"      <a class=\"abstract\" href=\"UTD.htm?3/37/3672/abstract/34\">",
"       34",
"      </a>",
"      ]. Height velocity and total height gain did not differ between the two groups, suggesting that interruption of treatment had no advantage.",
"     </li>",
"     <li>",
"      Concomitant suppression of puberty &mdash; In children who are SGA, the onset of puberty may occur early [",
"      <a class=\"abstract\" href=\"UTD.htm?3/37/3672/abstract/35\">",
"       35",
"      </a>",
"      ]. Thus, the effect of treatment with GH on the onset and overall duration of puberty may influence the adult height outcome. The effectiveness and safety of a three-year combined GH and a gonadotropin releasing hormone agonist (GnRHa) regimen has been assessed in a randomized controlled study in children with idiopathic short stature or SGA. Treatment with GnRHa for three years was effective in suppressing puberty and skeletal maturation while the addition of GH preserved height velocity during therapy. There was a considerable gain in predicted adult height (8 to 10 cm), but the children had not yet reached their adult height at the end of the study [",
"      <a class=\"abstract\" href=\"UTD.htm?3/37/3672/abstract/36\">",
"       36",
"      </a>",
"      ]. By contrast, reports from observational studies of children treated with GH suggest that adding GnRHa to the GH treatment regimen provides minimal benefit or even reduces growth outcomes [",
"      <a class=\"abstract\" href=\"UTD.htm?3/37/3672/abstract/37,38\">",
"       37,38",
"      </a>",
"      ]. Although the latter studies are limited by lack of a randomized control group, these combination regimens cannot be generally recommended at present.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Safety",
"    </span>",
"    &nbsp;&mdash;&nbsp;The safety of GH therapy depends upon the modality of treatment and the individual risk factors. To date, short-term observations during treatment with GH in short children born SGA have established no specific safety issues as compared to other groups of children treated with growth hormone. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/0/14345?source=see_link&amp;anchor=H10#H10\">",
"     \"Treatment of growth hormone deficiency in children\", section on 'Adverse effects'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Insulin resistance",
"    </span>",
"    &nbsp;&mdash;&nbsp;Individuals born SGA, especially those born at term, generally have reduced insulin sensitivity as compared to individuals with normal birth weight [",
"    <a class=\"abstract\" href=\"UTD.htm?3/37/3672/abstract/39\">",
"     39",
"    </a>",
"    ]. Because growth hormone treatment also has been associated with increased insulin levels and insulin resistance, concerns have been raised that this population might have additive risks for insulin resistance during growth hormone treatment.",
"   </p>",
"   <p>",
"    Several trials and postmarketing studies have addressed this issue. These have shown mild and reversible decreases in insulin sensitivity during growth hormone treatment, without impaired glucose tolerance or type 2 diabetes mellitus [",
"    <a class=\"abstract\" href=\"UTD.htm?3/37/3672/abstract/40-44\">",
"     40-44",
"    </a>",
"    ]. As an example, in a trial of 84 children born SGA treated with growth hormone in the United States, no patients developed impaired glucose tolerance or diabetes mellitus during growth hormone treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?3/37/3672/abstract/42\">",
"     42",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Cardiovascular risk factors",
"    </span>",
"    &nbsp;&mdash;&nbsp;Supraphysiological levels of growth hormone can cause adverse changes in blood pressure and lipid profiles, raising concerns about possible adverse effects of GH treatment on cardiovascular risk factors in children born SGA. However, these concerns have not been substantiated in clinical studies.",
"   </p>",
"   <p>",
"    In a large randomized study, children born SGA had higher baseline systolic blood pressures than age- or height-matched controls [",
"    <a class=\"abstract\" href=\"UTD.htm?3/37/3672/abstract/45\">",
"     45",
"    </a>",
"    ]. Growth hormone treatment for six years resulted in normalization of the blood pressure in these children. Mean values for serum lipids and the atherogenic index were normal at baseline, but also decreased during growth hormone treatment as compared to a reference population of healthy children. There were no significant differences in these cardiovascular risk factors between children treated with GH doses of 3",
"    <span class=\"nowrap\">",
"     IU/m2/day",
"    </span>",
"    as compared to 6",
"    <span class=\"nowrap\">",
"     IU/m2/day.",
"    </span>",
"    Of note, 28 percent of children in this study were growth hormone deficient in addition to being born SGA.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     Long-term effects",
"    </span>",
"    &nbsp;&mdash;&nbsp;Many studies have noted an association between intrauterine growth restriction and long-term health risks, including type 2 diabetes, the metabolic syndrome, and cardiovascular disease. However, the mechanisms underlying this association have not been established. It is still unclear whether growth hormone treatment exacerbates or improves these long-term risks.",
"   </p>",
"   <p>",
"    One study showed no difference in measures of insulin resistance in young adults who had been treated with GH during childhood as compared to untreated patients [",
"    <a class=\"abstract\" href=\"UTD.htm?3/37/3672/abstract/46\">",
"     46",
"    </a>",
"    ]. Cardiovascular risk factors, consisting of blood pressure and total cholesterol, were improved in the treated patients. These findings suggest that growth hormone treatment is neutral or advantageous to these long-term risks. However, the findings are preliminary and reflect relatively short follow-up (mean, 6.5 years after cessation of GH treatment). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/23/9593?source=see_link&amp;anchor=H21#H21\">",
"     \"Small for gestational age infant\", section on 'Outcomes'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Monitoring",
"    </span>",
"    &nbsp;&mdash;&nbsp;GH therapy should be initiated and monitored by a pediatric endocrinologist. Before GH therapy is initiated, the child's blood pressure; IGF-1; IGFBP-3; and fasting lipids, insulin, and glucose should be measured [",
"    <a class=\"abstract\" href=\"UTD.htm?3/37/3672/abstract/22\">",
"     22",
"    </a>",
"    ]. During GH therapy growth parameters, blood pressure and IGF-1 should be monitored. In our practice, we also monitor fasting insulin and glucose and serum lipids during GH therapy, based on the concern that GH tends to increase insulin resistance, although clinically significant increases in insulin resistance appear to be rare, as described in the section above [",
"    <a class=\"abstract\" href=\"UTD.htm?3/37/3672/abstract/6,22\">",
"     6,22",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H9\">",
"     'Safety'",
"    </a>",
"    above and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/0/14345?source=see_link&amp;anchor=H6#H6\">",
"     \"Treatment of growth hormone deficiency in children\", section on 'Dosing and monitoring'",
"    </a>",
"    .) &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Growth hormone is reasonably safe and effective in increasing linear growth in children who are born small for gestational age and who fail to have catch-up growth (usually defined as height &lt;-2 SDS, which corresponds to height less than the second percentile for age and gender) by early childhood [",
"    <a class=\"abstract\" href=\"UTD.htm?3/37/3672/abstract/19,23\">",
"     19,23",
"    </a>",
"    ]. Increases in short-term linear growth rates and in adult height have been shown in a variety of studies, but the treatment effect is highly variable and the potential advantages and disadvantages of treatment should be considered on a case-by-case basis.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      We suggest treatment with growth hormone in children who were SGA at birth and who have not had adequate catch-up growth (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). This suggestion assumes that the family has realistic understanding of the expected growth response and decides that this potential benefit outweighs the cost and burden of long-term treatment. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Indications'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The definition of adequate catch-up growth varies. In the United States, growth hormone is approved for use in short SGA children whose height remains less than 2 SDS below the mean for age and sex at 2 years of age [",
"      <a class=\"abstract\" href=\"UTD.htm?3/37/3672/abstract/6\">",
"       6",
"      </a>",
"      ]. In Europe, the approved indication is for short SGA children whose height is less than 2.5 SDS below the mean for age and sex at 4 years of age [",
"      <a class=\"abstract\" href=\"UTD.htm?3/37/3672/abstract/22\">",
"       22",
"      </a>",
"      ]. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Indications'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Growth hormone treatment is likely to yield only modest gains in height compared with no treatment (an increase in adult height of approximately 6 cm, provided the treatment is begun early and continued for at least seven years). Adult height will usually be below average despite therapy. When treatment is contemplated, it is critical for the provider to discuss realistic expectations with the patient and family. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Growth response'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      If treatment is chosen, we suggest beginning with doses similar to those used for treatment of growth hormone deficiency in children, approximately 40",
"      <span class=\"nowrap\">",
"       mcg/kg/day",
"      </span>",
"      based on ideal body weight. During growth hormone therapy, we readjust the growth hormone dose to maintain IGF-1 levels at approximately 1 SD above the mean. Children should be monitored for evidence of complications of the treatment. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?14/0/14345?source=see_link&amp;anchor=H6#H6\">",
"       \"Treatment of growth hormone deficiency in children\", section on 'Dosing and monitoring'",
"      </a>",
"      and",
"      <a class=\"local\" href=\"#H8\">",
"       'Dosing and administration'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H13\">",
"       'Monitoring'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Growth hormone treatment yields the greatest increases in height when treatment is initiated by mid-childhood and continued for more than seven years. Children who are younger or shorter at the beginning of therapy have the greatest response as compared to untreated children. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Growth response'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Short children born SGA are at increased risk for diabetes and cardiovascular disease when compared to children with normal birth weight. Whether treatment with growth hormone either improves or exacerbates these long-term risks has not been established. However, there appear to be no differences in the short-term risks of GH treatment in this population as compared with other children treated with growth hormone. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Safety'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/37/3672/abstract/1\">",
"      Hokken-Koelega AC, De Ridder MA, Lemmen RJ, et al. Children born small for gestational age: do they catch up? Pediatr Res 1995; 38:267.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/37/3672/abstract/2\">",
"      Hediger ML, Overpeck MD, Maurer KR, et al. Growth of infants and young children born small or large for gestational age: findings from the Third National Health and Nutrition Examination Survey. Arch Pediatr Adolesc Med 1998; 152:1225.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/37/3672/abstract/3\">",
"      Karlberg JP, Albertsson-Wikland K, Kwan EY, et al. The timing of early postnatal catch-up growth in normal, full-term infants born short for gestational age. Horm Res 1997; 48 Suppl 1:17.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/37/3672/abstract/4\">",
"      Karlberg J, Albertsson-Wikland K. Growth in full-term small-for-gestational-age infants: from birth to final height. Pediatr Res 1995; 38:733.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/37/3672/abstract/5\">",
"      Paz I, Seidman DS, Danon YL, et al. Are children born small for gestational age at increased risk of short stature? Am J Dis Child 1993; 147:337.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/37/3672/abstract/6\">",
"      Lee PA, Chernausek SD, Hokken-Koelega AC, et al. International Small for Gestational Age Advisory Board consensus development conference statement: management of short children born small for gestational age, April 24-October 1, 2001. Pediatrics 2003; 111:1253.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/37/3672/abstract/7\">",
"      Wit JM, Finken MJ, Rijken M, de Zegher F. Preterm growth restraint: a paradigm that unifies intrauterine growth retardation and preterm extrauterine growth retardation and has implications for the small-for-gestational-age indication in growth hormone therapy. Pediatrics 2006; 117:e793.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/37/3672/abstract/8\">",
"      Hindmarsh P, Brook C, Rodeck C, Nicolaides K. Hormonal levels in the human fetus between 14 and 22 weeks gestation. Early Hum Dev 1987; 15:253.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/37/3672/abstract/9\">",
"      Giudice LC, de Zegher F, Gargosky SE, et al. Insulin-like growth factors and their binding proteins in the term and preterm human fetus and neonate with normal and extremes of intrauterine growth. J Clin Endocrinol Metab 1995; 80:1548.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/37/3672/abstract/10\">",
"      de Zegher F, Bettendorf M, Kaplan SL, Grumbach MM. Hormone ontogeny in the ovine fetus: XXI. The effect of insulin-like growth factor-I on plasma fetal growth hormone, insulin and glucose concentrations. Endocrinology 1988; 123:658.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/37/3672/abstract/11\">",
"      Leger J, Noel M, Limal JM, Czernichow P. Growth factors and intrauterine growth retardation. II. Serum growth hormone, insulin-like growth factor (IGF) I, and IGF-binding protein 3 levels in children with intrauterine growth retardation compared with normal control subjects: prospective study from birth to two years of age. Study Group of IUGR. Pediatr Res 1996; 40:101.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/37/3672/abstract/12\">",
"      Deiber M, Chatelain P, Naville D, et al. Functional hypersomatotropism in small for gestational age (SGA) newborn infants. J Clin Endocrinol Metab 1989; 68:232.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/37/3672/abstract/13\">",
"      van Dijk M, Mulder P, Houdijk M, et al. High serum levels of growth hormone (GH) and insulin-like growth factor-I (IGF-I) during high-dose GH treatment in short children born small for gestational age. J Clin Endocrinol Metab 2006; 91:1390.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/37/3672/abstract/14\">",
"      I&ntilde;iguez G, Ong K, Bazaes R, et al. Longitudinal changes in insulin-like growth factor-I, insulin sensitivity, and secretion from birth to age three years in small-for-gestational-age children. J Clin Endocrinol Metab 2006; 91:4645.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/37/3672/abstract/15\">",
"      Van den Berghe G, de Zegher F, Lauwers P, Veldhuis JD. Growth hormone secretion in critical illness: effect of dopamine. J Clin Endocrinol Metab 1994; 79:1141.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/37/3672/abstract/16\">",
"      Gluckman PD, Cutfield W, Harding JE, et al. Metabolic consequences of intrauterine growth retardation. Acta Paediatr Suppl 1996; 417:3.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/37/3672/abstract/17\">",
"      Dennison E, Fall C, Cooper C, Barker D. Prenatal factors influencing long-term outcome. Horm Res 1997; 48 Suppl 1:25.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/37/3672/abstract/18\">",
"      de Zegher F, Du Caju MV, Heinrichs C, et al. Early, discontinuous, high dose growth hormone treatment to normalize height and weight of short children born small for gestational age: results over 6 years. J Clin Endocrinol Metab 1999; 84:1558.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/37/3672/abstract/19\">",
"      Clayton PE, Cianfarani S, Czernichow P, et al. Management of the child born small for gestational age through to adulthood: a consensus statement of the International Societies of Pediatric Endocrinology and the Growth Hormone Research Society. J Clin Endocrinol Metab 2007; 92:804.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/37/3672/abstract/20\">",
"      Hokken-Koelega AC, van Pareren Y, Sas T, Arends N. Final height data, body composition and glucose metabolism in growth hormone-treated short children born small for gestational age. Horm Res 2003; 60 Suppl 3:113.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/37/3672/abstract/21\">",
"      de Zegher F, Hokken-Koelega A. Growth hormone therapy for children born small for gestational age: height gain is less dose dependent over the long term than over the short term. Pediatrics 2005; 115:e458.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/37/3672/abstract/22\">",
"      Johnston LB, Savage MO. Should recombinant human growth hormone therapy be used in short small for gestational age children? Arch Dis Child 2004; 89:740.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/37/3672/abstract/23\">",
"      Chernausek SD. Treatment of short children born small for gestational age: US perspective, 2005. Horm Res 2005; 64 Suppl 2:63.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/37/3672/abstract/24\">",
"      de Zegher F, Albertsson-Wikland K, Wilton P, et al. Growth hormone treatment of short children born small for gestational age: metanalysis of four independent, randomized, controlled, multicentre studies. Acta Paediatr Suppl 1996; 417:27.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/37/3672/abstract/25\">",
"      Albanese A, Stanhope R. GH treatment induces sustained catch-up growth in children with intrauterine growth retardation: 7-year results. Horm Res 1997; 48:173.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/37/3672/abstract/26\">",
"      Boguszewski M, Albertsson-Wikland K, Aronsson S, et al. Growth hormone treatment of short children born small-for-gestational-age: the Nordic Multicentre Trial. Acta Paediatr 1998; 87:257.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/37/3672/abstract/27\">",
"      Ranke MB, Lindberg A, Cowell CT, et al. Prediction of response to growth hormone treatment in short children born small for gestational age: analysis of data from KIGS (Pharmacia International Growth Database). J Clin Endocrinol Metab 2003; 88:125.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/37/3672/abstract/28\">",
"      Van Pareren Y, Mulder P, Houdijk M, et al. Adult height after long-term, continuous growth hormone (GH) treatment in short children born small for gestational age: results of a randomized, double-blind, dose-response GH trial. J Clin Endocrinol Metab 2003; 88:3584.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/37/3672/abstract/29\">",
"      Dahlgren J, Wikland KA, Swedish Study Group for Growth Hormone Treatment. Final height in short children born small for gestational age treated with growth hormone. Pediatr Res 2005; 57:216.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/37/3672/abstract/30\">",
"      Lem AJ, van der Kaay DC, de Ridder MA, et al. Adult height in short children born SGA treated with growth hormone and gonadotropin releasing hormone analog: results of a randomized, dose-response GH trial. J Clin Endocrinol Metab 2012; 97:4096.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/37/3672/abstract/31\">",
"      Dos Santos C, Essioux L, Teinturier C, et al. A common polymorphism of the growth hormone receptor is associated with increased responsiveness to growth hormone. Nat Genet 2004; 36:720.",
"     </a>",
"    </li>",
"    <li>",
"     De Zegher F, Chatelain PG. Growth hormone treatment of short children born small for gestational age: Epianaylsis of controlled studies and clinical experience. In: Progress in Growth Hormone Therapy-10 Years of KIGS, Ranke M, Wilton P (Eds), J and J Verlag, Mannheim 1998.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/37/3672/abstract/33\">",
"      de Zegher F, Butenandt O, Chatelain P, et al. Growth hormone treatment of short children born small for gestational age: reappraisal of the rate of bone maturation over 2 years and metanalysis of height gain over 4 years. Acta Paediatr Suppl 1997; 423:207.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/37/3672/abstract/34\">",
"      Simon D, Leger J, Fjellestad-Paulsen A, et al. Intermittent recombinant growth hormone treatment in short children born small for gestational age: four-year results of a randomized trial of two different treatment regimens. Horm Res 2006; 66:118.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/37/3672/abstract/35\">",
"      Preece MA. Puberty in children with intrauterine growth retardation. Horm Res 1997; 48 Suppl 1:30.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/37/3672/abstract/36\">",
"      Kamp GA, Mul D, Waelkens JJ, et al. A randomized controlled trial of three years growth hormone and gonadotropin-releasing hormone agonist treatment in children with idiopathic short stature and intrauterine growth retardation. J Clin Endocrinol Metab 2001; 86:2969.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/37/3672/abstract/37\">",
"      Reiter EO, Lindberg A, Ranke MB, et al. The KIGS experience with the addition of gonadotropin-releasing hormone agonists to growth hormone (GH) treatment of children with idiopathic GH deficiency. Horm Res 2003; 60:68.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/37/3672/abstract/38\">",
"      Carel JC. Management of short stature with GnRH agonist and co-treatment with growth hormone: a controversial issue. Mol Cell Endocrinol 2006; 254-255:226.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/37/3672/abstract/39\">",
"      Woods KA, van Helvoirt M, Ong KK, et al. The somatotropic axis in short children born small for gestational age: relation to insulin resistance. Pediatr Res 2002; 51:76.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/37/3672/abstract/40\">",
"      Cutfield WS, Jackson WE, Jefferies C, et al. Reduced insulin sensitivity during growth hormone therapy for short children born small for gestational age. J Pediatr 2003; 142:113.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/37/3672/abstract/41\">",
"      de Zegher F, Ong K, van Helvoirt M, et al. High-dose growth hormone (GH) treatment in non-GH-deficient children born small for gestational age induces growth responses related to pretreatment GH secretion and associated with a reversible decrease in insulin sensitivity. J Clin Endocrinol Metab 2002; 87:148.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/37/3672/abstract/42\">",
"      Cutfield WS, Lindberg A, Rapaport R, et al. Safety of growth hormone treatment in children born small for gestational age: the US trial and KIGS analysis. Horm Res 2006; 65 Suppl 3:153.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/37/3672/abstract/43\">",
"      Tanaka T, Fujieda K, Yokoya S, et al. Efficacy and safety of growth hormone treatment in children born small for gestational age in Japan. J Pediatr Endocrinol Metab 2008; 21:423.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/37/3672/abstract/44\">",
"      Bachmann S, Bechtold S, Bonfig W, et al. Insulin sensitivity decreases in short children born small for gestational age treated with growth hormone. J Pediatr 2009; 154:509.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/37/3672/abstract/45\">",
"      Sas T, Mulder P, Hokken-Koelega A. Body composition, blood pressure, and lipid metabolism before and during long-term growth hormone (GH) treatment in children with short stature born small for gestational age either with or without GH deficiency. J Clin Endocrinol Metab 2000; 85:3786.",
"     </a>",
"    </li>",
"    <li>",
"     van Dijk, M. J Clin Endocrinol Metab 2006; Rapid Electronic Publication first published on Oct 24, 2006 as doi:doi:10.1210/jc.2006-1073.",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 5833 Version 7.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1105-122.72.76.133-07C7D38949-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f3_37_3672=[""].join("\n");
var outline_f3_37_3672=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H14\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      SMALL FOR GESTATIONAL AGE INFANTS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Fetal GH physiology",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      SGA children without catch-up growth",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      GROWTH HORMONE TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Indications",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Growth response",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Dosing and administration",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Safety",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Insulin resistance",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Cardiovascular risk factors",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - Long-term effects",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Monitoring",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/18/10537?source=related_link\">",
"      Causes of short stature",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/8/134?source=related_link\">",
"      Clinical features, diagnosis, and treatment of Prader-Willi syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/60/18376?source=related_link\">",
"      Diagnostic approach to short stature",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/52/18248?source=related_link\">",
"      Growth hormone treatment for idiopathic short stature",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/14/27881?source=related_link\">",
"      Growth hormone treatment in children with chronic kidney disease and postrenal transplantation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/63/14329?source=related_link\">",
"      Management of Turner syndrome (gonadal dysgenesis)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/23/9593?source=related_link\">",
"      Small for gestational age infant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/0/14345?source=related_link\">",
"      Treatment of growth hormone deficiency in children",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f3_37_3673="Overview of breast disorders in children and adolescents";
var content_f3_37_3673=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Overview of breast disorders in children and adolescents",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?3/37/3673/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?3/37/3673/contributors\">",
"     Chantay Banikarim, MD, MPH",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?3/37/3673/contributors\">",
"     Nirupama K De Silva, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?3/37/3673/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?3/37/3673/contributors\">",
"     Jan E Drutz, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?3/37/3673/contributors\">",
"     Amy B Middleman, MD, MPH, MS Ed",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?3/37/3673/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?3/37/3673/contributors\">",
"     Mary M Torchia, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?3/37/3673/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Nov 6, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Breast development during adolescence is an important marker of the transition to adulthood [",
"    <a class=\"abstract\" href=\"UTD.htm?3/37/3673/abstract/1\">",
"     1",
"    </a>",
"    ]. Abnormalities or anomalies of normal breast development can result in poor self-esteem or make the adolescent feel self-conscious, but most breast lesions in children and adolescents are otherwise benign and self-limited.",
"   </p>",
"   <p>",
"    An overview of breast disorders in children and adolescents will be presented here. Breast masses in children and adolescents, gynecomastia in male adolescents, and disorders of the breast in adult women are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/49/42776?source=see_link\">",
"     \"Overview of breast masses in children and adolescents\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/9/6294?source=see_link\">",
"     \"Epidemiology and pathogenesis of gynecomastia\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/47/27384?source=see_link\">",
"     \"Causes and evaluation of gynecomastia\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/15/24825?source=see_link\">",
"     \"Breast masses and other common breast problems\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/52/11081?source=see_link\">",
"     \"Overview of benign breast disease\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/33/8728?source=see_link\">",
"     \"Breast pain\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     BREAST DEVELOPMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The breasts start forming in the fifth week of embryonic life. They originate from endodermal elements termed mammary ridges. The mammary ridges extend from the embryonic axilla to the inguinal region, but only the area over the fourth intercostal space develops further, while the rest atrophies. Under the influence of steroid hormones during childhood growth and development, the breast buds enlarge, and glandular elements appear [",
"    <a class=\"abstract\" href=\"UTD.htm?3/37/3673/abstract/2\">",
"     2",
"    </a>",
"    ]. Adipose tissue and lactiferous ducts (lobes of the mammary gland at the tip of the nipple) grow in response to estrogens, while progesterone stimulation causes lobular growth and alveolar budding [",
"    <a class=\"abstract\" href=\"UTD.htm?3/37/3673/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Thelarche typically begins between the ages of 8 and 13 years, with an average age of onset of 10.3 years [",
"    <a class=\"abstract\" href=\"UTD.htm?3/37/3673/abstract/3\">",
"     3",
"    </a>",
"    ]. While the breast bud is one of the first signs of puberty, the estimated mean time for full breast development is 4.2 years [",
"    <a class=\"abstract\" href=\"UTD.htm?3/37/3673/abstract/4\">",
"     4",
"    </a>",
"    ]. Adolescent breast development is described according to the stages developed by Tanner in 1969 (",
"    <a class=\"graphic graphic_picture graphicRef72038 \" href=\"UTD.htm?10/43/10932\">",
"     picture 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?3/37/3673/abstract/4\">",
"     4",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/10/20649?source=see_link\">",
"     \"Breast development and morphology\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/25/1434?source=see_link\">",
"     \"Normal puberty\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     BREAST EXAMINATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;A breast examination should be included in the annual examination of all children and adolescents [",
"    <a class=\"abstract\" href=\"UTD.htm?3/37/3673/abstract/5,6\">",
"     5,6",
"    </a>",
"    ]. Examination of the newborn includes assessment of breast size, nipple position, presence of accessory nipples, and nipple discharge [",
"    <a class=\"abstract\" href=\"UTD.htm?3/37/3673/abstract/6\">",
"     6",
"    </a>",
"    ]. Asymmetric breast enlargement",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    a thin milky nipple discharge (\"witch's milk\") related to stimulation from maternal hormones can occur in both males and females. (See",
"    <a class=\"local\" href=\"#H5\">",
"     'Congenital abnormalities'",
"    </a>",
"    below and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/49/42776?source=see_link&amp;anchor=H4#H4\">",
"     \"Overview of breast masses in children and adolescents\", section on 'Neonates and infants'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Examination of the prepubertal child includes inspection and palpation of the chest wall for masses, pain, nipple discharge, and signs of premature thelarche in girls or prepubertal gynecomastia in boys. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/36/38471?source=see_link&amp;anchor=H4#H4\">",
"     \"The pediatric physical examination: Chest and abdomen\", section on 'Breasts'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/5/19546?source=see_link\">",
"     \"Definition, etiology, and evaluation of precocious puberty\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The American Academy of Pediatrics Bright Futures guidelines suggest that the breasts be assessed for sexual maturity rating between the ages of 11 and 20 years; clinical breast examination becomes routine after age 20 years [",
"    <a class=\"abstract\" href=\"UTD.htm?3/37/3673/abstract/7\">",
"     7",
"    </a>",
"    ]. Clinical examination of the adolescent breast includes observation for gross abnormalities (eg, asymmetry, dimpling, color changes, etc) while the female is in the upright position. Breast palpation is performed with the patient in the supine position; the arm ipsilateral to the breast that is being examined should be placed over the patient's head [",
"    <a class=\"abstract\" href=\"UTD.htm?3/37/3673/abstract/1,6\">",
"     1,6",
"    </a>",
"    ]. The breast tissue is examined with the flat finger pads using the vertical strip method, concentric circular method, or in a clockwise fashion like the spokes on a wheel [",
"    <a class=\"abstract\" href=\"UTD.htm?3/37/3673/abstract/6\">",
"     6",
"    </a>",
"    ]. The sexual maturity rating (also called the Tanner stages) should be noted (",
"    <a class=\"graphic graphic_picture graphicRef72038 \" href=\"UTD.htm?10/43/10932\">",
"     picture 1",
"    </a>",
"    ). A complete breast examination includes palpation for axillary, supraclavicular, and infraclavicular lymphadenopathy. In addition, the areola should be compressed to assess for nipple discharge. (See",
"    <a class=\"local\" href=\"#H19\">",
"     'Nipple discharge'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Self-examination",
"    </span>",
"    &nbsp;&mdash;&nbsp;Historically experts have recommended teaching adolescents self breast exams. However, there is lack of consensus among health care providers regarding breast self-examination (BSE) for adolescent patients as the impact of performing regular BSE on rates of breast cancer diagnosis, breast cancer death, or tumor stage or size has not been proven [",
"    <a class=\"abstract\" href=\"UTD.htm?3/37/3673/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The United States Preventive Services Task Force (USPSTF) recommends against teaching breast self-examination [",
"    <a class=\"abstract\" href=\"UTD.htm?3/37/3673/abstract/8\">",
"     8",
"    </a>",
"    ]. The American College of Obstetricians and Gynecologists recommends that adolescents be taught BSE no earlier than age 19 [",
"    <a class=\"abstract\" href=\"UTD.htm?3/37/3673/abstract/9\">",
"     9",
"    </a>",
"    ]. The USPSTF clinical practice guideline for screening for breast cancer, as well as other USPSTF guidelines, can be accessed through the Web site for the",
"    <a class=\"external\" href=\"file://www.ahrq.gov/clinic/uspstfix.htm\">",
"     Agency for Healthcare Research and Quality",
"    </a>",
"    . (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/49/41754?source=see_link&amp;anchor=H41#H41\">",
"     \"Screening for breast cancer\", section on 'Screening with breast self-examination'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     CONGENITAL ABNORMALITIES",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Accessory breast tissue",
"    </span>",
"    &nbsp;&mdash;&nbsp;Accessory breast tissue is present at the time of birth in 1 percent of the population (both males and females) [",
"    <a class=\"abstract\" href=\"UTD.htm?3/37/3673/abstract/5\">",
"     5",
"    </a>",
"    ]. The terminology for accessory breast tissue depends upon the type of tissue that is present. Polymastia refers to the presence of any accessory breast tissue. Polythelia refers to supernumerary (or accessory) nipples. Although polythelia is present at birth, it may not be recognized until later in life.",
"   </p>",
"   <p>",
"    In most cases, accessory breast tissue consists of a small areola and nipple. However, glandular tissue also may be present. Accessory nipples may occur at any point along the milk line from the axilla to the groin where appropriate regression during embryonic development did not occur (",
"    <a class=\"graphic graphic_figure graphicRef61921 \" href=\"UTD.htm?4/39/4720\">",
"     figure 1",
"    </a>",
"    ); the most common site is just inferior to the normal breast (",
"    <a class=\"graphic graphic_picture graphicRef86172 \" href=\"UTD.htm?34/22/35183\">",
"     picture 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?3/37/3673/abstract/10\">",
"     10",
"    </a>",
"    ]. The most common site for polymastia is the lower axilla [",
"    <a class=\"abstract\" href=\"UTD.htm?3/37/3673/abstract/11\">",
"     11",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Some studies have suggested an association between polythelia and renal anomalies [",
"    <a class=\"abstract\" href=\"UTD.htm?3/37/3673/abstract/12\">",
"     12",
"    </a>",
"    ]; renal ultrasonography may be indicated to evaluate this possibility in children with supernumerary nipples, particularly if they have other congenital anomalies [",
"    <a class=\"abstract\" href=\"UTD.htm?3/37/3673/abstract/6\">",
"     6",
"    </a>",
"    ]. Although there is little high quality data to guide the decision, we generally suggest renal ultrasonography for patients with supernumerary nipples after a discussion of the risks and benefits. If a renal anomaly is found, pelvic imaging may be warranted since the genitourinary systems develop together during embryogenesis, and concomitant genital abnormalities may be present.",
"   </p>",
"   <p>",
"    Supernumerary nipples usually are asymptomatic [",
"    <a class=\"abstract\" href=\"UTD.htm?3/37/3673/abstract/6\">",
"     6",
"    </a>",
"    ]. Surgical removal may be indicated if the patient is concerned about her appearance. Surgical excision of polymastia also may be warranted to prevent painful swelling during pregnancy [",
"    <a class=\"abstract\" href=\"UTD.htm?3/37/3673/abstract/1\">",
"     1",
"    </a>",
"    ]",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    the rare development of fibroadenoma or tumor in accessory breast tissue [",
"    <a class=\"abstract\" href=\"UTD.htm?3/37/3673/abstract/13-16\">",
"     13-16",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/49/42776?source=see_link\">",
"     \"Overview of breast masses in children and adolescents\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Athelia and amastia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Athelia refers to the absence of a nipple. Amastia refers to the absence of breast tissue. This is a rare condition that is thought to occur from obliteration of the milk line during embryogenesis. When bilateral, it is often associated with other congenital anomalies.",
"   </p>",
"   <p>",
"    Unilateral amastia is one of the manifestations of Poland syndrome (also called Poland sequence), which consists of unilateral absence or hypoplasia of the pectoralis muscle and a variable degree of ipsilateral hand and digit anomalies, including syndactyly, brachydactyly, and oligodactyly [",
"    <a class=\"abstract\" href=\"UTD.htm?3/37/3673/abstract/17\">",
"     17",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/10/20649?source=see_link&amp;anchor=H16#H16\">",
"     \"Breast development and morphology\", section on 'Abnormalities in breast development'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/58/24490?source=see_link&amp;anchor=H16#H16\">",
"     \"Diseases of the chest wall\", section on 'Poland syndrome'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Athelia and amastia may be treated with corrective surgery. (See",
"    <a class=\"local\" href=\"#H16\">",
"     'Breast augmentation'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     ABNORMALITIES OF SIZE AND SYMMETRY",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Neonatal breast hypertrophy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Benign neonatal breast hypertrophy is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/49/42776?source=see_link&amp;anchor=H4#H4\">",
"     \"Overview of breast masses in children and adolescents\", section on 'Neonates and infants'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Small breasts",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most adolescents with bilaterally small breasts (hypomastia, micromastia) and otherwise normal sexual development (eg, typical amount and distribution of sexual hair, regular menses) are normal and deserve reassurance [",
"    <a class=\"abstract\" href=\"UTD.htm?3/37/3673/abstract/6\">",
"     6",
"    </a>",
"    ]. Underlying conditions that should be considered in girls with small breasts and abnormalities of pubertal development include hypothyroidism, ovarian failure, and androgen excess. Significant hypomastia also can be associated with connective tissue disorders, mitral valve prolapse, or previous radiation to the chest wall [",
"    <a class=\"abstract\" href=\"UTD.htm?3/37/3673/abstract/18\">",
"     18",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/2/2089?source=see_link\">",
"     \"Etiology, diagnosis, and treatment of primary amenorrhea\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/56/34697?source=see_link\">",
"     \"Etiology, diagnosis, and treatment of secondary amenorrhea\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/8/40071?source=see_link\">",
"     \"Adrenal hyperandrogenism\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Breast asymmetry",
"    </span>",
"    &nbsp;&mdash;&nbsp;Breast asymmetry (",
"    <a class=\"graphic graphic_picture graphicRef86169 \" href=\"UTD.htm?6/25/6544\">",
"     picture 3",
"    </a>",
"    ) is a common presenting complaint among adolescents. Most mature women have some degree of breast asymmetry. Asymmetry may be more pronounced between Tanner stage 2 and 4, when the breast is developing, but often improves by Tanner stage 5 (",
"    <a class=\"graphic graphic_picture graphicRef72038 \" href=\"UTD.htm?10/43/10932\">",
"     picture 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?3/37/3673/abstract/19\">",
"     19",
"    </a>",
"    ]. Despite this improvement, 25 percent of adult women have some degree of breast asymmetry [",
"    <a class=\"abstract\" href=\"UTD.htm?3/37/3673/abstract/20\">",
"     20",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Breast asymmetry also may result from unilateral limitation of breast growth related to injury of the prepubertal breast (eg, trauma, infection, surgery) [",
"    <a class=\"abstract\" href=\"UTD.htm?3/37/3673/abstract/5\">",
"     5",
"    </a>",
"    ]. In addition, the appearance of breast asymmetry may be caused by an abnormality of the rib cage or scoliosis [",
"    <a class=\"abstract\" href=\"UTD.htm?3/37/3673/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    After performing a complete breast examination to exclude mass, cyst, or abscess in the larger breast, the size of each breast should be measured and recorded annually through middle adolescence. Each breast is measured with a tape measure in the horizontal and vertical dimensions; nipple measurements also should be recorded [",
"    <a class=\"abstract\" href=\"UTD.htm?3/37/3673/abstract/21,22\">",
"     21,22",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The early adolescent patient with breast asymmetry should be reassured that her breasts are still growing and that the final degree of asymmetry cannot be determined until the breasts have fully developed, which occurs around 18 years of age. Adolescents who are self-conscious about the asymmetry should be encouraged to wear a padded brassiere or a brassiere that is padded on the smaller side (often available from stores that service mastectomy patients) to help mask the asymmetry [",
"    <a class=\"abstract\" href=\"UTD.htm?3/37/3673/abstract/1\">",
"     1",
"    </a>",
"    ]. A major difference in size can be treated with a prosthetic insert (also available from stores that service mastectomy patients).",
"   </p>",
"   <p>",
"    If annual serial measurements of the breast demonstrate no further growth, and the patient is unhappy about the discrepancy in breast size, a referral to a breast or plastic surgeon for augmentation of the smaller breast",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    reduction of the larger breast may be warranted. (See",
"    <a class=\"local\" href=\"#H16\">",
"     'Breast augmentation'",
"    </a>",
"    below and",
"    <a class=\"local\" href=\"#H17\">",
"     'Breast reduction'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Tuberous breast",
"    </span>",
"    &nbsp;&mdash;&nbsp;Tuberous breast is a variant of breast development in which the base of the breast is limited and the nipple and areola are overdeveloped (",
"    <a class=\"graphic graphic_picture graphicRef86171 \" href=\"UTD.htm?9/7/9328\">",
"     picture 4",
"    </a>",
"    ). The etiology is unknown. If the breast examination is otherwise normal, the patient may be referred for cosmetic surgery. The available surgical options vary depending on the location of the hypoplastic breast tissue.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Breast atrophy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Atrophy of breast tissue commonly occurs secondary to weight loss from chronic diseases or eating disorders. Breast size may be restored with weight gain. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/2/23593?source=see_link\">",
"     \"Eating disorders: Epidemiology, pathogenesis, clinical features, and course of illness\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Juvenile breast hypertrophy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Juvenile breast hypertrophy (also called virginal breast hypertrophy and macromastia) refers to spontaneous overgrowth of breast tissue. It is extremely uncommon. The etiology is unclear, but may be related to an abnormal response to gonadal hormones [",
"    <a class=\"abstract\" href=\"UTD.htm?3/37/3673/abstract/23\">",
"     23",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The overgrowth may be unilateral or symmetric (more common) and begins around menarche. In adolescents with juvenile breast hypertrophy, each breast may weigh several pounds (",
"    <a class=\"graphic graphic_picture graphicRef86170 \" href=\"UTD.htm?27/30/28129\">",
"     picture 5",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?3/37/3673/abstract/24\">",
"     24",
"    </a>",
"    ]. Patients often complain of receiving negative attention from others as well as having back pain and limited physical activity. During phases of rapid growth, skin changes, such as peau d'orange or necrosis, may occur. Resolution is rare [",
"    <a class=\"abstract\" href=\"UTD.htm?3/37/3673/abstract/23\">",
"     23",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The differential diagnosis for juvenile breast hypertrophy includes juvenile fibroadenoma, non-breast cancers, and phyllodes tumors [",
"    <a class=\"abstract\" href=\"UTD.htm?3/37/3673/abstract/6,23,25\">",
"     6,23,25",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/49/42776?source=see_link\">",
"     \"Overview of breast masses in children and adolescents\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Treatment is based upon the stage of the patient's growth. Progesterone or antiestrogens can be used to control breast growth [",
"    <a class=\"abstract\" href=\"UTD.htm?3/37/3673/abstract/26\">",
"     26",
"    </a>",
"    ]. After achievement of full breast development, surgery should be considered for cosmetic reasons",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    chronic back pain. Patients should be counseled that reduction mammoplasty in the appropriate adolescent with realistic expectations has a high satisfaction rate and that this surgery usually affords the ability to breast-feed in the future [",
"    <a class=\"abstract\" href=\"UTD.htm?3/37/3673/abstract/27\">",
"     27",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Surgical management",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h3\">",
"     Breast augmentation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Teenagers may seek breast augmentation for reconstructive purposes related to congenital defects (eg, amastia, severe breast asymmetry, tuberous breast) or for purely aesthetic reasons [",
"    <a class=\"abstract\" href=\"UTD.htm?3/37/3673/abstract/28\">",
"     28",
"    </a>",
"    ]. The American Society of Plastic Surgeons has developed a policy for breast augmentation in teenagers [",
"    <a class=\"abstract\" href=\"UTD.htm?3/37/3673/abstract/29\">",
"     29",
"    </a>",
"    ]. The key points of the statement are outlined below:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Candidates for purely aesthetic breast augmentation should be at least 18 years of age (by which time the breasts should be fully developed); the adolescent should have realistic expectations about the surgery and its outcome",
"     </li>",
"     <li>",
"      Adolescents undergoing breast augmentation should understand the risks of the procedure (infection, bleeding, breast pain, implant leakage, rupture, wrinkling of the skin, permanent scarring, development of scar tissue around the implant, changes in nipple and breast sensation, and possible alteration in breast-feeding ability) [",
"      <a class=\"abstract\" href=\"UTD.htm?3/37/3673/abstract/30\">",
"       30",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Parental consent is required if breast augmentation is performed in a patient who is younger than 18 years of age",
"     </li>",
"     <li>",
"      Breast augmentation should be performed only by board-certified surgeons",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Resources for teenagers seeking breast augmentation surgery for aesthetic purposes are available from the",
"    <a class=\"external\" href=\"file://www.fda.gov/medicaldevices/productsandmedicalprocedures/implantsandprosthetics/breastimplants/default.htm\">",
"     United States Food and Drug Administration",
"    </a>",
"    .",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h3\">",
"     Breast reduction",
"    </span>",
"    &nbsp;&mdash;&nbsp;Potential indications for breast reduction in adolescents include juvenile breast hypertrophy, breast asymmetry, or large breasts that are debilitating to the adolescent [",
"    <a class=\"abstract\" href=\"UTD.htm?3/37/3673/abstract/28,31,32\">",
"     28,31,32",
"    </a>",
"    ]. Surgical therapy for gynecomastia is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/47/760?source=see_link&amp;anchor=H15#H15\">",
"     \"Management of gynecomastia\", section on 'Surgery'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    As with breast augmentation surgery, it is important that breast growth be complete, that the patient have a stable psychosocial history, and that the patient and her parents understand the risks and benefits of the procedure before surgery is undertaken [",
"    <a class=\"abstract\" href=\"UTD.htm?3/37/3673/abstract/31,33\">",
"     31,33",
"    </a>",
"    ]. Risks of breast reduction surgery include bleeding, infection, incisional separation, fat necrosis, scarring, loss of sensation in the",
"    <span class=\"nowrap\">",
"     breast/nipple,",
"    </span>",
"    and possible inability to lactate [",
"    <a class=\"abstract\" href=\"UTD.htm?3/37/3673/abstract/33\">",
"     33",
"    </a>",
"    ]. Breast reduction leaves many of the mammary ducts intact, so nursing is possible; however the capacity for milk production may be reduced. Long-term satisfaction appears to be high; 94 percent of patients contacted 1 to 20 years after reduction mammoplasty at age &lt;20 years would recommend the procedure to a friend with macromastia [",
"    <a class=\"abstract\" href=\"UTD.htm?3/37/3673/abstract/34\">",
"     34",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Adolescent patients who undergo breast reduction surgery should have a mammogram when breast scarring has stabilized (approximately one year after surgery) [",
"    <a class=\"abstract\" href=\"UTD.htm?3/37/3673/abstract/31\">",
"     31",
"    </a>",
"    ]. This establishes a baseline to avoid future confusion between carcinoma and scarring.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h1\">",
"     BREAST PAIN",
"    </span>",
"    &nbsp;&mdash;&nbsp;Breast pain (also called mastalgia or mastodynia) may occur in early pregnancy, during exercise, or premenstrually in association with fibrocystic changes. Information from the history can help to identify factors contributing to breast pain so that appropriate management can be undertaken. Important questions include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Is the pain cyclic, specifically occurring shortly before menstruation? In the absence of other findings, cyclic and poorly localized mastalgia may be considered to be the severe end of the spectrum of physiologic swelling. Treatment entails reassurance, a supportive brassiere, and analgesia [",
"      <a class=\"abstract\" href=\"UTD.htm?3/37/3673/abstract/33\">",
"       33",
"      </a>",
"      ]. Oral contraceptive pills have been shown to improve symptoms in a majority of females and can be used in adolescents [",
"      <a class=\"abstract\" href=\"UTD.htm?3/37/3673/abstract/5\">",
"       5",
"      </a>",
"      ]. In adult females,",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?5/11/5301?source=see_link\">",
"       danazol",
"      </a>",
"      and",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?42/6/43111?source=see_link\">",
"       tamoxifen",
"      </a>",
"      also have been effective, but these drugs have not been studied in adolescents. We suggest treatment with",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?7/48/7946?source=see_link\">",
"       ibuprofen",
"      </a>",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      oral contraceptive pills for adolescents [",
"      <a class=\"abstract\" href=\"UTD.htm?3/37/3673/abstract/35\">",
"       35",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Is the pain worse when caffeine is consumed? If so, limiting caffeine intake may provide relief for some patients, even though controlled studies have failed to demonstrate an association between caffeine and mastalgia [",
"      <a class=\"abstract\" href=\"UTD.htm?3/37/3673/abstract/36-38\">",
"       36-38",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Does the patient have large breasts, and if so, does she engage in vigorous physical activity? Adolescents with large breasts who are physically active may have pain related to stretching of Cooper's ligaments (fibrous bands between the skin and the pectoral fascia). They may obtain some relief by using a sports brassiere [",
"      <a class=\"abstract\" href=\"UTD.htm?3/37/3673/abstract/20\">",
"       20",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Is the breast pain localized or generalized? Focal tenderness may be suggestive of a tender cyst, rupture through the wall of an ectatic duct, or a particularly tender area of breast nodularity; focal tenderness also may be related to poorly fitting underwire bras; acute enlargement of cysts and periductal masses may cause severe localized pain with sudden onset [",
"      <a class=\"abstract\" href=\"UTD.htm?3/37/3673/abstract/39\">",
"       39",
"      </a>",
"      ]. Cyclic pain is usually generalized or poorly localized.",
"     </li>",
"     <li>",
"      Has the patient recently started oral contraception? Symptoms related to oral contraception typically improve within the first few months after initiation. If they do not, the practitioner and patient may have to reconsider the risks and benefits of continuing the medication. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?38/7/39034?source=see_link&amp;anchor=H2#H2\">",
"       \"Risks and side effects associated with estrogen-progestin contraceptives\", section on 'Side effects'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Is the patient taking any medications or using illicit substances? Mastalgia has been associated with certain drugs (eg,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?16/35/16950?source=see_link\">",
"       reserpine",
"      </a>",
"      , phenothiazines, exogenous hormones, and marijuana) [",
"      <a class=\"abstract\" href=\"UTD.htm?3/37/3673/abstract/5\">",
"       5",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Examination of the breasts and regional lymph nodes may reveal cysts, abscesses, or localized inflammation [",
"    <a class=\"abstract\" href=\"UTD.htm?3/37/3673/abstract/35\">",
"     35",
"    </a>",
"    ]. Palpation of the chest wall can help to identify extramammary causes of chest pain, such as inflammation of the costochondral junctions (Tietze's syndrome) [",
"    <a class=\"abstract\" href=\"UTD.htm?3/37/3673/abstract/35,39\">",
"     35,39",
"    </a>",
"    ]. Other causes of extramammary chest pain include cervical root syndromes, lung disease, and gallstones [",
"    <a class=\"abstract\" href=\"UTD.htm?3/37/3673/abstract/40\">",
"     40",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/9/2201?source=see_link&amp;anchor=H11#H11\">",
"     \"Major causes of musculoskeletal chest pain\", section on 'Tietze's syndrome'",
"    </a>",
"    .).",
"   </p>",
"   <p>",
"    Laboratory evaluation is usually not necessary. A pregnancy test should be performed if pregnancy is a possibility [",
"    <a class=\"abstract\" href=\"UTD.htm?3/37/3673/abstract/35\">",
"     35",
"    </a>",
"    ]. Ultrasonography to determine whether the mass is cystic or solid may be warranted if a mass is detected. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/49/42776?source=see_link\">",
"     \"Overview of breast masses in children and adolescents\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Treatment is geared toward removing the underlying cause.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h1\">",
"     NIPPLE DISCHARGE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Nipple discharge is uncommon in children and adolescents, and most cases are associated with benign lesions [",
"    <a class=\"abstract\" href=\"UTD.htm?3/37/3673/abstract/6,11\">",
"     6,11",
"    </a>",
"    ]. Nipple discharge in adult women is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/23/3449?source=see_link\">",
"     \"Nipple discharge\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    When a pediatric patient presents complaining of nipple discharge, it is important to attempt to express the fluid from the breast and to culture it. The appearance of the fluid (milky, purulent, serous, etc) helps to determine the potential cause and subsequent evaluation [",
"    <a class=\"abstract\" href=\"UTD.htm?3/37/3673/abstract/6,11\">",
"     6,11",
"    </a>",
"    ]. In addition, nipple discharge should be differentiated from areolar secretions. (See",
"    <a class=\"local\" href=\"#H21\">",
"     'Differential diagnosis'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Clinical evaluation",
"    </span>",
"    &nbsp;&mdash;&nbsp;The evaluation should determine whether the discharge is spontaneous or provoked by manipulation of the breast and whether it is unilateral or bilateral. A nipple discharge may occur during milk production (lactation) after childbirth, or as a result of mechanical stimulation of the nipple by fondling or sucking, or due to irritation from clothing. Cancers generally present with spontaneous (rather than provoked) grossly bloody discharge arising from a single duct and are exceedingly rare in children and adolescents [",
"    <a class=\"abstract\" href=\"UTD.htm?3/37/3673/abstract/39\">",
"     39",
"    </a>",
"    ]. Children and adolescents with spontaneous nipple discharge without an obvious cause should be referred to an appropriate specialist (eg, pediatric endocrinologist, pediatric gynecologist) [",
"    <a class=\"abstract\" href=\"UTD.htm?3/37/3673/abstract/40\">",
"     40",
"    </a>",
"    ]. Bilateral nipple discharge is essentially always due to an endocrinologic or physiologic process.",
"   </p>",
"   <p>",
"    A complete breast examination should be performed. The specific goals of the examination are to:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Elicit discharge from the nipple; the application of a warm compress and massage from the periphery of the breast toward the nipple areolar complex may facilitate detection of mammary secretion; gentle, firm pressure should be applied at the base of the areola (not on the nipple). It is important to observe whether the discharge comes from one or more ducts on the nipple; flow from one duct is more worrisome than that from multiple ducts [",
"      <a class=\"abstract\" href=\"UTD.htm?3/37/3673/abstract/39\">",
"       39",
"      </a>",
"      ]. A good light and magnifying lens can help with this identification.",
"     </li>",
"     <li>",
"      Delineate and document breast masses. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?41/49/42776?source=see_link\">",
"       \"Overview of breast masses in children and adolescents\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Note the symmetry and contour of the breasts, position of the nipples, scars, vascular pattern, skin retraction, dimpling, edema or erythema, ulceration or crusting of the nipple, and changes in skin color.",
"     </li>",
"     <li>",
"      Identify localized areas of tenderness and relate them to areas of pain noted by the woman and to other physical findings.",
"     </li>",
"     <li>",
"      Detect enlarged axillary, infraclavicular, or supraclavicular lymph nodes.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Differential diagnosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The appearance of the fluid (milky, purulent, serous, etc) helps to determine the potential cause and subsequent evaluation, as described below [",
"    <a class=\"abstract\" href=\"UTD.htm?3/37/3673/abstract/6,11\">",
"     6,11",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Milky discharge &ndash; Milky discharge is characteristic of galactorrhea, which is typically bilateral and may be caused by pregnancy, postpartum or postabortion states, hypothyroidism, hypogonadism, overstimulation from manual manipulation, certain drugs (",
"      <a class=\"graphic graphic_table graphicRef75914 \" href=\"UTD.htm?2/58/2988\">",
"       table 1",
"      </a>",
"      ), and prolactin-secreting tumors [",
"      <a class=\"abstract\" href=\"UTD.htm?3/37/3673/abstract/6,11,41\">",
"       6,11,41",
"      </a>",
"      ]. Hypothyroidism is the most common cause of galactorrhea in adolescents [",
"      <a class=\"abstract\" href=\"UTD.htm?3/37/3673/abstract/41\">",
"       41",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?21/41/22167?source=see_link\">",
"       \"Causes of hyperprolactinemia\"",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      Depending upon additional findings from the history and examination, the evaluation for galactorrhea in an adolescent may include a pregnancy test, prolactin level, thyroid function studies, luteinizing hormone, and follicular stimulating hormone [",
"      <a class=\"abstract\" href=\"UTD.htm?3/37/3673/abstract/1,6\">",
"       1,6",
"      </a>",
"      ]. If there is a question about whether the discharge is true galactorrhea, it can be sent for fat staining [",
"      <a class=\"abstract\" href=\"UTD.htm?3/37/3673/abstract/1\">",
"       1",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?18/51/19254?source=see_link\">",
"       \"Clinical manifestations and diagnosis of hyperprolactinemia\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?14/10/14503?source=see_link\">",
"       \"Clinical manifestations of hypothyroidism\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <span class=\"nowrap\">",
"       Multicolored/sticky",
"      </span>",
"      discharge &ndash; Multicolored, sticky nipple discharge associated with a cystic lesion may be associated with mammary duct ectasia, which is characterized by distension of subareolar ducts with fibrosis and inflammation [",
"      <a class=\"abstract\" href=\"UTD.htm?3/37/3673/abstract/5\">",
"       5",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?41/49/42776?source=see_link&amp;anchor=H12#H12\">",
"       \"Overview of breast masses in children and adolescents\", section on 'Mammary duct ectasia'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Purulent discharge &ndash; Purulent nipple discharge suggests an infection of the breast (eg, cellulitis or abscess) and should be sent for culture with susceptibility testing [",
"      <a class=\"abstract\" href=\"UTD.htm?3/37/3673/abstract/6\">",
"       6",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?4/36/4680?source=see_link\">",
"       \"Mastitis and breast abscess in infants, children, and adolescents\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Serous or serosanguineous discharge &ndash; Serous drainage from the nipple or areola may occur in association with excretion from Montgomery tubercles (also called Morgagni tubercles, small soft papules located around the areola) (",
"      <a class=\"graphic graphic_figure graphicRef76928 \" href=\"UTD.htm?26/62/27621\">",
"       figure 2",
"      </a>",
"      ) [",
"      <a class=\"abstract\" href=\"UTD.htm?3/37/3673/abstract/6,11\">",
"       6,11",
"      </a>",
"      ]. In girls (or boys) with Montgomery tubercles, a small subareolar lump may be palpable [",
"      <a class=\"abstract\" href=\"UTD.htm?3/37/3673/abstract/6\">",
"       6",
"      </a>",
"      ]. The management of Montgomery tubercles is discussed separately. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?41/49/42776?source=see_link&amp;anchor=H13#H13\">",
"       \"Overview of breast masses in children and adolescents\", section on 'Montgomery tubercles'",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      Serosanguineous nipple discharge also may be caused by intraductal papilloma, fibrocystic changes, or, rarely, cancer [",
"      <a class=\"abstract\" href=\"UTD.htm?3/37/3673/abstract/6\">",
"       6",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?41/49/42776?source=see_link&amp;anchor=H11#H11\">",
"       \"Overview of breast masses in children and adolescents\", section on 'Intraductal papilloma'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?41/49/42776?source=see_link&amp;anchor=H7#H7\">",
"       \"Overview of breast masses in children and adolescents\", section on 'Fibrocystic change'",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      Other causes of serosanguineous drainage include traumatic nipple erosions (\"jogger's nipple,\" which also can be grossly bloody) and eczema, both of which can be treated with nipple hygiene and warm compresses [",
"      <a class=\"abstract\" href=\"UTD.htm?3/37/3673/abstract/40\">",
"       40",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Bloody discharge &ndash; Bloody nipple discharge is rare in infants and young children [",
"      <a class=\"abstract\" href=\"UTD.htm?3/37/3673/abstract/42\">",
"       42",
"      </a>",
"      ]. The most common cause is mammary duct ectasia. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?41/49/42776?source=see_link&amp;anchor=H12#H12\">",
"       \"Overview of breast masses in children and adolescents\", section on 'Mammary duct ectasia'",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      Grossly bloody nipple discharge in adolescents may be caused by intraductal papilloma, chronic nipple irritation (eg, jogger's nipple) or cold trauma (eg, cyclist's nipple), mammary duct ectasia, chronic cystic mastitis, and, rarely, breast cancer [",
"      <a class=\"abstract\" href=\"UTD.htm?3/37/3673/abstract/1,40\">",
"       1,40",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?41/49/42776?source=see_link\">",
"       \"Overview of breast masses in children and adolescents\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?4/36/4680?source=see_link\">",
"       \"Mastitis and breast abscess in infants, children, and adolescents\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Apocrine chromhidrosis &ndash; Apocrine chromhidrosis, the secretion of colored sweat by the apocrine glands of the areola, may be confused with bloody nipple discharge [",
"      <a class=\"abstract\" href=\"UTD.htm?3/37/3673/abstract/6\">",
"       6",
"      </a>",
"      ]. Characteristically, the discharge occurs when the patient exercises or manually exerts pressure around the areola. Both cytologic examination and cultures are negative. No treatment is indicated for this condition [",
"      <a class=\"abstract\" href=\"UTD.htm?3/37/3673/abstract/43\">",
"       43",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h1\">",
"     BREAST INFECTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Breast infections in neonates, children, adolescents, and lactating women are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/49/42776?source=see_link\">",
"     \"Overview of breast masses in children and adolescents\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/15/17658?source=see_link\">",
"     \"Common problems of breastfeeding and weaning\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/28/454?source=see_link\">",
"     \"Lactational mastitis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h1\">",
"     BREAST MASSES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Breast masses in children and adolescents are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/49/42776?source=see_link\">",
"     \"Overview of breast masses in children and adolescents\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Most breast abnormalities in children and adolescents are benign and self-limited. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Breast asymmetry (",
"      <a class=\"graphic graphic_picture graphicRef86169 \" href=\"UTD.htm?6/25/6544\">",
"       picture 3",
"      </a>",
"      ) is a common finding during breast development; it persists after sexual maturity in approximately 25 percent of patients. (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Breast asymmetry'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In appropriate patients with the desire for breast surgery, breast surgery should occur after full growth is attained. Surgery should be performed only by qualified surgeons. (See",
"      <a class=\"local\" href=\"#H15\">",
"       'Surgical management'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Common causes of breast pain in adolescents include early pregnancy, fibrocystic changes, inadequate support of large breasts during exercise, certain drugs (exogenous, phenothiazines, marijuana), and breast masses. History and physical examination usually can distinguish between these etiologies. (See",
"      <a class=\"local\" href=\"#H18\">",
"       'Breast pain'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Nipple discharge is uncommon in children and adolescents; most cases are associated with benign lesions. (See",
"      <a class=\"local\" href=\"#H19\">",
"       'Nipple discharge'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/37/3673/abstract/1\">",
"      De Silva NK, Brandt ML. Disorders of the breast in children and adolescents, Part 1: Disorders of growth and infections of the breast. J Pediatr Adolesc Gynecol 2006; 19:345.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/37/3673/abstract/2\">",
"      Bock K, Duda VF, Hadji P, et al. Pathologic breast conditions in childhood and adolescence: evaluation by sonographic diagnosis. J Ultrasound Med 2005; 24:1347.",
"     </a>",
"    </li>",
"    <li>",
"     Pitts SA, Gordon CM. The physiology of puberty. In: Emans, Laufer, Goldstein's Pediatric &amp; Adolescent Gynecology, 6th, Emans SJ, Laufer MR.  (Eds), Lippincott Williams &amp; Wilkins, Philadelphia 2012. p.100.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/37/3673/abstract/4\">",
"      Marshall WA, Tanner JM. Variations in pattern of pubertal changes in girls. Arch Dis Child 1969; 44:291.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/37/3673/abstract/5\">",
"      Greydanus DE, Matytsina L, Gains M. Breast disorders in children and adolescents. Prim Care 2006; 33:455.",
"     </a>",
"    </li>",
"    <li>",
"     DiVasta AD, Weldon C, Labow BI. The breast: Examination and lesions. In: Emans, Laufer, Goldstein's Pediatric &amp; Adolescent Gynecology, 6th, Emans SJ, Laufer MR.  (Eds), Lippincott Williams &amp; Wilkins, Philadelphia 2012. p.405.",
"    </li>",
"    <li>",
"     Adolescence. In: Bright Futures: Guidelines for Health Supervision of Infants, Children, and Adolescents, 3rd ed, Hagan JF, Shaw JS, Duncan PM (Eds), American Academy of Pediatrics, Elk Grove Village, IL 2008. p.515.",
"    </li>",
"    <li>",
"     US Preventive Services Task Force. Screening for breast cancer. November 2009. www.uspreventiveservicestaskforce.org/uspstf/uspsbrca.htm (Accessed on November 29, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/37/3673/abstract/9\">",
"      American College of Obstetricians and Gynecologists Committee on Gynecologic Practice. ACOG Committee Opinion No. 483: Primary and preventive care: periodic assessments. Obstet Gynecol 2011; 117:1008.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/37/3673/abstract/10\">",
"      Dixon JM, Mansel RE. ABC of breast diseases. Congenital problems and aberrations of normal breast development and involution. BMJ 1994; 309:797.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/37/3673/abstract/11\">",
"      Templeman C, Hertweck SP. Breast disorders in the pediatric and adolescent patient. Obstet Gynecol Clin North Am 2000; 27:19.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/37/3673/abstract/12\">",
"      Ferrara P, Giorgio V, Vitelli O, et al. Polythelia: still a marker of urinary tract anomalies in children? Scand J Urol Nephrol 2009; 43:47.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/37/3673/abstract/13\">",
"      Grossl NA. Supernumerary breast tissue: historical perspectives and clinical features. South Med J 2000; 93:29.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/37/3673/abstract/14\">",
"      Aughsteen AA, Almasad JK, Al-Muhtaseb MH. Fibroadenoma of the supernumerary breast of the axilla. Saudi Med J 2000; 21:587.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/37/3673/abstract/15\">",
"      Oshida K, Miyauchi M, Yamamoto N, et al. Phyllodes tumor arising in ectopic breast tissue of the axilla. Breast Cancer 2003; 10:82.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/37/3673/abstract/16\">",
"      Martin VG, Pellettiere EV, Gress D, Miller AW. Paget's disease in an adolescent arising in a supernumerary nipple. J Cutan Pathol 1994; 21:283.",
"     </a>",
"    </li>",
"    <li>",
"     Skandalakis JE, Gray SW, Ricketts R, Skandalakis LJ. The anterior body wall. In: Embryology for Surgeons: The Embryological Basis for the Treatment of Congenital Anomalies, Skandalakis JE, Gray SW (Eds), Williams &amp; Wilkins, Baltimore 2004. p.552.",
"    </li>",
"    <li>",
"     Duflos D, Plu-Bureau G, Thibaud E, et al. Breast diseases in adolescents. In: Pediatric and Adolescent Gynecology: Evidence-Based Clinical Practice (Endocrine Development), Sultan C.  (Ed), Karger, Basel, Switzerland 2004. Vol 7, p.186.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/37/3673/abstract/19\">",
"      Eidlitz-Markus T, Mukamel M, Haimi-Cohen Y, et al. Breast asymmetry during adolescence: physiologic and non-physiologic causes. Isr Med Assoc J 2010; 12:203.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/37/3673/abstract/20\">",
"      Greydanus DE, Omar H, Pratt HD. The adolescent female athlete: current concepts and conundrums. Pediatr Clin North Am 2010; 57:697.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/37/3673/abstract/21\">",
"      Capraro VJ, Dewhurst CJ. Breast disorders in childhood and adolescence. Clin Obstet Gynecol 1975; 18:25.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/37/3673/abstract/22\">",
"      Rohn RD. Nipple (papilla) development in puberty: longitudinal observations in girls. Pediatrics 1987; 79:745.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/37/3673/abstract/23\">",
"      O'Hare PM, Frieden IJ. Virginal breast hypertrophy. Pediatr Dermatol 2000; 17:277.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/37/3673/abstract/24\">",
"      Piza-Katzer H. Reduction mammaplasty in teenagers. Aesthetic Plast Surg 2005; 29:385.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/37/3673/abstract/25\">",
"      Di Noto A, Pacheco BP, Vicala R, et al. Two cases of breast lymphoma mimicking juvenile hypertrophy. J Pediatr Adolesc Gynecol 1999; 12:33.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/37/3673/abstract/26\">",
"      Hoppe IC, Patel PP, Singer-Granick CJ, Granick MS. Virginal mammary hypertrophy: a meta-analysis and treatment algorithm. Plast Reconstr Surg 2011; 127:2224.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/37/3673/abstract/27\">",
"      Aillet S, Watier E, Chevrier S, et al. Breast feeding after reduction mammaplasty performed during adolescence. Eur J Obstet Gynecol Reprod Biol 2002; 101:79.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/37/3673/abstract/28\">",
"      DeSilva NK. Plastic surgery and the adolescent breast: preliminary patient counseling. J Pediatr Adolesc Gynecol 2010; 23:184.",
"     </a>",
"    </li>",
"    <li>",
"     American Society of Plastic Surgeons. Policy statement: Breast augmentation in teenagers. www.plasticsurgery.org/Documents/medical-professionals/health-policy/key-issues/Policy-Statement-on-Breast-Augmentation-in-Teenagers.pdf (Accessed on July 25, 2011).",
"    </li>",
"    <li>",
"     US Food and Drug Administration. Risks of breast implants www.fda.gov/MedicalDevices/ProductsandMedicalProcedures/ImplantsandProsthetics/BreastImplants/ucm064106.htm (Accessed on August 23, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/37/3673/abstract/31\">",
"      Quint E, Engelland A, Strauch B. Management quandary. Breast reduction in the adolescent. J Pediatr Adolesc Gynecol 2004; 17:147.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/37/3673/abstract/32\">",
"      Cerrato F, Webb ML, Rosen H, et al. The impact of macromastia on adolescents: a cross-sectional study. Pediatrics 2012; 130:e339.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/37/3673/abstract/33\">",
"      ACOG Committee on Adolescent Health Care. ACOG Committee Opinion No. 350, November 2006: Breast concerns in the adolescent. Obstet Gynecol 2006; 108:1329.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/37/3673/abstract/34\">",
"      McMahan JD, Wolfe JA, Cromer BA, Ruberg RL. Lasting success in teenage reduction mammaplasty. Ann Plast Surg 1995; 35:227.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/37/3673/abstract/35\">",
"      Gumm R, Cunnick GH, Mokbel K. Evidence for the management of mastalgia. Curr Med Res Opin 2004; 20:681.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/37/3673/abstract/36\">",
"      Schairer C, Brinton LA, Hoover RN. Methylxanthines and benign breast disease. Am J Epidemiol 1986; 124:603.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/37/3673/abstract/37\">",
"      Levinson W, Dunn PM. Nonassociation of caffeine and fibrocystic breast disease. Arch Intern Med 1986; 146:1773.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/37/3673/abstract/38\">",
"      Jacobson MF, Liebman BF. Caffeine and benign breast disease. JAMA 1986; 255:1438.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/37/3673/abstract/39\">",
"      Santen RJ, Mansel R. Benign breast disorders. N Engl J Med 2005; 353:275.",
"     </a>",
"    </li>",
"    <li>",
"     Baren JM. Breast lesion. In: Textbook of Pediatric Emergency Medicine, 5th ed, Fleisher GR, Ludwig S, Henretig FM (Eds), Lippincott Williams &amp; Wilkins, Philadelphia 2006. p.193.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/37/3673/abstract/41\">",
"      Rohn RD. Galactorrhea in the adolescent. J Adolesc Health Care 1984; 5:37.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/37/3673/abstract/42\">",
"      Kelly VM, Arif K, Ralston S, et al. Bloody nipple discharge in an infant and a proposed diagnostic approach. Pediatrics 2006; 117:e814.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/37/3673/abstract/43\">",
"      Saff DM, Owens R, Kahn TA. Apocrine chromhidrosis involving the areolae in a 15-year-old amateur figure skater. Pediatr Dermatol 1995; 12:48.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 102 Version 11.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1105-217.117.136.88-94DAD92080-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f3_37_3673=[""].join("\n");
var outline_f3_37_3673=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H24\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      BREAST DEVELOPMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      BREAST EXAMINATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Self-examination",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      CONGENITAL ABNORMALITIES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Accessory breast tissue",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Athelia and amastia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      ABNORMALITIES OF SIZE AND SYMMETRY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Neonatal breast hypertrophy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Small breasts",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Breast asymmetry",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Tuberous breast",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Breast atrophy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Juvenile breast hypertrophy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Surgical management",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      - Breast augmentation",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      - Breast reduction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      BREAST PAIN",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      NIPPLE DISCHARGE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Clinical evaluation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Differential diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      BREAST INFECTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      BREAST MASSES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PEDS/102\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/102|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?4/39/4720\" title=\"figure 1\">",
"      Mammary line",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?26/62/27621\" title=\"figure 2\">",
"      Nipple and breast anatomy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/102|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?10/43/10932\" title=\"picture 1\">",
"      Sexual maturity rating of breast development in girls",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?34/22/35183\" title=\"picture 2\">",
"      Supernumerary nipple",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?6/25/6544\" title=\"picture 3\">",
"      Breast asymmetry",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?9/7/9328\" title=\"picture 4\">",
"      Tuberous breast deformity",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?27/30/28129\" title=\"picture 5\">",
"      Macromastia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/102|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?2/58/2988\" title=\"table 1\">",
"      Drugs cause hyperprolactinemia",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/8/40071?source=related_link\">",
"      Adrenal hyperandrogenism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/10/20649?source=related_link\">",
"      Breast development and morphology",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/15/24825?source=related_link\">",
"      Breast masses and other common breast problems",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/33/8728?source=related_link\">",
"      Breast pain",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/47/27384?source=related_link\">",
"      Causes and evaluation of gynecomastia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/41/22167?source=related_link\">",
"      Causes of hyperprolactinemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/51/19254?source=related_link\">",
"      Clinical manifestations and diagnosis of hyperprolactinemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/10/14503?source=related_link\">",
"      Clinical manifestations of hypothyroidism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/15/17658?source=related_link\">",
"      Common problems of breastfeeding and weaning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/5/19546?source=related_link\">",
"      Definition, etiology, and evaluation of precocious puberty",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/58/24490?source=related_link\">",
"      Diseases of the chest wall",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/2/23593?source=related_link\">",
"      Eating disorders: Epidemiology, pathogenesis, clinical features, and course of illness",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/9/6294?source=related_link\">",
"      Epidemiology and pathogenesis of gynecomastia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/2/2089?source=related_link\">",
"      Etiology, diagnosis, and treatment of primary amenorrhea",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/56/34697?source=related_link\">",
"      Etiology, diagnosis, and treatment of secondary amenorrhea",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/28/454?source=related_link\">",
"      Lactational mastitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/9/2201?source=related_link\">",
"      Major causes of musculoskeletal chest pain",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/47/760?source=related_link\">",
"      Management of gynecomastia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/36/4680?source=related_link\">",
"      Mastitis and breast abscess in infants, children, and adolescents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/23/3449?source=related_link\">",
"      Nipple discharge",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/25/1434?source=related_link\">",
"      Normal puberty",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/52/11081?source=related_link\">",
"      Overview of benign breast disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/49/42776?source=related_link\">",
"      Overview of breast masses in children and adolescents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/7/39034?source=related_link\">",
"      Risks and side effects associated with estrogen-progestin contraceptives",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/49/41754?source=related_link\">",
"      Screening for breast cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/36/38471?source=related_link\">",
"      The pediatric physical examination: Chest and abdomen",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f3_37_3674="Ampullary carcinoma: Treatment and prognosis";
var content_f3_37_3674=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Ampullary carcinoma: Treatment and prognosis",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?3/37/3674/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?3/37/3674/contributors\">",
"     David P Ryan, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?3/37/3674/contributors\">",
"     Harvey Mamon, MD, PhD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?3/37/3674/contributors\">",
"     Carlos Fernandez-del Castillo, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?3/37/3674/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?3/37/3674/contributors\">",
"     Kenneth K Tanabe, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?3/37/3674/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?3/37/3674/contributors\">",
"     Diane MF Savarese, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?3/37/3674/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jul 19, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Periampullary tumors are neoplasms that arise in the vicinity of the ampulla of Vater. Neoplasms that arise in this site can originate from the pancreas, duodenum, distal common bile duct (CBD), or the structures of the ampullary complex.",
"   </p>",
"   <p>",
"    The ampulla of Vater is formed by the duodenal aspect of the sphincter of Oddi muscle, which surrounds the confluence of the distal CBD and main pancreatic duct as well as the papilla of Vater, a mucosal papillary mound at the distal insertion of these ducts on the medial wall of the duodenum (",
"    <a class=\"graphic graphic_figure graphicRef78786 \" href=\"UTD.htm?27/17/27924\">",
"     figure 1",
"    </a>",
"    ). Ampullary carcinomas are defined as those that arise within the ampullary complex, distal to the confluence of the distal common bile duct and the pancreatic duct (",
"    <a class=\"graphic graphic_figure graphicRef53240 \" href=\"UTD.htm?5/49/5908\">",
"     figure 2",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    It can be difficult to distinguish a primary ampullary carcinoma from other periampullary tumors preoperatively. However, true ampullary cancers have a better prognosis than periampullary malignancies of pancreatic or bile duct origin. Resectability rates are higher, and five-year survival rates are approximately 30 to 50 percent in patients with limited lymph node involvement. In contrast, fewer than 10 percent of patients with completely resected node-positive pancreatic cancer are alive at two years. Thus, an aggressive approach to diagnosis and treatment of periampullary tumors is needed to ensure that patients with these comparatively favorable cancers are treated optimally.",
"   </p>",
"   <p>",
"    This topic review will cover the treatment and prognosis of ampullary carcinomas. The epidemiology, biologic behavior, clinical manifestations, diagnosis and staging are covered separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/52/43848?source=see_link\">",
"     \"Ampullary carcinoma: Epidemiology, clinical manifestations, diagnosis and staging\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     TREATMENT FOR LOCALIZED DISEASE",
"    </span>",
"    &nbsp;&mdash;&nbsp;The only potentially curative treatment for ampullary carcinoma is surgical resection. Complete tumor resection with negative margins (R0 resection) is a prerequisite for cure.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Pancreaticoduodenectomy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pancreaticoduodenectomy (Whipple operation) is considered the standard approach for ampullary cancer (",
"    <a class=\"graphic graphic_figure graphicRef82519 \" href=\"UTD.htm?16/57/17303\">",
"     figure 3",
"    </a>",
"    ). This can be done as a pylorus-preserving procedure or as a conventional pancreaticoduodenectomy, which includes an antrectomy (",
"    <a class=\"graphic graphic_figure graphicRef60689 \" href=\"UTD.htm?5/43/5810\">",
"     figure 4",
"    </a>",
"    ). Although some authors claim advantages of a pylorus-preserving procedure because of a shorter operative time and less intraoperative blood loss [",
"    <a class=\"abstract\" href=\"UTD.htm?3/37/3674/abstract/1\">",
"     1",
"    </a>",
"    ], this is based on European variations of the technique which require creation of a Roux-en-Y to anastomose separately the gastric from the pancreatic and biliary anastomosis. Otherwise, there are no differences in long-term survival, and some series have shown higher incidence of delayed gastric emptying with the pylorus preservation. The impact of a pylorus-preserving procedure on long-term gastrointestinal function is less certain. Some studies suggest an improved nutritional state (as reflected by faster weight gain in the first postoperative year), but results have been inconsistent. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/34/8746?source=see_link&amp;anchor=H15#H15\">",
"     \"Surgery in the treatment of exocrine pancreatic cancer and prognosis\", section on 'Pylorus-preserving pancreaticoduodenectomy'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/44/43721?source=see_link\">",
"     \"Pancreaticoduodenectomy (Whipple procedure): Techniques\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Surgical outcomes from pancreaticoduodenectomy for ampullary cancer have improved over time. In contemporary single-institution series, rates of potentially curative resection have increased from approximately 80 to over 90 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?3/37/3674/abstract/2-6\">",
"     2-6",
"    </a>",
"    ]. Long-term survival is possible after pancreaticoduodenectomy, even for patients with lymph node metastases or invasion beyond the duodenal wall (T3 disease, (",
"    <a class=\"graphic graphic_table graphicRef77606 \" href=\"UTD.htm?39/13/40156\">",
"     table 1",
"    </a>",
"    )). (See",
"    <a class=\"local\" href=\"#H11\">",
"     'Prognosis'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Although pancreaticoduodenectomy has been associated with high perioperative morbidity and mortality rates in the past, contemporary series show that in experienced hands, perioperative (30-day) mortality rates are between 0 and 5 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?3/37/3674/abstract/2-10\">",
"     2-10",
"    </a>",
"    ]. Perioperative morbidity rates are between 20 and 40 percent, with the most common problems being pneumonia, intraabdominal infection, anastomotic (pancreatic) leak, and delayed gastric emptying [",
"    <a class=\"abstract\" href=\"UTD.htm?3/37/3674/abstract/11,12\">",
"     11,12",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H5\">",
"     'Complications'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    These improved outcomes have been attributed to better operative technique and postoperative care. One of the most important reasons for this is the greater experience of a limited number of surgeons who perform the procedure regularly in high-volume institutions [",
"    <a class=\"abstract\" href=\"UTD.htm?3/37/3674/abstract/13-15\">",
"     13-15",
"    </a>",
"    ]. Good outcomes have been described even in patients older than 80 years in such centers. However, even within high-volume hospitals, operative mortality rates from pancreaticoduodenectomy vary considerably depending upon the experience of the individual surgeon [",
"    <a class=\"abstract\" href=\"UTD.htm?3/37/3674/abstract/16\">",
"     16",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h3\">",
"     Preoperative biliary drainage",
"    </span>",
"    &nbsp;&mdash;&nbsp;The most common presenting symptom of ampullary carcinoma is obstructive jaundice (80 percent) caused by compression of the distal bile duct by the tumor. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/52/43848?source=see_link\">",
"     \"Ampullary carcinoma: Epidemiology, clinical manifestations, diagnosis and staging\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The role of preoperative biliary drainage in patients with periampullary tumors is controversial. Because obstructive jaundice can impair hepatic, renal, and immune function, it was hoped that preoperative relief of jaundice would correct these defects and decrease postoperative morbidity and mortality rates from pancreaticoduodenectomy. However, the available data from randomized trials of preoperative drainage versus no drainage are conflicting. Furthermore, three meta-analyses examining the benefit of preoperative biliary drainage for patients with obstructive jaundice have come to different conclusions, with one finding neither an adverse nor a favorable impact of preoperative stenting on the incidence of postoperative morbidity or mortality, another finding an overall adverse impact of stenting on the postoperative complication rate, and the third, significantly fewer postoperative complications in the stented group but no impact on postsurgical mortality. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/34/8746?source=see_link&amp;anchor=H5#H5\">",
"     \"Surgery in the treatment of exocrine pancreatic cancer and prognosis\", section on 'Role of biliary drainage'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In the specific setting of ampullary cancer, the benefit of preoperative biliary drainage was addressed in a retrospective series of 82 patients undergoing potentially curative surgery at a single hospital in Singapore; 35 were drained preoperatively and 47 were not [",
"    <a class=\"abstract\" href=\"UTD.htm?3/37/3674/abstract/17\">",
"     17",
"    </a>",
"    ]. Preoperative drainage was associated with a significantly reduced incidence of postoperative wound infection (3 versus 26 percent), but there was no favorable impact on other postoperative complications or survival.",
"   </p>",
"   <p>",
"    Uncertainty as to the benefit of preoperative drainage has led to differing approaches. Some surgeons routinely decompress jaundiced patients with an endoscopically placed stent prior to surgery. However, others reserve biliary decompression for selected patients in whom surgery will be delayed or those with debilitating pruritus or a clinical picture of cholangitis with fever and leucocytosis.",
"   </p>",
"   <p>",
"    In practice, the majority of patients who present with obstructive jaundice will have been stented by a gastroenterologist before the diagnosis is established and it is known whether or not the patient is a surgical candidate; the surgeon usually has little influence on the decision. For those who are not stented, our preference is to proceed with ERCP and stenting only when there is high grade jaundice (&gt;15",
"    <span class=\"nowrap\">",
"     mg/dl",
"    </span>",
"    of bilirubin) and surgery will not take place within the following week.",
"   </p>",
"   <p>",
"    The prognostic implication of obstructive jaundice at presentation on prognosis is discussed below. (See",
"    <a class=\"local\" href=\"#H15\">",
"     'Obstructive jaundice'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h3\">",
"     Complications",
"    </span>",
"    &nbsp;&mdash;&nbsp;The most frequent treatment-related complication of pancreaticoduodenectomy is pancreatic fistula, and the rates are higher for patients with ampullary cancer than for pancreas cancer because the pancreatic parenchyma is typically normal in ampullary carcinoma. Other complications include delayed gastric emptying, hemorrhage, sepsis, bile leaks, and postoperative diabetes as a result of pancreatic resection. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/44/43721?source=see_link&amp;anchor=H33#H33\">",
"     \"Pancreaticoduodenectomy (Whipple procedure): Techniques\", section on 'Complications'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Local resection",
"    </span>",
"    &nbsp;&mdash;&nbsp;Many patients with ampullary cancer are elderly and have significant comorbidities. This has generated interest in less aggressive surgical options, such as local resection or ampullectomy for selected patients.",
"   </p>",
"   <p>",
"    Experience with this approach is limited to small published series, in which most of the patients were considered high-risk candidates for surgery [",
"    <a class=\"abstract\" href=\"UTD.htm?3/37/3674/abstract/2,18-28\">",
"     2,18-28",
"    </a>",
"    ]. Comparison of these studies with each other is limited by different eligibility criteria for ampullectomy and the fact that the extent of surgery (eg, \"ampullectomy\" versus \"local resection\") has not always been clearly specified.",
"   </p>",
"   <p>",
"    In the aggregate, the available data indicate that local resection is associated with lower morbidity than pancreaticoduodenectomy, but at the expense of higher recurrence rates and inferior survival, at least in the setting of invasive disease [",
"    <a class=\"abstract\" href=\"UTD.htm?3/37/3674/abstract/11,21,23,29-33\">",
"     11,21,23,29-33",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The largest series included 37 patients who were planned for ampullectomy rather than pancreaticoduodenectomy at Memorial Sloan-Kettering Cancer Center because of significant comorbidity or a small ampullary lesion (median 1.5 cm, range 0.4 to 4.2 cm) that was thought to represent a benign adenoma after a preoperative biopsy [",
"    <a class=\"abstract\" href=\"UTD.htm?3/37/3674/abstract/31\">",
"     31",
"    </a>",
"    ]. Intraoperatively, eight cases were converted from ampullectomy to pancreaticoduodenectomy because of disease extent or a frozen-section finding of invasive tumor. Eight of the 29 patients treated by ampullectomy alone had invasive tumor on the final histology; seven recurred, and only one was alive at last follow-up. In contrast, of the 91 patients undergoing pancreaticoduodenectomy during the same time period for invasive adenocarcinoma, 68 were still alive at the end of the study period, 49 without recurrence.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     Early, low-grade tumors",
"    </span>",
"    &nbsp;&mdash;&nbsp;In contrast to pancreaticoduodenectomy, ampullectomy does not accomplish removal of the regional lymph nodes. Because of the low rate of nodal metastases (less than 4 percent in most series), some have suggested that local resection is a reasonable approach for well-differentiated small (&lt;6 mm) tumors that do not penetrate through the ampullary musculature (ie, Tis, T1, (",
"    <a class=\"graphic graphic_table graphicRef77606 \" href=\"UTD.htm?39/13/40156\">",
"     table 1",
"    </a>",
"    )) [",
"    <a class=\"abstract\" href=\"UTD.htm?3/37/3674/abstract/28,34-37\">",
"     28,34-37",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    However, the majority of the patients reported in these series had ampullary adenomas, and few had carcinomas. A major concern is the inferior cancer-specific survival following local resection of small ampullary invasive carcinomas in the analysis from Sloan-Kettering described above [",
"    <a class=\"abstract\" href=\"UTD.htm?3/37/3674/abstract/35\">",
"     35",
"    </a>",
"    ]. Furthermore, in other series, 45 percent of patients with pathologically confirmed T1 invasive ampullary adenocarcinomas had lymph node metastases [",
"    <a class=\"abstract\" href=\"UTD.htm?3/37/3674/abstract/38\">",
"     38",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Thus, while local ampullary excision could be considered for high-risk patients with well-differentiated T1 ampullary cancers that are less than 6 mm based on endoscopic ultrasound (EUS), a more aggressive surgical approach is preferred by most surgeons for invasive tumors, including well-differentiated T1 lesions, as long as the patient is a reasonable candidate for pancreaticoduodenectomy.",
"   </p>",
"   <p>",
"    In our view, local resection (ampullectomy with lymph node sampling) is a reasonable alternative to pancreaticoduodenectomy for selected patients with noninvasive (pTis) tumors (",
"    <a class=\"graphic graphic_table graphicRef77606 \" href=\"UTD.htm?39/13/40156\">",
"     table 1",
"    </a>",
"    ). However, pancreaticoduodenectomy is preferred for any invasive adenocarcinoma, if the patient can tolerate this approach.",
"   </p>",
"   <p>",
"    Recommendations for management of ampullary carcinoma are not included in published guidelines from either the National Comprehensive Cancer Network (NCCN) [",
"    <a class=\"abstract\" href=\"UTD.htm?3/37/3674/abstract/39\">",
"     39",
"    </a>",
"    ] or the European Society for Medical Oncology (ESMO) [",
"    <a class=\"abstract\" href=\"UTD.htm?3/37/3674/abstract/40\">",
"     40",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Minimally-invasive nonsurgical therapies",
"    </span>",
"    &nbsp;&mdash;&nbsp;Minimally invasive nonsurgical therapies for ampullary carcinoma include endoscopic snare resection, Nd:YAG laser ablation, and photodynamic therapy. The literature on these techniques in the setting of ampullary carcinoma is limited to single-case reports and small series.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Endoscopic snare resection (papillectomy) is an effective means of treating ampullary adenomas. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?13/36/13897?source=see_link\">",
"       \"Treatment of ampullary adenomas\"",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      Endoscopic papillectomy has been attempted in early stage (Tis, T1) well differentiated ampullary cancers without angiolymphatic invasion [",
"      <a class=\"abstract\" href=\"UTD.htm?3/37/3674/abstract/35\">",
"       35",
"      </a>",
"      ]. However, acceptance of this method for definitive treatment is hampered by the inadequacy of biopsy in terms of correct pathologic characterization of the lesion (and therefore its risk of harboring lymph node metastases) and the inability to predict successful, margin-negative endoscopic resection [",
"      <a class=\"abstract\" href=\"UTD.htm?3/37/3674/abstract/20,41-44\">",
"       20,41-44",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      Endoscopic debulking has been used mainly preoperatively to permit stent insertion and decompression of the biliary tree. The controversy surrounding the need for preoperative biliary decompression is discussed above (see",
"      <a class=\"local\" href=\"#H4\">",
"       'Preoperative biliary drainage'",
"      </a>",
"      above).",
"     </li>",
"     <li>",
"      Laser ablation offers the potential for control of local tumor growth in patients who are unfit for more aggressive therapy. In one such series of 12 patients with ampullary cancer, duodenal obstruction was relieved in one, and the longest survival was 36 months (median 21 months) [",
"      <a class=\"abstract\" href=\"UTD.htm?3/37/3674/abstract/45\">",
"       45",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Compared with laser ablation, photodynamic therapy (PDT) eradicates local tumor with less surrounding tissue destruction. PDT uses a photosensitizing drug (a hematoporphyrin derivative, Photofrin&reg;), which is disproportionately retained by malignant tissue after intravenous administration. Irradiation with visible light via a light-transmitting catheter (light-guide) placed through an endoscope and targeted at the tumor energizes the photosensitizing molecule within the tumor and catalyzes oxygen free-radical generation leading to cell death [",
"      <a class=\"abstract\" href=\"UTD.htm?3/37/3674/abstract/46\">",
"       46",
"      </a>",
"      ]. The major side effect of PDT is prolonged cutaneous photosensitivity after the procedure, requiring the patient to avoid sunlight and wear appropriate clothing to protect the skin for several weeks after treatment. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?25/27/26039?source=see_link\">",
"       \"Photodynamic therapy for ablation of Barrett's esophagus\"",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      In the largest series of PDT involving 10 patients with ampullary cancer, remission was achieved for 8 to 12 months in three who had small tumors confined to the ampulla [",
"      <a class=\"abstract\" href=\"UTD.htm?3/37/3674/abstract/47\">",
"       47",
"      </a>",
"      ]. Tumor bulk was greatly reduced in four additional patients, while little effect was observed in the remaining three.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Summary",
"    </span>",
"    &nbsp;&mdash;&nbsp;While potentially curative in the setting of ampullary adenomas, all three modalities of nonsurgical treatment provide palliative rather than curative benefit for patients with ampullary carcinoma. These methods are appropriate only for patients who are not operative candidates and those who refuse surgery.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     PROGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The outcome of resected ampullary cancer depends upon the extent of local invasion, status of the surgical margins, and the presence or absence of nodal metastases [",
"    <a class=\"abstract\" href=\"UTD.htm?3/37/3674/abstract/5,11,48-50\">",
"     5,11,48-50",
"    </a>",
"    ]. Five-year survival rates following pancreaticoduodenectomy range from 64 to 80 percent for patients with node-negative disease, and from 17 to 50 percent for node-positive disease [",
"    <a class=\"abstract\" href=\"UTD.htm?3/37/3674/abstract/2,4,7-11,13,18,29,30,51-56\">",
"     2,4,7-11,13,18,29,30,51-56",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Five-year overall survival in one retrospective single-institution series, stratified according to surgical stage (",
"    <a class=\"graphic graphic_table graphicRef77606 \" href=\"UTD.htm?39/13/40156\">",
"     table 1",
"    </a>",
"    ) was as follows [",
"    <a class=\"abstract\" href=\"UTD.htm?3/37/3674/abstract/11\">",
"     11",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Stage I &ndash; 84 percent",
"     </li>",
"     <li>",
"      Stage II &ndash; 70 percent",
"     </li>",
"     <li>",
"      Stage III &ndash; 27 percent",
"     </li>",
"     <li>",
"      Stage IV &ndash; 0 percent",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    About two-thirds of patients surviving five years after pancreaticoduodenectomy for ampullary carcinoma are also alive at 10 years [",
"    <a class=\"abstract\" href=\"UTD.htm?3/37/3674/abstract/57\">",
"     57",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Outcomes tend to be somewhat worse in population-based analyses. As an example, five-year survival rates stratified by stage at presentation from a series of 1301 patients with ampullary cancer reported to the National Cancer Institute SEER (Surveillance, Epidemiology and End Results) database between 1988 and 2003 are presented in the table (",
"    <a class=\"graphic graphic_table graphicRef76691 \" href=\"UTD.htm?1/32/1548\">",
"     table 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?3/37/3674/abstract/50\">",
"     50",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    These survival data are better than similar presentations for pancreatic cancer, particularly for those with node-positive disease. It is unclear whether this represents a true difference in biology or earlier presentation of ampullary cancers due to earlier biliary obstruction. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/52/43848?source=see_link&amp;anchor=H2#H2\">",
"     \"Ampullary carcinoma: Epidemiology, clinical manifestations, diagnosis and staging\", section on 'Epidemiology and biologic behavior'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Prognostic factors",
"    </span>",
"    &nbsp;&mdash;&nbsp;The following sections will summarize the available data on predictors of recurrence.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     Histology",
"    </span>",
"    &nbsp;&mdash;&nbsp;In addition to depth of tumor invasion (the T stage, (",
"    <a class=\"graphic graphic_table graphicRef77606 \" href=\"UTD.htm?39/13/40156\">",
"     table 1",
"    </a>",
"    )), high-grade histology and positive surgical margins are associated with a worse prognosis [",
"    <a class=\"abstract\" href=\"UTD.htm?3/37/3674/abstract/2,6,9,11,18,54,55,58-64\">",
"     2,6,9,11,18,54,55,58-64",
"    </a>",
"    ]. The incidence of positive margins is low (3 percent in one series [",
"    <a class=\"abstract\" href=\"UTD.htm?3/37/3674/abstract/6\">",
"     6",
"    </a>",
"    ]), particularly when compared to the incidence of positive margins in resected pancreatic adenocarcinoma (40 percent in the same series).",
"   </p>",
"   <p>",
"    Whether there is a correlation between prognosis and morphologic type (ie, intestinal versus pancreaticobiliary) is unclear; the available data are conflicting, with some suggesting no difference, and others, a worse prognosis for the pancreaticobiliary type [",
"    <a class=\"abstract\" href=\"UTD.htm?3/37/3674/abstract/65,66\">",
"     65,66",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h3\">",
"     Nodal metastases",
"    </span>",
"    &nbsp;&mdash;&nbsp;The presence of nodal involvement portends a worse prognosis. However, among patients with nodal metastases, the number of affected nodes, particularly compared to the total number of examined nodes, is also of prognostic importance [",
"    <a class=\"abstract\" href=\"UTD.htm?3/37/3674/abstract/6,60,67-69\">",
"     6,60,67-69",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a report of 66 patients undergoing resection for an ampullary cancer, five-year survival rates were similar among the 13 patients with two or fewer positive lymph nodes and the 38 with node-negative disease (approximately 50 percent) [",
"      <a class=\"abstract\" href=\"UTD.htm?3/37/3674/abstract/60\">",
"       60",
"      </a>",
"      ]. In contrast, none of the 15 patients with three or more involved nodes remained alive beyond 28 months.",
"     </li>",
"     <li>",
"      The number of involved nodes divided by the total number of examined nodes is referred to as the lymph node ratio (LNR). One study evaluated the utility of using the LNR for predicting recurrence and survival in 90 patients who underwent resection of ampullary carcinoma [",
"      <a class=\"abstract\" href=\"UTD.htm?3/37/3674/abstract/67\">",
"       67",
"      </a>",
"      ]. The median number of resected nodes was 16, and patients with 16 or more examined nodes had a significantly lower recurrence rate and better five-year survival (81 versus 45 percent) than patients whose pathology material contained 16 or fewer nodes.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Five-year survival was also predicted by the LNR:",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      LNR=0 &ndash; 75 percent",
"     </li>",
"     <li>",
"      LNR &gt;0 to &le;0.2 &ndash; 49 percent",
"     </li>",
"     <li>",
"      LNR &gt;0.2 to &le;0.4 &ndash; 38 percent",
"     </li>",
"     <li>",
"      LNR &gt;0.4 &ndash; 0 percent",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In contrast to other GI tumor sites, the number of lymph nodes does not influence N stage (",
"    <a class=\"graphic graphic_table graphicRef77606 \" href=\"UTD.htm?39/13/40156\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?3/37/3674/abstract/70\">",
"     70",
"    </a>",
"    ]. The implications of these data on the extent of lymph node dissection (ie, whether there is a role for extended lymphadenectomy) are unclear. A prospective, randomized study of 62 patients who underwent resection of ampullary carcinoma found no difference in the five-year survival in the group undergoing standard versus extended lymphadenectomy (56 versus 60 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?3/37/3674/abstract/71\">",
"     71",
"    </a>",
"    ]. The authors concluded that the added morbidity of extended lymphadenectomy could not be justified by the better oncologic outcomes. We agree with this conclusion, and do not routinely perform extended lymphadenectomy in these patients. The surgeon and pathologist should aim to dissect and analyze at least 12 lymph nodes.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h3\">",
"     Obstructive jaundice",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients who present with obstructive jaundice tend to have a worse prognosis. In one study, five- and ten-year survival rates were 70 and 49 percent, respectively, in patients who did not present with obstructive jaundice versus 34 and 29 percent, respectively, in patients who were jaundiced at presentation [",
"    <a class=\"abstract\" href=\"UTD.htm?3/37/3674/abstract/72\">",
"     72",
"    </a>",
"    ]. These data could be interpreted as demonstrating that early detection of ampullary carcinoma prior to the onset of obstructive jaundice is associated with a better oncologic outcome. The role of preoperative biliary drainage in patients who present with obstructive jaundice is addressed above (see",
"    <a class=\"local\" href=\"#H4\">",
"     'Preoperative biliary drainage'",
"    </a>",
"    above).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h3\">",
"     Intraoperative blood transfusion",
"    </span>",
"    &nbsp;&mdash;&nbsp;In a systematic review, patients who required intraoperative transfusion of more than three units of red blood cell units had worse outcomes than those requiring less blood [",
"    <a class=\"abstract\" href=\"UTD.htm?3/37/3674/abstract/73\">",
"     73",
"    </a>",
"    ]. However, patients who require transfusion tend to be sicker as a group (or their tumors are more advanced, requiring more intraoperative dissection) than those who do not require transfusion. Therefore, the independent contribution of intraoperative blood transfusion to outcomes remains uncertain.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h3\">",
"     Tumor marker elevation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Elevated preoperative levels of the serum tumor markers CA 19-9 and CEA are associated with a poorer prognosis relative to individuals with normal values [",
"    <a class=\"abstract\" href=\"UTD.htm?3/37/3674/abstract/52,74\">",
"     52,74",
"    </a>",
"    ]. In one study, the optimal cutoff levels of CA 19-9 to stratify risk for disease recurrence was &gt;150",
"    <span class=\"nowrap\">",
"     units/mL",
"    </span>",
"    in non-jaundiced patients and &gt;300",
"    <span class=\"nowrap\">",
"     units/mL",
"    </span>",
"    in the presence of cholestasis [",
"    <a class=\"abstract\" href=\"UTD.htm?3/37/3674/abstract/74\">",
"     74",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/52/43848?source=see_link&amp;anchor=H16#H16\">",
"     \"Ampullary carcinoma: Epidemiology, clinical manifestations, diagnosis and staging\", section on 'Serum tumor markers'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Patterns of recurrence",
"    </span>",
"    &nbsp;&mdash;&nbsp;In many series, recurrences are about evenly split between locoregional recurrence and distant spread [",
"    <a class=\"abstract\" href=\"UTD.htm?3/37/3674/abstract/10,75\">",
"     10,75",
"    </a>",
"    ], although others note a predominance of distant metastases [",
"    <a class=\"abstract\" href=\"UTD.htm?3/37/3674/abstract/52,63\">",
"     52,63",
"    </a>",
"    ]. The risk factors for locoregional and distant recurrence are slightly different. This was shown in a series of 127 patients who underwent pancreaticoduodenectomy with regional lymphadenectomy for ampullary carcinoma [",
"    <a class=\"abstract\" href=\"UTD.htm?3/37/3674/abstract/10\">",
"     10",
"    </a>",
"    ]. The median time to recurrence was 11.4 months, and the risk factors for locoregional recurrence were the presence of pancreatic invasion and tumor size. In contrast, lymph node metastasis was the sole risk factor for distant recurrence. Both pancreatic invasion and lymph node involvement were significant predictors of inferior survival.",
"   </p>",
"   <p>",
"    The most common site of distant spread is the liver, but other sites include peritoneum, bone, supraclavicular lymph nodes and lung [",
"    <a class=\"abstract\" href=\"UTD.htm?3/37/3674/abstract/10,52,75\">",
"     10,52,75",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h1\">",
"     ADJUVANT THERAPY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Despite the high rate of potentially curative resections in contemporary series, more than one-half of patients die from recurrent disease, suggesting the need for effective adjuvant therapy. There are few published data to guide the use of adjuvant therapy in patients with resected ampullary cancer.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Chemoradiotherapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Benefit from postoperative chemoradiotherapy in patients with completely resected disease has been suggested in several uncontrolled series [",
"    <a class=\"abstract\" href=\"UTD.htm?3/37/3674/abstract/58,76-81\">",
"     58,76-81",
"    </a>",
"    ]. In one of the largest reports from the Mayo Clinic, 29 of 125 patients who underwent definitive surgery for an ampullary cancer received adjuvant RT with concurrent 5-FU, while the remainder received no adjuvant therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?3/37/3674/abstract/76\">",
"     76",
"    </a>",
"    ]. In multivariate analysis, lymph node status emerged as the only significant predictor of outcome. Overall survival rates at one, three, and five years in the adjuvant therapy group were 91, 54, and 48 percent, compared to 66, 22, and 11 percent in the control group. Within the high-risk node-positive subgroup (n = 54), the 24 patients who received adjuvant therapy survived significantly longer than the 30 who did not receive it.",
"   </p>",
"   <p>",
"    On the other hand, other retrospective comparisons [",
"    <a class=\"abstract\" href=\"UTD.htm?3/37/3674/abstract/82,83\">",
"     82,83",
"    </a>",
"    ], and the only phase III randomized trial that included a substantial number of patients with ampullary carcinoma have failed to show a benefit for postoperative chemoradiotherapy. In a trial from the EORTC, 218 patients with resected pancreatic or other periampullary cancers were randomly assigned to postoperative RT (40 Gy in split courses) plus concurrent 5-FU (25",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per day by continuous infusion) or observation [",
"    <a class=\"abstract\" href=\"UTD.htm?3/37/3674/abstract/84\">",
"     84",
"    </a>",
"    ]. For the 104 periampullary cancers (which included cancers of the ampulla, distal common bile duct or duodenum), there was no difference in the two-year survival rate (67 versus 63 percent) or in the incidence of locoregional recurrence in the treated patients compared to controls. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/33/22042?source=see_link&amp;anchor=H5#H5\">",
"     \"Adjuvant and neoadjuvant therapy for exocrine pancreatic cancer\", section on 'EORTC study'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Chemotherapy alone",
"    </span>",
"    &nbsp;&mdash;&nbsp;The benefit of adjuvant chemotherapy for resected ampullary adenocarcinomas was directly studied in the international ESPAC-3 trial, in which 428 patients with periampullary malignancies (297 ampullary, 96 bile duct, 35 other) were randomly assigned to one of three arms: observation alone,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/54/24423?source=see_link\">",
"     leucovorin",
"    </a>",
"    -modulated 5-FU (six courses of leucovorin 20",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    IV bolus followed by 5-FU 425",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"     ,",
"    </span>",
"    daily for five days, once per month), or single agent",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/1/31769?source=see_link\">",
"     gemcitabine",
"    </a>",
"    (1000",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    weekly for three of every four weeks for six months) [",
"    <a class=\"abstract\" href=\"UTD.htm?3/37/3674/abstract/85\">",
"     85",
"    </a>",
"    ]. A complete (R0) resection was achieved in 84 percent of patients, and 59 percent had node-positive disease.",
"   </p>",
"   <p>",
"    The use of adjuvant chemotherapy was associated with a potentially meaningful overall survival advantage but it was not statistically significant (median 43 versus 35 months, HR 0.86, 95% CI 0.66 to 1.11). Although of a greater magnitude, the difference in median survival between",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/1/31769?source=see_link\">",
"     gemcitabine",
"    </a>",
"    -treated and observed patients was still not statistically significant (median 46 versus 35 months, HR 0.77, 95% CI 0.57-1.05). However, in secondary multivariate analysis adjusting for predefined prognostic variables, there was a statistically significant survival benefit for any chemotherapy (HR for death 0.75, 95% CI 0.57-0.98) and for gemcitabine alone (HR 0.70, 95% CI 0.51-0.97). Furthermore, when the analysis was restricted to patients with ampullary cancer, those treated with gemcitabine had a median survival that was almost twice as long as those in the observation group (median 71 versus 41 months); the median survival in the",
"    <span class=\"nowrap\">",
"     FU/",
"     <a class=\"drug drug_general\" href=\"UTD.htm?23/54/24423?source=see_link\">",
"      leucovorin",
"     </a>",
"    </span>",
"    group was 57.8 months. &nbsp;",
"   </p>",
"   <p>",
"    There was no difference in overall survival between the chemotherapy arms, but grade 3 or 4 stomatitis (11 versus 0 percent) and diarrhea (14 versus 4 percent) were significantly more common with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/54/24423?source=see_link\">",
"     leucovorin",
"    </a>",
"    -modulated FU, and there were more serious adverse effects in the FU group as well. &nbsp;",
"   </p>",
"   <p>",
"    The only other randomized trial that addressed the benefit of adjuvant chemotherapy was a multicenter randomized trial from Japan that compared surgery with and without postoperative chemotherapy (two courses of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/16/38144?source=see_link\">",
"     mitomycin",
"    </a>",
"    C plus infusional 5-FU, followed by prolonged oral administration of 5-FU until tumor progression) in 508 patients with pancreaticobiliary tract cancer (56 with ampullary cancer) [",
"    <a class=\"abstract\" href=\"UTD.htm?3/37/3674/abstract/86\">",
"     86",
"    </a>",
"    ]. A significant survival benefit for adjuvant chemotherapy was seen in the patients with gallbladder cancer (5-year survival 26 versus 14 percent), but not in those with ampullary cancer (five-year survival 28 versus 34 percent in the chemotherapy and control groups, respectively).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Summary",
"    </span>",
"    &nbsp;&mdash;&nbsp;The results of clinical trials are not definitive, and there is no consensus regarding the optimal management of patients after resection of an ampullary cancer. Recommendations for management of ampullary carcinoma are not included in published guidelines from either the NCCN [",
"    <a class=\"abstract\" href=\"UTD.htm?3/37/3674/abstract/39\">",
"     39",
"    </a>",
"    ] or ESMO [",
"    <a class=\"abstract\" href=\"UTD.htm?3/37/3674/abstract/40\">",
"     40",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Many clinicians do not recommend adjuvant chemoradiotherapy or chemotherapy for resected ampullary cancers, citing the more favorable prognosis of ampullary as compared to other biliary tract cancers and the lack of data from randomized trials proving a survival advantage. However, we suggest that these patients be managed in a manner similar to the approach used for resected pancreatic cancer.",
"   </p>",
"   <p>",
"    The approach differs in Europe and in the United States. Based upon the ESPAC-1 trial [",
"    <a class=\"abstract\" href=\"UTD.htm?3/37/3674/abstract/87\">",
"     87",
"    </a>",
"    ], which showed that 5-FU-containing chemotherapy (but not chemoradiotherapy) prolongs survival in resected pancreatic cancer, results of the German CONKO trial [",
"    <a class=\"abstract\" href=\"UTD.htm?3/37/3674/abstract/88\">",
"     88",
"    </a>",
"    ] showing a survival benefit from adjuvant",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/1/31769?source=see_link\">",
"     gemcitabine",
"    </a>",
"    in the same patient population, and the report of the ESPAC-3 trial, which suggests a potentially clinically meaningful but statistically insignificant improvement in overall with adjuvant gemcitabine or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/54/24423?source=see_link\">",
"     leucovorin",
"    </a>",
"    -modulated 5-FU [",
"    <a class=\"abstract\" href=\"UTD.htm?3/37/3674/abstract/85\">",
"     85",
"    </a>",
"    ], most European clinicians use chemotherapy alone after resection of either a pancreatic or ampullary cancer. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/33/22042?source=see_link\">",
"     \"Adjuvant and neoadjuvant therapy for exocrine pancreatic cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The American approach differs with regard to chemoradiotherapy. We treat all patients with resected ampullary cancer stage IB or higher (",
"    <a class=\"graphic graphic_table graphicRef77606 \" href=\"UTD.htm?39/13/40156\">",
"     table 1",
"    </a>",
"    ) like we do those with resected pancreatic adenocarcinoma using concurrent chemoradiotherapy with infusional 5-FU. Given the risk for distant recurrence and the results from RTOG 9704 [",
"    <a class=\"abstract\" href=\"UTD.htm?3/37/3674/abstract/89\">",
"     89",
"    </a>",
"    ], combined with those from the German CONKO trial [",
"    <a class=\"abstract\" href=\"UTD.htm?3/37/3674/abstract/88\">",
"     88",
"    </a>",
"    ], we also add a course of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/1/31769?source=see_link\">",
"     gemcitabine",
"    </a>",
"    adjuvant chemotherapy to chemoradiotherapy, as we do in patients with pancreatic adenocarcinoma, although this approach remains unproven for resected ampullary tumors. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/33/22042?source=see_link\">",
"     \"Adjuvant and neoadjuvant therapy for exocrine pancreatic cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    As with pancreatic cancer, the optimal way to sequence 5-FU-based chemoradiotherapy and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/1/31769?source=see_link\">",
"     gemcitabine",
"    </a>",
"    alone is unclear. An acceptable regimen is that used in RTOG 9704, which consists of three weekly doses of gemcitabine alone (1000",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    per week), followed by chemoradiotherapy with concurrent infusional 5-FU (250",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    daily), and starting three to five weeks later, three months of single agent gemcitabine (1000",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    weekly for three of every four weeks) [",
"    <a class=\"abstract\" href=\"UTD.htm?3/37/3674/abstract/89\">",
"     89",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/33/22042?source=see_link\">",
"     \"Adjuvant and neoadjuvant therapy for exocrine pancreatic cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Initial 5-FU-based chemoradiotherapy followed by four months of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/1/31769?source=see_link\">",
"     gemcitabine",
"    </a>",
"    alone is an acceptable alternative, as is concurrent 5-FU-based chemoradiotherapy alone, an approach used for resected extrahepatic cholangiocarcinoma. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/33/25114?source=see_link\">",
"     \"Treatment of localized cholangiocarcinoma: Surgical management and adjuvant therapy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h1\">",
"     POSTTREATMENT SURVEILLANCE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Posttreatment surveillance to detect recurrent or persistent disease is performed at regular intervals, although the optimal surveillance strategy is undefined [",
"    <a class=\"abstract\" href=\"UTD.htm?3/37/3674/abstract/39\">",
"     39",
"    </a>",
"    ]. NCCN guidelines are not available. Many clinicians follow patients every six months for five years and annually thereafter. Follow-up visits usually include history and clinical examination, and serum tumor markers (typically CEA and CA 19-9). The utility of periodic CT scan of the abdomen is unclear.",
"   </p>",
"   <p>",
"    While the need for endoscopic surveillance is universally accepted, most published recommendations are similar to those reported after local resection of ampullary adenomas. A reasonable approach is surveillance endoscopy every six months for two years, then annually for an additional three to five years. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/36/13897?source=see_link\">",
"     \"Treatment of ampullary adenomas\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h1\">",
"     CHEMOTHERAPY FOR ADVANCED DISEASE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Limited data exist to guide physicians in the choice of chemotherapy, largely because of the rarity of this disease. Much of the data on chemotherapy for advanced ampullary cancer are in combined series that include patients with small bowel, pancreatic and ampullary adenocarcinomas, or more commonly, ampullary plus biliary tract cancers. However, particularly because of recent advances in treatment of advanced disease, the distinction as to whether periampullary tumors are of intestinal, biliary, or pancreatic origin is particularly important for the selection of the treatment approach. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/8/21642?source=see_link&amp;anchor=H8#H8\">",
"     \"Treatment of small bowel neoplasms\", section on 'Unresectable or metastatic disease'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/32/10761?source=see_link\">",
"     \"Systemic therapy for advanced cholangiocarcinoma\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/12/39114?source=see_link&amp;anchor=H84834598#H84834598\">",
"     \"Chemotherapy for advanced exocrine pancreatic cancer\", section on 'FOLFIRINOX'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    There is no consensus on the best management for patients with advanced ampullary carcinoma. Patients with ampullary cancer were included in the ABC trial of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/1/31769?source=see_link\">",
"     gemcitabine",
"    </a>",
"    with and without",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/51/21305?source=see_link\">",
"     cisplatin",
"    </a>",
"    , although they represented a small minority [",
"    <a class=\"abstract\" href=\"UTD.htm?3/37/3674/abstract/90\">",
"     90",
"    </a>",
"    ]. There was a significant survival advantage to the combination both in terms of progression-free and overall survival, compared to gemcitabine alone. Many consider this to represent the standard regimen for advanced ampullary as well as biliary tract cancers, although others disagree, treating these patients more like those with advanced pancreatic cancer or small bowel adenocarcinoma. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/32/10761?source=see_link&amp;anchor=H10#H10\">",
"     \"Systemic therapy for advanced cholangiocarcinoma\", section on 'Gemcitabine plus cisplatin'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/12/39114?source=see_link\">",
"     \"Chemotherapy for advanced exocrine pancreatic cancer\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/8/21642?source=see_link&amp;anchor=H8#H8\">",
"     \"Treatment of small bowel neoplasms\", section on 'Unresectable or metastatic disease'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;It can be difficult to distinguish a primary ampullary carcinoma from other periampullary tumors (mainly pancreatic carcinoma or distal cholangiocarcinoma) preoperatively. However, true ampullary cancers have a better prognosis than pancreatic head cancers or distal cholangiocarcinomas. Resectability rates are higher, and five-year survival rates are 30 to 50 percent in selected patients with limited lymph node involvement. Thus, an aggressive approach to diagnosis and treatment of periampullary tumors is needed to ensure that patients with these comparatively favorable cancers are treated optimally. (See",
"    <a class=\"local\" href=\"#H1\">",
"     'Introduction'",
"    </a>",
"    above and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/52/43848?source=see_link\">",
"     \"Ampullary carcinoma: Epidemiology, clinical manifestations, diagnosis and staging\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h2\">",
"     Primary treatment",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      We recommend pancreaticoduodenectomy rather than local resection for most patients with invasive ampullary carcinomas (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Pancreaticoduodenectomy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We suggest local ampullary excision rather than pancreaticoduodenectomy for patients with noninvasive ampullary tumors (pTis, (",
"      <a class=\"graphic graphic_table graphicRef77606 \" href=\"UTD.htm?39/13/40156\">",
"       table 1",
"      </a>",
"      ))&nbsp;(",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ).",
"      <br/>",
"      <br/>",
"      Ampullectomy is also a reasonable approach for poor surgical candidates who have a well-differentiated T1 tumor that is less than 6 mm in size (based upon endoscopic ultrasound [EUS]). However, a more aggressive surgical approach is preferred for patients who are candidates for pancreaticoduodenectomy because of better outcomes. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Local resection'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Nonsurgical treatment modalities (ie, endoscopic snare resection, laser ablation, photodynamic therapy) provide palliative rather than curative benefit for patients with ampullary carcinoma. These methods should be restricted to patients who are not operative candidates and those who refuse surgery. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Minimally-invasive nonsurgical therapies'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h2\">",
"     Adjuvant therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is no consensus regarding the optimal management of patients after resection of an ampullary adenocarcinoma. There are scant data to guide adjuvant treatment decisions, and the true benefit of such therapy remains uncertain. Nevertheless, many clinicians, including our group, treat these patients in a similar manner as those with resected pancreatic head adenocarcinomas. We offer adjuvant therapy to all patients with resected ampullary cancer stage IB or higher (",
"    <a class=\"graphic graphic_table graphicRef77606 \" href=\"UTD.htm?39/13/40156\">",
"     table 1",
"    </a>",
"    ). (See",
"    <a class=\"local\" href=\"#H19\">",
"     'Adjuvant therapy'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    The approach differs in Europe and in the United States:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Based upon the ESPAC-1 trial, which showed that 5-FU-containing chemotherapy (but not chemoradiotherapy) prolongs survival in resected pancreatic cancer, the German CONKO trial showing a survival benefit from adjuvant",
"      <a class=\"drug drug_general\" href=\"UTD.htm?31/1/31769?source=see_link\">",
"       gemcitabine",
"      </a>",
"      in the same patient population, and a preliminary report of the ESPAC-3 trial, suggesting a potentially clinically meaningful but statistically insignificant improvement in overall survival with adjuvant gemcitabine or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?23/54/24423?source=see_link\">",
"       leucovorin",
"      </a>",
"      -modulated 5-FU in ampullary cancer, most European clinicians use chemotherapy alone after resection of an ampullary neoplasm. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?21/33/22042?source=see_link\">",
"       \"Adjuvant and neoadjuvant therapy for exocrine pancreatic cancer\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      The American approach more often includes chemoradiotherapy as well as adjuvant chemotherapy. The following represents our approach to patients with resected ampullary tumors:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Eligible patients should be encouraged to enroll in clinical trials evaluating the potential benefits of chemotherapy",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      chemoradiotherapy as well as new therapies.",
"     </li>",
"     <li>",
"      Off-protocol, we suggest a combination of concurrent chemoradiotherapy and chemotherapy for patients with resected ampullary cancers stage IB or higher (",
"      <a class=\"graphic graphic_table graphicRef77606 \" href=\"UTD.htm?39/13/40156\">",
"       table 1",
"      </a>",
"      ) rather than observation alone (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). During the concurrent chemoradiotherapy portion, we prefer infusional 5-FU, and we use",
"      <a class=\"drug drug_general\" href=\"UTD.htm?31/1/31769?source=see_link\">",
"       gemcitabine",
"      </a>",
"      alone for the chemotherapy portion.",
"     </li>",
"     <li>",
"      The optimal way to sequence 5-FU-based chemoradiotherapy and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?31/1/31769?source=see_link\">",
"       gemcitabine",
"      </a>",
"      chemotherapy is unclear. An acceptable regimen is that used in the RTOG 9704 trial [",
"      <a class=\"abstract\" href=\"UTD.htm?3/37/3674/abstract/89\">",
"       89",
"      </a>",
"      ], which consists of three weekly doses of gemcitabine alone (1000",
"      <span class=\"nowrap\">",
"       mg/m",
"       <sup>",
"        2",
"       </sup>",
"      </span>",
"      per week), followed by chemoradiotherapy using concurrent infusional 5-FU. Although the RTOG trial used 250",
"      <span class=\"nowrap\">",
"       mg/m",
"       <sup>",
"        2",
"       </sup>",
"      </span>",
"      daily continuously, many clinicians, including our group, consider this too toxic and use 225",
"      <span class=\"nowrap\">",
"       mg/m",
"       <sup>",
"        2",
"       </sup>",
"      </span>",
"      daily, five days per week. Following chemoradiotherapy and starting three to five weeks later, three months of single agent gemcitabine (",
"      <a class=\"graphic graphic_table graphicRef81436 \" href=\"UTD.htm?26/2/26669\">",
"       table 3",
"      </a>",
"      ) are given. An alternative approach that is often used for pancreatic cancer is to administer all six months of chemotherapy upfront and to pursue concurrent fluoropyrimidine-based chemoradiotherapy only for patients who remain free of metastatic disease. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?21/33/22042?source=see_link&amp;anchor=H9#H9\">",
"       \"Adjuvant and neoadjuvant therapy for exocrine pancreatic cancer\", section on 'Gemcitabine-based approaches'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?33/48/34561?source=see_link\">",
"       \"Treatment protocols for hepatobiliary cancer\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h2\">",
"     Metastatic disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Distinction as to whether periampullary tumors are of intestinal, biliary, or pancreatic origin is particularly important in patients with metastatic disease as the approach differs. The optimal regimen for systemic therapy of true ampullary tumors has not been established. Based upon the results of the ABC trial, the combination of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/1/31769?source=see_link\">",
"     gemcitabine",
"    </a>",
"    plus",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/51/21305?source=see_link\">",
"     cisplatin",
"    </a>",
"    is a reasonable approach for patients who are able to tolerate it. Others use&nbsp;a single agent gemcitabine initially (",
"    <a class=\"graphic graphic_table graphicRef60330 \" href=\"UTD.htm?35/56/36749\">",
"     table 4",
"    </a>",
"    ) followed by an oxaliplatin-based regimen, or vice versa,&nbsp;in a manner similar to treatment of pancreatic cancer. (See",
"    <a class=\"local\" href=\"#H24\">",
"     'Chemotherapy for advanced disease'",
"    </a>",
"    above.)",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/37/3674/abstract/1\">",
"      Diener MK, Knaebel HP, Heukaufer C, et al. A systematic review and meta-analysis of pylorus-preserving versus classical pancreaticoduodenectomy for surgical treatment of periampullary and pancreatic carcinoma. Ann Surg 2007; 245:187.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/37/3674/abstract/2\">",
"      Allema JH, Reinders ME, van Gulik TM, et al. Results of pancreaticoduodenectomy for ampullary carcinoma and analysis of prognostic factors for survival. Surgery 1995; 117:247.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/37/3674/abstract/3\">",
"      Bettschart V, Rahman MQ, Engelken FJ, et al. Presentation, treatment and outcome in patients with ampullary tumours. Br J Surg 2004; 91:1600.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/37/3674/abstract/4\">",
"      Yeo CJ, Sohn TA, Cameron JL, et al. Periampullary adenocarcinoma: analysis of 5-year survivors. Ann Surg 1998; 227:821.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/37/3674/abstract/5\">",
"      Roberts RH, Krige JE, Bornman PC, Terblanche J. Pancreaticoduodenectomy of ampullary carcinoma. Am Surg 1999; 65:1043.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/37/3674/abstract/6\">",
"      Sommerville CA, Limongelli P, Pai M, et al. Survival analysis after pancreatic resection for ampullary and pancreatic head carcinoma: an analysis of clinicopathological factors. J Surg Oncol 2009; 100:651.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/37/3674/abstract/7\">",
"      Duffy JP, Hines OJ, Liu JH, et al. Improved survival for adenocarcinoma of the ampulla of Vater: fifty-five consecutive resections. Arch Surg 2003; 138:941.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/37/3674/abstract/8\">",
"      Brown KM, Tompkins AJ, Yong S, et al. Pancreaticoduodenectomy is curative in the majority of patients with node-negative ampullary cancer. Arch Surg 2005; 140:529.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/37/3674/abstract/9\">",
"      Howe JR, Klimstra DS, Moccia RD, et al. Factors predictive of survival in ampullary carcinoma. Ann Surg 1998; 228:87.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/37/3674/abstract/10\">",
"      Hsu HP, Yang TM, Hsieh YH, et al. Predictors for patterns of failure after pancreaticoduodenectomy in ampullary cancer. Ann Surg Oncol 2007; 14:50.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/37/3674/abstract/11\">",
"      Beger HG, Treitschke F, Gansauge F, et al. Tumor of the ampulla of Vater: experience with local or radical resection in 171 consecutively treated patients. Arch Surg 1999; 134:526.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/37/3674/abstract/12\">",
"      Yeo CJ. Pylorus-preserving pancreaticoduodenectomy. Surg Oncol Clin N Am 1998; 7:143.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/37/3674/abstract/13\">",
"      Matory YL, Gaynor J, Brennan M. Carcinoma of the ampulla of Vater. Surg Gynecol Obstet 1993; 177:366.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/37/3674/abstract/14\">",
"      Birkmeyer JD, Siewers AE, Finlayson EV, et al. Hospital volume and surgical mortality in the United States. N Engl J Med 2002; 346:1128.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/37/3674/abstract/15\">",
"      Birkmeyer JD, Warshaw AL, Finlayson SR, et al. Relationship between hospital volume and late survival after pancreaticoduodenectomy. Surgery 1999; 126:178.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/37/3674/abstract/16\">",
"      Birkmeyer JD, Stukel TA, Siewers AE, et al. Surgeon volume and operative mortality in the United States. N Engl J Med 2003; 349:2117.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/37/3674/abstract/17\">",
"      Abdullah SA, Gupta T, Jaafar KA, et al. Ampullary carcinoma: effect of preoperative biliary drainage on surgical outcome. World J Gastroenterol 2009; 15:2908.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/37/3674/abstract/18\">",
"      Monson JR, Donohue JH, McEntee GP, et al. Radical resection for carcinoma of the ampulla of Vater. Arch Surg 1991; 126:353.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/37/3674/abstract/19\">",
"      Chappuis CW, Divincenti FC, Cohn I Jr. Villous tumors of the duodenum. Ann Surg 1989; 209:593.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/37/3674/abstract/20\">",
"      Rattner DW, Fernandez-del Castillo C, Brugge WR, Warshaw AL. Defining the criteria for local resection of ampullary neoplasms. Arch Surg 1996; 131:366.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/37/3674/abstract/21\">",
"      Branum GD, Pappas TN, Meyers WC. The management of tumors of the ampulla of Vater by local resection. Ann Surg 1996; 224:621.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/37/3674/abstract/22\">",
"      Isaksson G, Ihse I, Andr&eacute;n-Sandberg A, et al. Local excision for ampullary carcinoma. An alternative treatment for patients unfit for pancreatectomy. Acta Chir Scand 1982; 148:163.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/37/3674/abstract/23\">",
"      Schlippert W, Lucke D, Anuras S, Christensen J. Carcinoma of the papilla of Vater. A review of fifty-seven cases. Am J Surg 1978; 135:763.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/37/3674/abstract/24\">",
"      Gray G, Browder W. Villous tumors of the ampulla of Vater: local resection versus pancreatoduodenectomy. South Med J 1989; 82:917.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/37/3674/abstract/25\">",
"      Sharp KW, Brandes JL. Local resection of tumors of the ampulla of Vater. Am Surg 1990; 56:214.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/37/3674/abstract/26\">",
"      Newman RJ, Pittam MR. Local excision in the treatment of carcinoma of the ampulla of Vater. J R Coll Surg Edinb 1982; 27:154.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/37/3674/abstract/27\">",
"      Kahn MB, Rush BF Jr. The overlooked technique of ampullary excision. Surg Gynecol Obstet 1989; 169:253.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/37/3674/abstract/28\">",
"      Asbun HJ, Rossi RL, Munson JL. Local resection for ampullary tumors. Is there a place for it? Arch Surg 1993; 128:515.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/37/3674/abstract/29\">",
"      Chareton B, Coiffic J, Landen S, et al. Diagnosis and therapy for ampullary tumors: 63 cases. World J Surg 1996; 20:707.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/37/3674/abstract/30\">",
"      Tarazi RY, Hermann RE, Vogt DP, et al. Results of surgical treatment of periampullary tumors: a thirty-five-year experience. Surgery 1986; 100:716.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/37/3674/abstract/31\">",
"      Roggin KK, Yeh JJ, Ferrone CR, et al. Limitations of ampullectomy in the treatment of nonfamilial ampullary neoplasms. Ann Surg Oncol 2005; 12:971.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/37/3674/abstract/32\">",
"      Lindell G, Borch K, Tingstedt B, et al. Management of cancer of the ampulla of Vater: does local resection play a role? Dig Surg 2003; 20:511.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/37/3674/abstract/33\">",
"      Grobmyer SR, Stasik CN, Draganov P, et al. Contemporary results with ampullectomy for 29 \"benign\" neoplasms of the ampulla. J Am Coll Surg 2008; 206:466.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/37/3674/abstract/34\">",
"      B&ouml;ttger TC, Boddin J, Heintz A, Junginger T. Clinicopathologic study for the assessment of resection for ampullary carcinoma. World J Surg 1997; 21:379.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/37/3674/abstract/35\">",
"      Woo SM, Ryu JK, Lee SH, et al. Feasibility of endoscopic papillectomy in early stage ampulla of Vater cancer. J Gastroenterol Hepatol 2009; 24:120.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/37/3674/abstract/36\">",
"      Yamaguchi K, Enjoji M. Carcinoma of the ampulla of vater. A clinicopathologic study and pathologic staging of 109 cases of carcinoma and 5 cases of adenoma. Cancer 1987; 59:506.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/37/3674/abstract/37\">",
"      Clary BM, Tyler DS, Dematos P, et al. Local ampullary resection with careful intraoperative frozen section evaluation for presumed benign ampullary neoplasms. Surgery 2000; 127:628.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/37/3674/abstract/38\">",
"      Hornick JR, Johnston FM, Simon PO, et al. A single-institution review of 157 patients presenting with benign and malignant tumors of the ampulla of Vater: management and outcomes. Surgery 2011; 150:169.",
"     </a>",
"    </li>",
"    <li>",
"     National Comprehensive Cancer Network (NCCN) guidelines. Available at: www.nccn.org (Accessed on May 15, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/37/3674/abstract/40\">",
"      Eckel F, Jelic S. Biliary cancer: ESMO clinical recommendation for diagnosis, treatment and follow-up. Ann Oncol 2009; 20(4 suppl):iv46.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/37/3674/abstract/41\">",
"      Kozarek RA. Endoscopic resection of ampullary neoplasms. J Gastrointest Surg 2004; 8:932.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/37/3674/abstract/42\">",
"      Boix J, Lorenzo-Z&uacute;&ntilde;iga V, Moreno de Vega V, et al. Endoscopic resection of ampullary tumors: 12-year review of 21 cases. Surg Endosc 2009; 23:45.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/37/3674/abstract/43\">",
"      Menzel J, Poremba C, Dietl KH, et al. Tumors of the papilla of Vater--inadequate diagnostic impact of endoscopic forceps biopsies taken prior to and following sphincterotomy. Ann Oncol 1999; 10:1227.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/37/3674/abstract/44\">",
"      Yamaguchi K, Enjoji M, Kitamura K. Endoscopic biopsy has limited accuracy in diagnosis of ampullary tumors. Gastrointest Endosc 1990; 36:588.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/37/3674/abstract/45\">",
"      Fowler AL, Barham CP, Britton BJ, Barr H. Laser ablation of ampullary carcinoma. Endoscopy 1999; 31:745.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/37/3674/abstract/46\">",
"      Sibata CH, Colussi VC, Oleinick NL, Kinsella TJ. Photodynamic therapy in oncology. Expert Opin Pharmacother 2001; 2:917.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/37/3674/abstract/47\">",
"      Abulafi AM, Allardice JT, Williams NS, et al. Photodynamic therapy for malignant tumours of the ampulla of Vater. Gut 1995; 36:853.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/37/3674/abstract/48\">",
"      Benhamiche AM, Jouve JL, Manfredi S, et al. Cancer of the ampulla of Vater: results of a 20-year population-based study. Eur J Gastroenterol Hepatol 2000; 12:75.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/37/3674/abstract/49\">",
"      Sellner FJ, Riegler FM, Machacek E. Implications of histological grade of tumour for the prognosis of radically resected periampullary adenocarcinoma. Eur J Surg 1999; 165:865.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/37/3674/abstract/50\">",
"      O'Connell JB, Maggard MA, Manunga J Jr, et al. Survival after resection of ampullary carcinoma: a national population-based study. Ann Surg Oncol 2008; 15:1820.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/37/3674/abstract/51\">",
"      Neoptolemos JP, Talbot IC, Shaw DC, Carr-Locke DL. Long-term survival after resection of ampullary carcinoma is associated independently with tumor grade and a new staging classification that assesses local invasiveness. Cancer 1988; 61:1403.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/37/3674/abstract/52\">",
"      Todoroki T, Koike N, Morishita Y, et al. Patterns and predictors of failure after curative resections of carcinoma of the ampulla of Vater. Ann Surg Oncol 2003; 10:1176.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/37/3674/abstract/53\">",
"      Willett CG, Warshaw AL, Convery K, Compton CC. Patterns of failure after pancreaticoduodenectomy for ampullary carcinoma. Surg Gynecol Obstet 1993; 176:33.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/37/3674/abstract/54\">",
"      Talamini MA, Moesinger RC, Pitt HA, et al. Adenocarcinoma of the ampulla of Vater. A 28-year experience. Ann Surg 1997; 225:590.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/37/3674/abstract/55\">",
"      Delcore R Jr, Connor CS, Thomas JH, et al. Significance of tumor spread in adenocarcinoma of the ampulla of Vater. Am J Surg 1989; 158:593.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/37/3674/abstract/56\">",
"      Shutze WP, Sack J, Aldrete JS. Long-term follow-up of 24 patients undergoing radical resection for ampullary carcinoma, 1953 to 1988. Cancer 1990; 66:1717.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/37/3674/abstract/57\">",
"      Yamaguchi K, Enjoji M, Tsuneyoshi M. Pancreatoduodenal carcinoma: a clinicopathologic study of 304 patients and immunohistochemical observation for CEA and CA19-9. J Surg Oncol 1991; 47:148.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/37/3674/abstract/58\">",
"      Lee JH, Whittington R, Williams NN, et al. Outcome of pancreaticoduodenectomy and impact of adjuvant therapy for ampullary carcinomas. Int J Radiat Oncol Biol Phys 2000; 47:945.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/37/3674/abstract/59\">",
"      Albores-Saavedra J, Schwartz AM, Batich K, Henson DE. Cancers of the ampulla of vater: demographics, morphology, and survival based on 5,625 cases from the SEER program. J Surg Oncol 2009; 100:598.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/37/3674/abstract/60\">",
"      Roder JD, Schneider PM, Stein HJ, Siewert JR. Number of lymph node metastases is significantly associated with survival in patients with radically resected carcinoma of the ampulla of Vater. Br J Surg 1995; 82:1693.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/37/3674/abstract/61\">",
"      Mori K, Ikei S, Yamane T, et al. Pathological factors influencing survival of carcinoma of the ampulla of Vater. Eur J Surg Oncol 1990; 16:183.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/37/3674/abstract/62\">",
"      Park JS, Yoon DS, Kim KS, et al. Factors influencing recurrence after curative resection for ampulla of Vater carcinoma. J Surg Oncol 2007; 95:286.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/37/3674/abstract/63\">",
"      Kim RD, Kundhal PS, McGilvray ID, et al. Predictors of failure after pancreaticoduodenectomy for ampullary carcinoma. J Am Coll Surg 2006; 202:112.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/37/3674/abstract/64\">",
"      Qiao QL, Zhao YG, Ye ML, et al. Carcinoma of the ampulla of Vater: factors influencing long-term survival of 127 patients with resection. World J Surg 2007; 31:137.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/37/3674/abstract/65\">",
"      Zhou H, Schaefer N, Wolff M, Fischer HP. Carcinoma of the ampulla of Vater: comparative histologic/immunohistochemical classification and follow-up. Am J Surg Pathol 2004; 28:875.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/37/3674/abstract/66\">",
"      Kim WS, Choi DW, Choi SH, et al. Clinical significance of pathologic subtype in curatively resected ampulla of vater cancer. J Surg Oncol 2012; 105:266.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/37/3674/abstract/67\">",
"      Falconi M, Crippa S, Dom&iacute;nguez I, et al. Prognostic relevance of lymph node ratio and number of resected nodes after curative resection of ampulla of Vater carcinoma. Ann Surg Oncol 2008; 15:3178.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/37/3674/abstract/68\">",
"      Sierzega M, Nowak K, Kulig J, et al. Lymph node involvement in ampullary cancer: the importance of the number, ratio, and location of metastatic nodes. J Surg Oncol 2009; 100:19.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/37/3674/abstract/69\">",
"      Sakata J, Shirai Y, Wakai T, et al. Number of positive lymph nodes independently affects long-term survival after resection in patients with ampullary carcinoma. Eur J Surg Oncol 2007; 33:346.",
"     </a>",
"    </li>",
"    <li>",
"     American Joint Committee on Cancer Staging Manual, 7th, Edge SB, Byrd DR, Compton CC, et al (Eds), Springer, New York 2010. p.235.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/37/3674/abstract/71\">",
"      Yeo CJ, Cameron JL, Lillemoe KD, et al. Pancreaticoduodenectomy with or without distal gastrectomy and extended retroperitoneal lymphadenectomy for periampullary adenocarcinoma, part 2: randomized controlled trial evaluating survival, morbidity, and mortality. Ann Surg 2002; 236:355.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/37/3674/abstract/72\">",
"      Kamisawa T, Tu Y, Egawa N, et al. Clinicopathologic features of ampullary carcinoma without jaundice. J Clin Gastroenterol 2006; 40:162.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/37/3674/abstract/73\">",
"      Yao HS, Wang Q, Wang WJ, Hu ZQ. Intraoperative allogeneic red blood cell transfusion in ampullary cancer outcome after curative pancreatoduodenectomy: a clinical study and meta-analysis. World J Surg 2008; 32:2038.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/37/3674/abstract/74\">",
"      Smith RA, Ghaneh P, Sutton R, et al. Prognosis of resected ampullary adenocarcinoma by preoperative serum CA19-9 levels and platelet-lymphocyte ratio. J Gastrointest Surg 2008; 12:1422.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/37/3674/abstract/75\">",
"      Balachandran P, Sikora SS, Kapoor S, et al. Long-term survival and recurrence patterns in ampullary cancer. Pancreas 2006; 32:390.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/37/3674/abstract/76\">",
"      Bhatia S, Miller RC, Haddock MG, et al. Adjuvant therapy for ampullary carcinomas: the Mayo Clinic experience. Int J Radiat Oncol Biol Phys 2006; 66:514.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/37/3674/abstract/77\">",
"      Mehta VK, Fisher GA, Ford JM, et al. Adjuvant chemoradiotherapy for \"unfavorable\" carcinoma of the ampulla of Vater: preliminary report. Arch Surg 2001; 136:65.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/37/3674/abstract/78\">",
"      Chakravarthy A, Abrams RA, Yeo CJ, et al. Intensified adjuvant combined modality therapy for resected periampullary adenocarcinoma: acceptable toxicity and suggestion of improved 1-year disease-free survival. Int J Radiat Oncol Biol Phys 2000; 48:1089.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/37/3674/abstract/79\">",
"      Krishnan S, Rana V, Evans DB, et al. Role of adjuvant chemoradiation therapy in adenocarcinomas of the ampulla of vater. Int J Radiat Oncol Biol Phys 2008; 70:735.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/37/3674/abstract/80\">",
"      Kim K, Chie EK, Jang JY, et al. Role of adjuvant chemoradiotherapy for ampulla of Vater cancer. Int J Radiat Oncol Biol Phys 2009; 75:436.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/37/3674/abstract/81\">",
"      Palta M, Patel P, Broadwater G, et al. Carcinoma of the ampulla of Vater: patterns of failure following resection and benefit of chemoradiotherapy. Ann Surg Oncol 2012; 19:1535.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/37/3674/abstract/82\">",
"      Sikora SS, Balachandran P, Dimri K, et al. Adjuvant chemo-radiotherapy in ampullary cancers. Eur J Surg Oncol 2005; 31:158.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/37/3674/abstract/83\">",
"      Zhou J, Hsu CC, Winter JM, et al. Adjuvant chemoradiation versus surgery alone for adenocarcinoma of the ampulla of Vater. Radiother Oncol 2009; 92:244.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/37/3674/abstract/84\">",
"      Klinkenbijl JH, Jeekel J, Sahmoud T, et al. Adjuvant radiotherapy and 5-fluorouracil after curative resection of cancer of the pancreas and periampullary region: phase III trial of the EORTC gastrointestinal tract cancer cooperative group. Ann Surg 1999; 230:776.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/37/3674/abstract/85\">",
"      Neoptolemos JP, Moore MJ, Cox TF, et al. Effect of adjuvant chemotherapy with fluorouracil plus folinic acid or gemcitabine vs observation on survival in patients with resected periampullary adenocarcinoma: the ESPAC-3 periampullary cancer randomized trial. JAMA 2012; 308:147.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/37/3674/abstract/86\">",
"      Takada T, Amano H, Yasuda H, et al. Is postoperative adjuvant chemotherapy useful for gallbladder carcinoma? A phase III multicenter prospective randomized controlled trial in patients with resected pancreaticobiliary carcinoma. Cancer 2002; 95:1685.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/37/3674/abstract/87\">",
"      Neoptolemos JP, Stocken DD, Friess H, et al. A randomized trial of chemoradiotherapy and chemotherapy after resection of pancreatic cancer. N Engl J Med 2004; 350:1200.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/37/3674/abstract/88\">",
"      Oettle H, Post S, Neuhaus P, et al. Adjuvant chemotherapy with gemcitabine vs observation in patients undergoing curative-intent resection of pancreatic cancer: a randomized controlled trial. JAMA 2007; 297:267.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/37/3674/abstract/89\">",
"      Regine WF, Winter KA, Abrams RA, et al. Fluorouracil vs gemcitabine chemotherapy before and after fluorouracil-based chemoradiation following resection of pancreatic adenocarcinoma: a randomized controlled trial. JAMA 2008; 299:1019.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?3/37/3674/abstract/90\">",
"      Valle J, Wasan H, Palmer DH, et al. Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer. N Engl J Med 2010; 362:1273.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 2506 Version 11.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-201.211.0.116-39486C3A7C-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f3_37_3674=[""].join("\n");
var outline_f3_37_3674=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H25\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      TREATMENT FOR LOCALIZED DISEASE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Pancreaticoduodenectomy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      - Preoperative biliary drainage",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      - Complications",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Local resection",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - Early, low-grade tumors",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Minimally-invasive nonsurgical therapies",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Summary",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      PROGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Prognostic factors",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - Histology",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      - Nodal metastases",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      - Obstructive jaundice",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      - Intraoperative blood transfusion",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      - Tumor marker elevation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Patterns of recurrence",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      ADJUVANT THERAPY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Chemoradiotherapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Chemotherapy alone",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Summary",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      POSTTREATMENT SURVEILLANCE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      CHEMOTHERAPY FOR ADVANCED DISEASE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      Primary treatment",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      Adjuvant therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      Metastatic disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ONC/2506\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ONC/2506|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?27/17/27924\" title=\"figure 1\">",
"      Sphincter of Oddi",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?5/49/5908\" title=\"figure 2\">",
"      Locations ampullary tumors",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?16/57/17303\" title=\"figure 3\">",
"      Conventional pancreaticoduodenectomy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?5/43/5810\" title=\"figure 4\">",
"      Pylorus-preserving pancreaticoduodenectomy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ONC/2506|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?39/13/40156\" title=\"table 1\">",
"      TNM staging ampullary CA",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?1/32/1548\" title=\"table 2\">",
"      Progn ampullary CA",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?26/2/26669\" title=\"table 3\">",
"      Gemcitabine for nonmetastatic pancreatic and biliary cancer",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?35/56/36749\" title=\"table 4\">",
"      Gemcitabine for metastatic pancreatic and biliary tract cancer",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/33/22042?source=related_link\">",
"      Adjuvant and neoadjuvant therapy for exocrine pancreatic cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/52/43848?source=related_link\">",
"      Ampullary carcinoma: Epidemiology, clinical manifestations, diagnosis and staging",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/12/39114?source=related_link\">",
"      Chemotherapy for advanced exocrine pancreatic cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/44/43721?source=related_link\">",
"      Pancreaticoduodenectomy (Whipple procedure): Techniques",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/27/26039?source=related_link\">",
"      Photodynamic therapy for ablation of Barrett's esophagus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/34/8746?source=related_link\">",
"      Surgery in the treatment of exocrine pancreatic cancer and prognosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/32/10761?source=related_link\">",
"      Systemic therapy for advanced cholangiocarcinoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/36/13897?source=related_link\">",
"      Treatment of ampullary adenomas",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/33/25114?source=related_link\">",
"      Treatment of localized cholangiocarcinoma: Surgical management and adjuvant therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/8/21642?source=related_link\">",
"      Treatment of small bowel neoplasms",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/48/34561?source=related_link\">",
"      Treatment protocols for hepatobiliary cancer",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f3_37_3675="Revised Amsterdam criteria";
var content_f3_37_3675=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F59832&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F59832&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Revised Amsterdam criteria by the International Collaborative Group on HNPCC",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td>",
"        There should be at least three relatives with an HNPCC-associated cancer (colorectal cancer, cancer of the endometrium, small bowel, ureter, or renal pelvis)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        One should be a first degree relative of the other two",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        At least two successive generations should be affected",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        At least&nbsp;one should be diagnosed before age 50",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Familial adenomatous polyposis should be excluded in the colorectal cancer case(s) if any",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Tumors should be verified by pathological examination",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     HNPCC: hereditary nonpolyposis colorectal cancer.",
"    </div>",
"    <div class=\"reference\">",
"     Adapted from Vasen HF, Watson P, Mecklin JP, et al. Gastroenterology 1999; 116:1453.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f3_37_3675=[""].join("\n");
var outline_f3_37_3675=null;
var title_f3_37_3676="Rx cystitis children and adolescents";
var content_f3_37_3676=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F67989&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F67989&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Antibacterial agents for oral treatment of acute cystitis in children and adolescents",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Antibacterial agent",
"       </td>",
"       <td class=\"subtitle1\">",
"        Dose",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Trimethoprim-sulfamethoxazole (TMP-SMX)*",
"       </td>",
"       <td>",
"        6 to 12 mg/kg per day TMP/30 to 60 mg/kg SMX per day divided in two doses; maximum dose 160 mg TMP/800 mg SMZ",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Amoxicillin",
"        <sup>",
"         &bull;",
"        </sup>",
"       </td>",
"       <td>",
"        40 mg/kg per day divided in three doses; maximum dose 500 mg",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Cephalexin",
"        <sup>",
"         &Delta;",
"        </sup>",
"       </td>",
"       <td>",
"        25 to 50 mg/kg per day divided in four doses; maximum dose 1 g",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Cefixime",
"       </td>",
"       <td>",
"        8 mg/kg per day divided in two doses; maximum dose 200 mg",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Cefpodoxime",
"       </td>",
"       <td>",
"        10 mg/kg per day divided in two doses; maximum dose 400 mg",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Nitrofurantoin",
"        <sup>",
"         &loz;",
"        </sup>",
"       </td>",
"       <td>",
"        5 to 7 mg/kg per day divided in four doses; maximum dose 100 mg",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Loracarbef",
"       </td>",
"       <td>",
"        15 to 30 mg/kg per day divided in two doses; maximum dose 400 mg",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     *",
"     <em>",
"      Escherichia coli",
"     </em>",
"     strains may be resistant to trimethoprim-sulfamethoxazole.",
"     <br>",
"      &bull; Many strains of",
"      <em>",
"       E. coli",
"      </em>",
"      are resistant to amoxicillin.",
"      <br>",
"       &Delta;",
"       <em>",
"        E. coli",
"       </em>",
"       also may be resistant to cephalexin.",
"       <br>",
"        &loz; Should not be used if occult prostatitis is suspected in a male adolescent since it does not achieve reliable tissue concentrations.",
"       </br>",
"      </br>",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"     Data from: Hellerstein S. Urinary tract infections. Old and new concepts. Pediatr Clin North Am 1995; 42:1433.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f3_37_3676=[""].join("\n");
var outline_f3_37_3676=null;
var title_f3_37_3677="LR of Down syndrome based on presence of an isolated soft marker";
var content_f3_37_3677=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F82498&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F82498&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Likelihood ratio of Down syndrome based on the presence of an isolated soft marker (pooled results)",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <colgroup span=\"4\" width=\"25%\">",
"     </colgroup>",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Finding",
"       </td>",
"       <td class=\"subtitle1\">",
"        Sensitivity Down syndrome,",
"        <br/>",
"        percent",
"       </td>",
"       <td class=\"subtitle1\">",
"        False positive rate",
"        <br/>",
"        (ie, marker detected in euploid karyotype), percent",
"       </td>",
"       <td class=\"subtitle1\">",
"        Positive likelihood ratio if the marker is isolated,",
"        <br/>",
"        percent*",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Absent or hypoplastic nasal bone",
"       </td>",
"       <td class=\"centered\">",
"        48.9 to 69.9",
"       </td>",
"       <td class=\"centered\">",
"        1.9 to 4.0",
"       </td>",
"       <td class=\"centered\">",
"        6.58",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Aberrant right subclavian artery",
"       </td>",
"       <td class=\"centered\">",
"        17.9 to 47.4",
"       </td>",
"       <td class=\"centered\">",
"        1.0 to 2.1",
"       </td>",
"       <td class=\"centered\">",
"        3.94",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Ventriculomegaly",
"        <sup>",
"         &bull;",
"        </sup>",
"       </td>",
"       <td class=\"centered\">",
"        4.2 to 12.9",
"       </td>",
"       <td class=\"centered\">",
"        0.1 to 0.4",
"       </td>",
"       <td class=\"centered\">",
"        3.81",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Increased nuchal fold",
"        <sup>",
"         &Delta;",
"        </sup>",
"       </td>",
"       <td class=\"centered\">",
"        20.3 to 32.9",
"       </td>",
"       <td class=\"centered\">",
"        0.5 to 1.9",
"       </td>",
"       <td class=\"centered\">",
"        3.79",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Hyperechoic bowel",
"        <sup>",
"         &loz;",
"        </sup>",
"       </td>",
"       <td class=\"centered\">",
"        13.4 to 20.7",
"       </td>",
"       <td class=\"centered\">",
"        0.8 to 1.5",
"       </td>",
"       <td class=\"centered\">",
"        1.65",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Pyelectasis",
"        <sup>",
"         &sect;",
"        </sup>",
"       </td>",
"       <td class=\"centered\">",
"        11.2 to 17.2",
"       </td>",
"       <td class=\"centered\">",
"        1.4 to 2.0",
"       </td>",
"       <td class=\"centered\">",
"        1.08",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Echogenic intracardiac focus",
"       </td>",
"       <td class=\"centered\">",
"        20.9 to 28.2",
"       </td>",
"       <td class=\"centered\">",
"        3.4 to 4.5",
"       </td>",
"       <td class=\"centered\">",
"        0.95",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Short humerus",
"       </td>",
"       <td class=\"centered\">",
"        17.1 to 47.9",
"       </td>",
"       <td class=\"centered\">",
"        2.8 to 7.4",
"       </td>",
"       <td class=\"centered\">",
"        0.78",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Short femur",
"       </td>",
"       <td class=\"centered\">",
"        19.3 to 38.1",
"       </td>",
"       <td class=\"centered\">",
"        4.7 to 8.8",
"       </td>",
"       <td class=\"centered\">",
"        0.61",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    Results from meta-analysis of data pooled from 48 studies of low and high risk populations. Gestational age at ultrasound 14 to 24 weeks. Most studies involved women at increased risk.",
"    <br/>",
"    The authors concluded that if a systematic ultrasound examination is performed by expert sonologists and all of these markers are absent, the risk of Down syndrome is the mother's a priori risk based on maternal serum screening multiplied by 0.13.",
"    <div class=\"footnotes\">",
"     * Derived by multiplying the positive likelihood ratio for the marker by the negative likelihood ratio for each of the other markers.",
"     <br/>",
"     <span class=\"bullet\">",
"      &bull;",
"     </span>",
"     Diameter of lateral cerebral ventricle &ge;10 mm.",
"     <br/>",
"     &Delta; Thickness &ge;6 mm.",
"     <br/>",
"     <span class=\"lozenge\">",
"      &loz;",
"     </span>",
"     Echogenicity the same as bone.",
"     <br/>",
"     &sect; Anteroposterior diameter 3 to 5 mm.",
"    </div>",
"    <div class=\"reference\">",
"     Data from: Agathokleous M, Chaveeva P, Poon LCY,&nbsp;et al.&nbsp;Meta-analysis of second trimester markers for trisomy 21. Ultrasound Obstet Gynecol 2013; 41:247.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f3_37_3677=[""].join("\n");
var outline_f3_37_3677=null;
var title_f3_37_3678="Antihypertensive drugs for infants";
var content_f3_37_3678=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F63077&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F63077&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Recommended doses for selected agents to treat hypertensive infants",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Class",
"       </td>",
"       <td class=\"subtitle1\">",
"        Drug",
"       </td>",
"       <td class=\"subtitle1\">",
"        Route",
"       </td>",
"       <td class=\"subtitle1\">",
"        Dose range",
"       </td>",
"       <td class=\"subtitle1\">",
"        Interval",
"       </td>",
"       <td class=\"subtitle1\">",
"        Comments",
"       </td>",
"      </tr>",
"      <tr>",
"       <td rowspan=\"4\">",
"        ACE inhibitors",
"       </td>",
"       <td rowspan=\"2\">",
"        Captopril",
"       </td>",
"       <td rowspan=\"2\">",
"        Oral",
"       </td>",
"       <td>",
"        &lt;3 months: 0.01-0.5 mg/kg/dose",
"        <br/>",
"        Max 2 mg/kg/day",
"       </td>",
"       <td rowspan=\"2\">",
"        Three to four times per day",
"       </td>",
"       <td rowspan=\"4\">",
"        <ol>",
"         <li>",
"          First dose may cause rapid drop in BP, especially if receiving diuretics",
"         </li>",
"         <li>",
"          In infants already receiving a diuretic, start at the lowest recommended dose",
"         </li>",
"         <li>",
"          Monitor serum creatinine and potassium",
"         </li>",
"         <li>",
"          Intravenous enalaprilat NOT recommended - see text",
"         </li>",
"         <li>",
"          Only captopril and enalapril are US Food &amp; Drug Administration approved in infancy",
"         </li>",
"         <li>",
"          ACE inhibitors should not be used in infants who are less than 44 weeks post conceptual age",
"         </li>",
"        </ol>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &gt;3 months: 0.15-0.3 mg/kg/dose",
"        <br/>",
"        Max 6 mg/kg/day",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Enalapril",
"       </td>",
"       <td>",
"        Oral",
"       </td>",
"       <td>",
"        0.08-0.6 mg/kg/day",
"       </td>",
"       <td>",
"        Once or twice daily",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Lisinopril",
"       </td>",
"       <td>",
"        Oral",
"       </td>",
"       <td>",
"        0.07-0.6 mg/kg/day",
"       </td>",
"       <td>",
"        Once daily",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td rowspan=\"4\">",
"        Alpha and beta antagonists",
"       </td>",
"       <td rowspan=\"3\">",
"        Labetalol",
"       </td>",
"       <td>",
"        Oral",
"       </td>",
"       <td>",
"        0.5-1 mg/kg/dose",
"        <br/>",
"        Max 10 mg/kg/day",
"       </td>",
"       <td>",
"        Two or three times daily",
"       </td>",
"       <td rowspan=\"3\">",
"        Acute decompensated heart failure, bronchopulmonary dysplasia relative contraindications",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        IV bolus",
"       </td>",
"       <td>",
"        0.2-1 mg/kg/dose",
"       </td>",
"       <td>",
"        Administer every four to six hours",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        IV infusion",
"       </td>",
"       <td>",
"        0.25-3 mg/kg/hr",
"       </td>",
"       <td>",
"        Continuous infusion",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Carvedilol",
"       </td>",
"       <td>",
"        Oral",
"       </td>",
"       <td>",
"        0.1 mg/kg/dose up to 0.5 mg/kg/dose",
"       </td>",
"       <td>",
"        Twice per day",
"       </td>",
"       <td>",
"        May be useful in chronic heart failure",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td rowspan=\"2\">",
"        Beta antagonists",
"       </td>",
"       <td>",
"        Esmolol",
"       </td>",
"       <td>",
"        IV infusion",
"       </td>",
"       <td>",
"        100-500 mcg/kg/min",
"       </td>",
"       <td>",
"        Continuous infusion",
"       </td>",
"       <td>",
"        Very short-acting; constant infusion necessary. May be useful for management of acute hypertension after repair of aortic coarctation.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Propranolol",
"       </td>",
"       <td>",
"        Oral",
"       </td>",
"       <td>",
"        0.5-1 mg/kg/dose",
"        <br/>",
"        Max 8-10 mg/kg/day",
"       </td>",
"       <td>",
"        Three to four times per day",
"       </td>",
"       <td>",
"        Monitor heart rate; avoid in bronchopulmonary dysplasia",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td rowspan=\"3\">",
"        Calcium channel blockers",
"       </td>",
"       <td>",
"        Amlodipine",
"       </td>",
"       <td>",
"        Oral",
"       </td>",
"       <td>",
"        0.05-0.3 mg/kg/dose",
"        <br/>",
"        Max 0.6 mg/kg/day",
"       </td>",
"       <td>",
"        Once per day",
"       </td>",
"       <td>",
"        May cause mild reflex tachycardia. Some infants may benefit by dividing dose twice per day. Full effect of dose adjustment may require one week or more.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Isradipine",
"       </td>",
"       <td>",
"        Oral",
"       </td>",
"       <td>",
"        0.05-0.15 mg/kg/dose",
"        <br/>",
"        Max 0.8 mg/kg/day",
"       </td>",
"       <td>",
"        Four times per day",
"       </td>",
"       <td rowspan=\"2\">",
"        May cause mild reflex tachycardia",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Nicardipine",
"       </td>",
"       <td>",
"        IV infusion",
"       </td>",
"       <td>",
"        0.5-4 mcg/kg/min",
"       </td>",
"       <td>",
"        Continuous infusion",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        Central alpha-agonist",
"       </td>",
"       <td>",
"        Clonidine",
"       </td>",
"       <td>",
"        Oral",
"       </td>",
"       <td>",
"        5-10 mcg/kg/day",
"        <br/>",
"        Max 25 mcg/kg/day",
"       </td>",
"       <td>",
"        Divided two to four times daily",
"       </td>",
"       <td>",
"        May cause mild sedation",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td rowspan=\"3\">",
"        Diuretics",
"       </td>",
"       <td>",
"        Chlorothiazide",
"       </td>",
"       <td>",
"        Oral",
"       </td>",
"       <td>",
"        5-15 mg/kg/dose",
"       </td>",
"       <td>",
"        Twice per day",
"       </td>",
"       <td rowspan=\"3\">",
"        Monitor electrolytes",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Hydrochlorothiazide",
"       </td>",
"       <td>",
"        Oral",
"       </td>",
"       <td>",
"        1-3 mg/kg/day",
"       </td>",
"       <td>",
"        Once daily or as two divided doses per day",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Spironolactone",
"       </td>",
"       <td>",
"        Oral",
"       </td>",
"       <td>",
"        0.5-1.5 mg/kg/dose",
"       </td>",
"       <td>",
"        Twice per day",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td rowspan=\"4\">",
"        Vasodilators",
"       </td>",
"       <td rowspan=\"2\">",
"        Hydralazine",
"       </td>",
"       <td>",
"        Oral",
"       </td>",
"       <td>",
"        0.25-1 mg/kg/dose",
"        <br/>",
"        Max 7.5 mg/kg/day",
"       </td>",
"       <td>",
"        Three to four times per day",
"       </td>",
"       <td rowspan=\"2\">",
"        Tachycardia and fluid retention are common side effects",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        IV bolus",
"       </td>",
"       <td>",
"        0.15-0.6 mg/kg/dose",
"       </td>",
"       <td>",
"        Q four hours",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Minoxidil",
"       </td>",
"       <td>",
"        Oral",
"       </td>",
"       <td>",
"        0.1-0.2 mg/kg/dose",
"       </td>",
"       <td>",
"        Two to three times per day",
"       </td>",
"       <td>",
"        Tachycardia and fluid retention common side effects; prolonged use causes hypertrichosis; pericardial effusion may occur",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Nitroprusside",
"       </td>",
"       <td>",
"        IV infusion",
"       </td>",
"       <td>",
"        0.5-10 mcg/kg/min",
"       </td>",
"       <td>",
"        Continuous infusion",
"       </td>",
"       <td>",
"        Thiocyanate toxicity can occur with prolonged (&gt;72 h) use or in renal failure",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     ACE inhibitor: angiotensin converting enzyme inhibitor.",
"    </div>",
"    <div class=\"reference\">",
"     Adapted from: Dionne JM, Abitbol CL, Flynn JT. Hypertension in infancy: diagnosis, management, and outcome. Pediatr Nephrol 2011 with kind permission from Springer Science + Business Media B.V. Copyright &copy; 2011.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f3_37_3678=[""].join("\n");
var outline_f3_37_3678=null;
var title_f3_37_3679="Treatment strategy for Lambert-Eaton myasthenic syndrome";
var content_f3_37_3679=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEURO%2F54686&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEURO%2F54686&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 497px\">",
"   <div class=\"ttl\">",
"    Treatment strategy for Lambert-Eaton myasthenic syndrome",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 477px; height: 511px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f3_37_3679=[""].join("\n");
var outline_f3_37_3679=null;
